U.S. patent application number 15/698661 was filed with the patent office on 2018-01-04 for glut-1 as a receptor for htlv envelopes and its uses.
The applicant listed for this patent is CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER II. Invention is credited to Jean-Luc BATTINI, Felix KIM, Sandrina KINET, Nicolas MANEL, Marc SITBON, Naomi TAYLOR.
Application Number | 20180002383 15/698661 |
Document ID | / |
Family ID | 53051672 |
Filed Date | 2018-01-04 |
United States Patent
Application |
20180002383 |
Kind Code |
A1 |
BATTINI; Jean-Luc ; et
al. |
January 4, 2018 |
GLUT-1 AS A RECEPTOR FOR HTLV ENVELOPES AND ITS USES
Abstract
The present application relates to a method for diagnosing a
glucose transporter type 1 (GLUT1) deficiency syndrome that
utilizes polypeptides derived from the soluble part of the
glycoprotein of the enveloped virus of primate T-cell leukemia
virus (PTLV). The polypeptides, named receptor binding domain
ligands (RBD), are selected for their ability to bind specifically
to GLUT1. The method involves determining the level of GLUT 1
expression at the cell surface and comparing the level to a
reference value.
Inventors: |
BATTINI; Jean-Luc;
(Montpellier, FR) ; MANEL; Nicolas; (Paris,
FR) ; KIM; Felix; (New York City, NY) ; KINET;
Sandrina; (Claret, FR) ; TAYLOR; Naomi;
(Montpellier, FR) ; SITBON; Marc; (Montpellier,
FR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
UNIVERSITE MONTPELLIER II |
Paris Cedex
Montpellier Cedex |
|
FR
FR |
|
|
Family ID: |
53051672 |
Appl. No.: |
15/698661 |
Filed: |
September 8, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14575132 |
Dec 18, 2014 |
9777044 |
|
|
15698661 |
|
|
|
|
12547924 |
Aug 26, 2009 |
8945583 |
|
|
14575132 |
|
|
|
|
10555289 |
Jul 3, 2006 |
7642061 |
|
|
PCT/EP2004/004624 |
Apr 30, 2004 |
|
|
|
12547924 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
G01N 2333/62 20130101;
C12N 2810/6054 20130101; C12N 2740/15045 20130101; A61K 38/00
20130101; C07K 14/62 20130101; C12N 2740/14022 20130101; C12N
2740/14033 20130101; C12N 2740/15022 20130101; C07K 14/705
20130101; G01N 33/566 20130101; G01N 33/57484 20130101; C07K 14/005
20130101 |
International
Class: |
C07K 14/005 20060101
C07K014/005; G01N 33/574 20060101 G01N033/574; G01N 33/566 20060101
G01N033/566; C07K 14/62 20060101 C07K014/62; C07K 14/705 20060101
C07K014/705 |
Foreign Application Data
Date |
Code |
Application Number |
May 2, 2003 |
EP |
03291067.1 |
Claims
1. A method for diagnosing a glucose transporter type 1 (GLUT1)
deficiency syndrome, comprising: a) collecting sample from a
subject, b) determining the level of GLUT1 expression at a cell
surface using an isolated polypeptide, wherein said polypeptide is
a soluble receptor binding domain (RBD) ligand derived from the
soluble part of the glycoprotein of a primate T-lymphotropic virus
binding to GLUT1 or a fragment thereof, and c) comparing said level
to a reference value.
2. The method of claim 1, wherein GLUT1 comprises an amino acid
sequence presenting a sequence identity of at least 70% with SEQ ID
NO: 2.
3. The method of claim 1, wherein the RBD ligand binds to at least
one of the following fragments of GLUT1: TABLE-US-00008 SEQ ID NO:
42 (IVGMCFQYVEQLC) SEQ ID NO: 35 (NAPQKVIEEFY) SEQ ID NO: 36
(NQTWVHRYGESILPTTLTTLWS) SEQ ID NO: 37 (KSFEMLILGR) SEQ ID NO: 38
(DSIMGNKDL) SEQ ID NO: 39 (YSTSIFEKAGVQQP) SEQ ID NO: 40
(EQLPWMSYLS) SEQ ID NO: 41 (QYVEQLC)
4. The method of claim 1, wherein the RBD ligand is selected from
the group consisting of human T-cell leukemia virus (HTLV) 2.RBD,
HTLV1.RBD, HTLV4.RBD, HTLV3.RBD, simian T-cell leukemia virus
(STLV) 1.RBD, STLV2.RBD and STLV3.RBD.
5. The method of claim 4, wherein HTLV2.RBD comprises the amino
acid sequence SEQ ID NO: 4 or SEQ ID NO: 5 or SEQ ID NO: 7 or SEQ
ID NO: 43 or fragments or variants thereof.
6. The method of claim 4, wherein HTLV1.RBD comprises the amino
acid sequence SEQ ID NO: 9 or SEQ ID NO: 10 or SEQ ID NO: 11 or SEQ
ID NO: 13 or SEQ ID NO: 15 or SEQ ID NO: 17 or SEQ ID NO: 19 or SEQ
ID NO: 21 or fragments or variants thereof.
7. The method of claim 4, wherein HTLV4.RBD comprises the amino
acid sequence SEQ ID NO: 22 or SEQ ID NO: 23 or SEQ ID NO: 51 or
fragments or variants thereof.
8. The method of claim 4, wherein HTLV3.RBD comprises the amino
acid sequence SEQ ID NO: 53 or fragments or variants thereof.
9. The method of claim 4, wherein STLV1.RBD comprises the amino
acid sequence SEQ ID NO: 25 or fragments or variants thereof.
10. The method of claim 4, wherein STLV2.RBD comprises the amino
acid sequence SEQ ID NO: 27 or fragments or variants thereof.
11. The method of claim 4, wherein STLV3.RBD comprises the amino
acid sequence SEQ ID NO: 29 or SEQ ID NO: 55 or fragments or
variants thereof.
12. The method of claim 1, wherein the RBD ligand is fused to a
tag, an antibody constant fragment or a fluorescent protein.
13. The method of claim 1, wherein the reference value consists of
the level of GLUT1 expression at the cell surface determined in a
sample from a substantially healthy subject.
14. The method of claim 1, wherein the reference value consists of
the level of GLUT1 expression at the cell surface determined in
samples from a reference population comprising at least 100
substantially healthy subjects.
15. The method of claim 1, wherein the reference value consists of
the level of GLUT1 expression at the cell surface determined in a
sample from a subject having a GLUT1 deficiency syndrome.
16. The method of claim 1, wherein the reference value consists of
the level of GLUT1 expression at the cell surface determined in
samples from a reference population comprising at least 10 subjects
having a GLUT1 deficiency syndrome.
17. The method of claim 1, wherein the GLUT1 deficiency syndrome is
characterized by an encephalopathy marked by childhood epilepsy
that is refractory to treatment, deceleration of cranial growth
leading to microcephaly, psychomotor retardation, spasticity,
ataxia, dysarthria or other paroxysmal neurological phenomena often
occurring before meals.
18. The method of claim 1, wherein the GLUT1 deficiency syndrome is
associated with de novo or inherited mutations in the SLC2A1
gene.
19. The method of claim 1, wherein the GLUT1 deficiency syndrome is
associated with low glucose level and low lactate concentration in
the cerebrospinal fluid (CSF) in the absence of hypoglycemia.
Description
FIELD OF INVENTION
[0001] The invention relates to the use of the ubiquitous
vertebrate glucose transporter GLUT1, or of fragments or sequences
derived thereof, for the in vitro diagnosis of cancers, when used
as a tumor marker, or for the screening of compounds useful for the
preparation of drugs for the prevention or the treatment of
pathologies linked to an infection of an individual with a primate
T-lymphotropic virus (PTLV), or pathologies linked to an
overexpression of GLUT1 on cell surfaces, or the in vitro detection
of GLUT1 on cell surfaces. The invention also relates to
pharmaceutical compositions containing GLUT1, or fragments or
sequences derived thereof, and to their uses such as in the frame
of the prevention or the treatment of pathologies linked to an
infection of an individual with a PTLV.
[0002] The present application also relates to polypeptides derived
from the soluble part of the glycoprotein of a Primate T-cell
leukemia virus (PTLV), or fragments or variants thereof named
receptor binding domain ligands (RBD) selected for their ability to
bind specifically to the Glucose Transporter 1 (GLUT1).
BACKGROUND OF INVENTION
[0003] The human T-cell leukemia virus (HTLV) is associated with
leukemia and neurological syndromes. The role of viral envelopes in
HTLV physiopathology is unclear and the envelope receptor, found in
all vertebrate cell lines, remains unidentified.
[0004] HTLV envelope glycoproteins induce syncytium formation in
vitro but their physiopathological effects are unclear. All
vertebrate cell lines express functional HTLV envelope receptors,
including cells resistant to HTLV envelope-mediated syncytium
formation.
[0005] The Applicant found that expression of the HTLV
receptor-binding domain decreased lactate production due to
diminished glucose consumption whereas binding-defective envelope
mutants did not alter glucose metabolism. Glucose starvation
increased HTLV receptor expression, reminiscent of nutrient sensing
responses. Accordingly, overexpression of Glucose Transporter 1
(GLUT1), the ubiquitous vertebrate glucose transporter,
specifically increased HTLV envelope binding and GLUT1 colocalized
with HTLV envelopes. Moreover, HTLV envelope binding was highest in
human erythrocytes, where GLUT1 is abundantly expressed and is the
sole glucose transporter isoform.
[0006] In the present invention, the Applicant identified specific
fragments of PTLV envelope protein that bind to GLUT1.
SUMMARY
[0007] The present application relates to an isolated polypeptide
wherein said polypeptide is a soluble receptor binding domain (RBD)
ligand derived from the soluble part of the glycoprotein of a
primate T-lymphotropic virus binding to the Glucose Transporter 1
(GLUT1).
[0008] The present application also relates to an isolated
polypeptide comprising human T-cell leukemia virus (HTLV) 2.RBD and
comprising the amino acid sequence SEQ ID NO: 4 or SEQ ID NO: 5 or
SEQ ID NO: 7 or SEQ ID NO: 43 or fragments or variants thereof.
[0009] The present application also relates to an isolated
polypeptide comprising HTLV1.RBD and comprising the amino acid
sequence SEQ ID NO: 9 or SEQ ID NO: 10 or SEQ ID NO: 11 or SEQ ID
NO: 13 or SEQ ID NO: 15 or SEQ ID NO: 17 or SEQ ID NO: 19 or SEQ ID
NO: 21 or fragments or variants thereof.
[0010] The present application also relates to an isolated
polypeptide comprising HTLV4.RBD and comprising the amino acid
sequence SEQ ID NO: 22 or SEQ ID NO: 23 or SEQ ID NO: 51 or
fragments or variants thereof.
[0011] The present application also relates to an isolated
polypeptide comprising HTLV3.RBD and comprising the amino acid
sequence SEQ ID NO: 53 or fragments or variants thereof.
[0012] The present application also relates to an isolated
polypeptide comprising simian T-cell leukemia virus (STLV) 1.RBD
and comprising the amino acid sequence SEQ ID NO: 25 or fragments
or variants thereof.
[0013] The present application also relates to an isolated
polypeptide comprising STLV2.RBD and comprising the amino acid
sequence SEQ ID NO: 27 or fragments or variants thereof.
[0014] The present application also relates to an isolated
polypeptide comprising STLV3.RBD and comprising the amino acid
sequence SEQ ID NO: 29 or SEQ ID NO: 55 or fragments or variants
thereof.
[0015] In one embodiment, the isolated polypeptide further
comprises a Tag or being fused to an antibody constant fragment or
to a fluorescent protein.
[0016] The present application also relates to a composition
comprising at least one isolated polypeptide wherein said
polypeptide is a soluble receptor binding domain (RBD) ligand
derived from the soluble part of the glycoprotein of a primate
T-lymphotropic virus binding to the Glucose Transporter 1
(GLUT1).
[0017] In one embodiment, the composition is a pharmaceutical
composition and further comprises a pharmaceutically acceptable
excipient.
[0018] In another embodiment, the composition is a medicament.
[0019] The present application also relates to a method for
diagnosing a GLUT1 related disease comprising: [0020] a) collecting
sample from a subject, [0021] b) determining the level of GLUT1
expression at a cell surface using an isolated polypeptide wherein
said polypeptide is a soluble receptor binding domain (RBD) ligand
derived from the soluble part of the glycoprotein of a primate
T-lymphotropic virus binding to the Glucose Transporter 1 (GLUT1),
and [0022] c) comparing said level to a reference value.
[0023] In one embodiment, the GLUT1 related disease is GLUT1
deficiency syndrome. In another embodiment, the GLUT1 related
disease is a cancer disease.
[0024] The present application also relates to a kit of parts
comprising at least one isolated polypeptide wherein said
polypeptide is a soluble receptor binding domain (RBD) ligand
derived from the soluble part of the glycoprotein of a primate
T-lymphotropic virus binding to the Glucose Transporter 1
(GLUT1).
DEFINITIONS
[0025] In the present invention, the following terms have the
following meanings: [0026] As used herein; the term "identity",
when used in a relationship between the sequences of two or more
polypeptides or of two or more DNA sequences, refers to the degree
of sequence relatedness between polypeptides or DNA sequences
(respectively), as determined by the number of matches between
strings of two or more amino acid residues or of two or more
nucleotides respectively. "Identity" measures the percent of
identical matches between the smaller of two or more sequences with
gap alignments (if any) addressed by a particular mathematical
model or computer program (i.e., "algorithms"). Identity of related
polypeptides or DNA sequences can be readily calculated by known
methods. Such methods include, but are not limited to, those
described in Computational Molecular Biology, Lesk, A. M., ed.,
Oxford University Press, New York, 1988; Biocomputing: Informatics
and Genome Projects, Smith, D. W., ed., Academic Press, New York,
1993; Computer Analysis of Sequence Data, Part 1, Griffin, A. M.,
and Griffin, H. G., eds., Humana Press, New Jersey, 1994; Sequence
Analysis in Molecular Biology, von Heinje, G., Academic Press,
1987; Sequence Analysis Primer, Gribskov, M. and Devereux, J.,
eds., M. Stockton Press, New York, 1991; and Carillo et al., SIAM
J. Applied Math, 48, 1073 (1988). Preferred methods for determining
identity are designed to give the largest match between the
sequences tested. Methods of determining identity are described in
publicly available computer programs. Preferred computer program
methods for determining identity between two sequences include the
GCG program package, including GAP (Devereux et al., Nucl. Acid.
Res. \2, 387 (1984); Genetics Computer Group, University of
Wisconsin, Madison, Wis.), BLASTP, BLASTN, and FASTA (Altschul et
al., J. Mol. Biol. 215, 403-410 (1990)). The BLASTX program is
publicly available from the National Center for Biotechnology
Information (NCBI) and other sources (BLAST Manual, Altschul et al.
NCB/NLM/NIH Bethesda, Md. 20894; Altschul et al., supra). The
well-known Smith Waterman algorithm may also be used to determine
identity. [0027] "GLUT1": refers to a nutrient transporter which is
a glucose importer expressed by metazoans, in particular by humans,
used as receptor by Human T Leukemia viruses (HTLV) in particular.
In one embodiment, GLUT1 is human GLUT1 (accession number
NP_006507.2, SEQ ID NO: 2) encoded by SEQ ID NO: 1 (accession
number NM_006516.2). In one embodiment GLUT1 comprises or consists
of an amino acid sequence presenting a sequence identity of at
least 70% with SEQ ID NO: 2, preferably a sequence identity of at
least 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or more
with SEQ ID NO: 2. In one embodiment GLUT1 is encoded by a
nucleotide sequence presenting a sequence identity of at least 70%
with SEQ ID NO: 1, preferably a sequence identity of at least 75,
80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or more with SEQ ID
NO: 1. In one embodiment, GLUT1 comprises or consists of a fragment
of SEQ ID NO: 2, preferably a fragment of at least about 100 amino
acids, more preferably of at least about 150, 200, 250, 300, 350,
400 or 450 amino acids. [0028] "Ligand" refers to any substance
that forms a complex with a cell surface nutrient transporter.
Typical ligands include, but are not limited to, polypeptides and
proteins. As used herein, a polypeptide refers to a linear polymer
of amino acids (preferably at least 50 amino acids) linked together
by peptide bonds. A protein specifically refers to a functional
entity formed of one or more polypeptides, and optionally of
non-polypeptides cofactors. [0029] "About" proceeding a figure
means plus or less 10% of the value of said figure.
DETAILED DESCRIPTION
[0030] The present application relates to peptides or polypeptides
derived from the soluble part of the glycoprotein of a Primate
T-cell leukemia virus (PTLV), or fragments or variants thereof,
said polypeptides binding specifically to the ubiquitous vertebrate
glucose transporter GLUT1 as set forth SEQ ID NO: 2. In one
embodiment, said polypeptides are selected for their ability to
bind specifically to the ubiquitous vertebrate glucose transporter
GLUT1 as set forth SEQ ID NO: 2.
[0031] The present application thus relates to isolated
polypeptides that are receptor binding domain ligands, wherein said
receptor binding domain (RBD) ligands comprise or consist of a part
or the totality of a receptor binding domain derived from the
soluble part of a glycoprotein of an enveloped virus that binds to
the glucose transporter GLUT1.
[0032] The term "derived from the soluble part of the glycoprotein
of an enveloped virus" means that the ligand is a fragment or a
part of a glycoprotein contained in the envelope of a virus and can
be obtained, for example, by cloning.
[0033] The retroviruses of the invention encode an envelope (Env)
glycoprotein present in mature retroviral virions. The Env protein
is synthesized in the form of a propeptide, which is cleaved in
Golgi apparatus by furine peptidase, resulting in two polypeptides:
the transmembrane (TM) and the cell surface (SU) components. The SU
domain contains two major subdomains: a domain of interaction with
the TM domain and the RBD, the second being liable to interact with
host cell membrane receptors.
[0034] An example of such envelope is represented in FIG. 6.
[0035] In one embodiment, the isolated peptide of the invention
comprises the SU domain of the glycoprotein envelope of a virus or
a fragment of the SU domain, such as, for example, the RBD.
[0036] In another embodiment, the isolated peptide of the invention
does not comprise the TM domain of the glycoprotein envelope of a
virus. Therefore, in one embodiment of the invention, the isolated
peptide of the invention is a soluble peptide, such as, for
example, a soluble RBD. As used herein, the term "soluble peptide"
refers to a peptide which is not anchored within a membrane, such
as, for example, by a transmembrane domain.
[0037] The term "glycoprotein" is to be understood as meaning an
envelope glycoprotein, a coat glycoprotein or a fusion
glycoprotein", wherein the term "glycoprotein" refers to a protein
containing oligosaccharide chains covalently attached to
polypeptide side-chains.
[0038] The term "binds to", "binding to" means that the
glycoprotein is liable to recognize the glucose transporter GLUT1
present on the surface of the cell. In one embodiment, a ligand
that hinds to GLUT1 will thus form a complex with glucose
transporter GLUT1, which complex may be detected by a method
described herein. This complex can be detected if the ligand has
been for example, but not limited to, covalently coupled with a
detectable molecule such as an antibody constant fragment (Fc) or a
fluorescent compound (e.g. Cyanine dye, Alexa dye, Quantum dye,
etc). The complex can also be detected if the ligand has been
tagged with different means well known to the person skilled in the
art. For example, but without limitation, a tag used with the
invention can be a tag selected from the group comprising or
consisting of Hemaglutinin Tag, Poly Arginine Tag, Poly Histidine
Tage, Myc Tag, Strep Tag, S-Tag, HAT Tag, 3.times. Flag Tag,
Calmodulin-binding peptide Tag, SBP Tag, Chitin binding domain Tag,
GST Tag, Maltose-Binding protein Tag, Fluorescent Protein Tag, T7
Tag, V5 Tag and Xpress Tag. The use of the ligand therefore allows
on the one hand the identification and detection of the cell
surface nutrient transporter depending on the ligand used, and on
the other hand the quantification of the complex formed.
[0039] Methods for determining and/or quantifying binding of a RBD
ligand on GLUT1 on the surface of a cell are well known by the
skilled artisan. They include but are not limited to:
immunoprecipitation assay, enzyme-linked immunosorbent assay
(ELISA), Western blotting, flow cytometry, immunofluorescence or
image analysis, for example high content analysis, fluorescence
polarization (FP), fluorescence resonance energy transfer (FRET),
and surface plasmon resonance (SPR).
[0040] In one embodiment, the receptor binding domain ligand
containing part or the totality of the RBD can be fused to a
fluorescent protein such as GFP, to an antibody constant fragment
(such as, for example, Fc fragment from rabbit or from mouse),
and/or chemically modified to add a fluorochrome, or a fluorescent
compound (e.g. Cyanine dye, Alexa dye, Quantum dye, etc), and/or
other tagged protein (e.g. Hemaglutinin Tag, Poly Arginine Tag,
Poly Histidine Tage, Myc Tag, Strep Tag, S-Tag, HAT Tag, 3.times.
Flag Tag, Calmodulin-binding peptide Tag, SBP Tag, Chitin binding
domain Tag, GST Tag, Maltose-Binding protein Tag, T7 Tag, V5 Tag
and Xpress Tag).
[0041] RBDs are found, in particular, in glycoproteins of the
envelope of viruses, therefore, the receptor binding domain ligand
contains the total RBD or a fragment or part of the RBD.
[0042] In one embodiment, said virus is selected from the group
comprising retroviruses primate T cell leukemia virus (PTLV)
selected from human T cell leukemia virus (HTLV) and simian T cell
leukemia virus (STLV) which comprise or consist of HTLV-1, HTLV-2,
HTLV-3, HTLV-4, STLV-2, STLV-3.
[0043] In one embodiment, the soluble receptor binding domain
ligand is isolated from the glycoprotein of Human T Leukemia
Virus-2, and is herein referred as HTLV2.RBD.
[0044] In one embodiment, said HTLV2.RBD comprises or consists of
the amino acid sequence SEQ ID NO: 4 or fragments thereof.
[0045] In one embodiment, said fragments comprise or consist of
amino acids 19 to 224 of SEQ ID NO: 4, or comprise or consist of
amino acids 20 to 224 of SEQ ID NO: 4 or comprises or consists of
amino acids 21 to 224 of SEQ ID NO: 4.
[0046] In one embodiment, said fragments comprise or consist of
amino acids 1 to 179, 180, 181, 182, 183, 184, 185, 186, 187, 188,
189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201,
202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214,
215, 216, 217, 218, 219, 220, 221, 222 or 223 of SEQ ID NO: 4.
[0047] In another embodiment, said fragments comprise or consist of
amino acids 19, 20 or 21 to 179, 180, 181, 182, 183, 184, 185, 186,
187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199,
200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 2.11, 212,
213, 214, 215, 216, 217, 218, 219, 220, 221, 222 or 223 of SEQ ID
NO: 4.
[0048] In another embodiment, said fragments comprise or consist of
SEQ ID NO: 4, encoded by the DNA sequence SEQ ID NO: 3.
[0049] In another embodiment, said fragments comprise or consist of
amino acids 19, 20 or 21 to 178 of SEQ ID NO: 4.
[0050] In one embodiment, said HTLV2.RBD comprises or consists of
the amino acid sequence SEQ ID NO: 5 or fragments thereof, encoded
by the DNA sequence SEQ ID NO: 6.
[0051] In one embodiment, said HTLV2.RBD comprises or consists of
the amino acid sequence SEQ ID NO: 7 or fragments thereof.
[0052] In one embodiment, said HTLV2.RBD comprises or consists of
the amino acid sequence SEQ ID NO: 43 or fragments thereof.
[0053] In one embodiment, the soluble receptor binding domain
ligand is isolated from the glycoprotein of Human T Leukemia.
Virus-1, and is herein referred as HTLV LRBD. In one embodiment,
said HTLV1.RBD comprises or consists of the amino acid sequence SEQ
ID NO: 9 (encoded by SEQ ID NO: 8) or fragments thereof.
[0054] In one embodiment, said HTLV1.RBD comprises or consists of
the amino acid sequence SEQ ID NO: 10 or fragments thereof.
[0055] In one embodiment, said fragments comprise or consist of
amino acids 1 to 183, 184, 185, 186, 187, 188, 189, 190, 191, 192,
193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205,
206, 207 or 208 of SEQ ID NO: 10.
[0056] In one embodiment, said fragments comprise or consist of
amino acids 21 to 183, 184, 185, 186, 187, 188, 189, 190, 191, 192,
193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205,
206, 207 or 208 of SEQ ID NO: 10.
[0057] In another embodiment, said fragments comprise or consist in
SEQ ID NO: 11 (corresponding to amino acids 1 to 182 of SEQ ID NO:
10).
[0058] In one embodiment, said fragments comprise or consist of
amino acids 21 to 182 of SEQ ID NO: 10.
[0059] In one embodiment, said HTLV1.RBD comprises or consists of
the amino acid sequence SEQ ID NO: 11 or fragments thereof.
[0060] In one embodiment, said HTLVLRBD comprises or consists of
the amino acid sequence SEQ ID NO: 13 (encoded by SEQ ID NO: 12) or
fragments thereof.
[0061] In one embodiment, said HTLV1.RBD comprises or consists of
the amino acid sequence SEQ ID NO: 15 (encoded by the DNA sequence
SEQ ID NO: 14) or fragments thereof.
[0062] In one embodiment, said HTL1.RBD comprises or consists of
the amino acid sequence SEQ ID NO: 17 (encoded by the DNA sequence
SEQ ID NO: 16) or fragments thereof.
[0063] In one embodiment, said HTLV1.RBD comprises or consists of
the amino acid sequence SEQ ID NO: 19 (encoded by the DNA sequence
SEQ ID NO: 18) or fragments thereof.
[0064] In one embodiment, said HTLV1.RBD comprises or consists of
the amino acid sequence SEQ ID NO: 21 (encoded by the DNA sequence
SEQ ID NO: 20) or fragments thereof.
[0065] In one embodiment, the soluble receptor binding domain
ligand is isolated from the glycoprotein of Human T Leukemia
Virus-4, and is herein referred as HTLV4.RBD. In one embodiment,
said HTLV4.RBD comprises or consists of the amino acid sequence SEQ
ID NO: 51 or fragments thereof.
[0066] In one embodiment, said fragments comprise or consist of
amino acids 1 to 237, 238, 239, 240, 241, 242, 243, 244, 245, 246,
247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259,
260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272,
273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285,
286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298,
299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311,
312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324,
325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337,
338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350,
351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363,
364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376,
377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389,
390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402,
403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415,
416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428,
429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441,
442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454,
455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467,
468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,
481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493,
494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506,
507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519,
520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532,
533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545,
546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558,
559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571,
572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584,
585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597,
598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610,
611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623,
624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636,
637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649,
650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662,
663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675,
676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688,
689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 710,
711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723,
724, 725, 726, 727, 728, 729, 730, 731, 732, 733, or 734 of SEQ ID
NO: 51.
[0067] In one embodiment, said fragments comprise or consist of
amino acids 24 to 237, 238, 239, 240, 241, 242, 243, 244, 245, 246,
247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259,
260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272,
273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285,
286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298,
299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311,
312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324,
325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337,
338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350,
351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363,
364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376,
377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389,
390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402,
403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415,
416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428,
429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441,
442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454,
455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467,
468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480,
481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493,
494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506,
507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519,
520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532,
533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545,
546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558,
559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571,
572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584,
585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597,
598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610,
611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623,
624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636,
637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649,
650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662,
663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675,
676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688,
689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 710,
711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723,
724, 725, 726, 727, 728, 729, 730, 731, 732, 733, or 734 of SEQ ID
NO: 51.
[0068] In another embodiment, said fragments comprise or consist of
amino acids 22 to 237 of SEQ ID NO: 51, or comprise or consist of
amino acids 23 to 237 of SEQ ID NO: 51, or comprise or consist of
amino acids 24 to 237 of SEQ ID NO: 51.
[0069] In another embodiment, said fragments comprise or consist of
amino acids 1 to 236 of SEQ ID NO: 51. In another embodiment, said
fragments comprise or consist of amino acids 24 to 236 of SEQ ID
NO: 51.
[0070] In another embodiment, said fragments comprise or consist of
SEQ ID NO: 51, encoded by the DNA sequence SEQ ID NO: 50.
[0071] In one embodiment, said HTLV4.RBD comprises or consists of
the amino acid sequence SEQ ID NO: 22 or fragments thereof.
[0072] In one embodiment, said fragments comprises or consists of
amino acids 1 to 179, 180, 181, 182, 183, 184, 185, 186, 187, 188,
189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201,
202, 203 or 204 of SEQ ID NO: 22.
[0073] In one embodiment, said fragments comprise or consist of
amino acids 21 to 179, 180, 181, 182, 183, 184, 185, 186, 187, 188,
189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201,
202, 203 or 204 of SEQ ID NO: 22.
[0074] In another embodiment, said fragments comprise or consist in
SEQ ID NO: 23 (corresponding to amino acids 1 to 178 of SEQ ID NO:
22).
[0075] In another embodiment, said fragments comprise or consist in
amino acids 21 to 178 of SEQ ID NO: 22.
[0076] In one embodiment, the soluble receptor binding domain
ligand is isolated from the glycoprotein of Human T Leukemia
Virus-3, and is herein referred as HTLV3.RBD. In one embodiment,
said HTLV3.RBD comprises or consists of the amino acid sequence SEQ
ID NO: 53 or fragments thereof.
[0077] In one embodiment, said fragments comprises or consists of
amino acids 1 to 181, 182, 183, 184, 185, 186, 187, 188, 189, 190,
191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203,
204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216,
217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229,
230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242,
243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255,
256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268,
269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281,
282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294,
295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307,
308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320,
321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333,
334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346,
347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359,
360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372,
373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385,
386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398,
399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411,
412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424,
425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437,
438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450,
451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463,
464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476,
477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489,
490, 491, or 492 of SEQ ID NO: 53 or fragments thereof.
[0078] In one embodiment, said fragments comprise or consist of
amino acids 23 to 181, 182, 183, 184, 185, 186, 187, 188, 189, 190,
191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203,
204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216,
217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229,
230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242,
243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255,
256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268,
269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281,
282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294,
295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307,
308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320,
321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333,
334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346,
347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359,
360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372,
373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385,
386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398,
399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411,
412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424,
425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437,
438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450,
451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463,
464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476,
477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489,
490, 491, or 492 of SEQ ID NO: 53 or fragments thereof.
[0079] In another embodiment, said fragments comprise or consist of
amino acids 1 to 180 of SEQ ID NO: 53. In another embodiment, said
fragments comprise or consist of amino acids 23 to 180 of SEQ ID
NO: 53.
[0080] In another embodiment, said fragments comprise or consist of
SEQ ID NO: 53, encoded by the DNA sequence SEQ ID NO: 52.
[0081] In one embodiment, the soluble receptor binding domain
ligand is isolated from the glycoprotein of Simian 1' Leukemia
Virus-1, and is herein referred as STLV1.RBD. In one embodiment,
said STLV 1.RBD comprises or consists of the amino acid sequence
SEQ ID NO: 25 or fragments thereof.
[0082] In one embodiment, said fragments comprises or consists of
amino acids 1 to 180, 181, 182, 183, 184, 185, 186, 187, 188, 189,
190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202,
203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215,
216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,
229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241,
242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254,
255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267,
268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280,
281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293,
294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306,
307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319,
320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332,
333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345,
346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358,
359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371,
372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384,
385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397,
398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,
411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423,
424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436,
437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449,
450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462,
463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475,
476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, or 487 of
SEQ ID NO: 25 or fragments thereof.
[0083] In one embodiment, said fragments comprises or consists of
amino acids 21 to 180, 181, 182, 183, 184, 185, 186, 187, 188, 189,
190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202,
203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215,
216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228,
229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241,
242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254,
255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267,
268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280,
281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293,
294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306,
307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319,
320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332,
333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345,
346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358,
359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371,
372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384,
385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397,
398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410,
411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423,
424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436,
437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449,
450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462,
463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475,
476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, or 487 of
SEQ ID NO: 25 or fragments thereof.
[0084] In another embodiment, said fragments comprise or consist of
amino acids 1 to 180 of SEQ ID NO: 25. In another embodiment, said
fragments comprise or consist of amino acids 21 to 180 of SEQ ID
NO: 25.
[0085] In another embodiment, said fragments comprise or consist of
SEQ ID NO: 25, encoded by the DNA sequence SEQ ID NO: 24.
[0086] In one embodiment, the soluble receptor binding domain
ligand is isolated from the glycoprotein of Simian T Leukemia
Virus-2, and is herein referred as STLV2.RBD. In one embodiment,
said STLV2.RBD comprises or consists of the amino acid sequence SEQ
ID NO: 27 or fragments thereof.
[0087] In one embodiment, said fragments comprises or consists of
amino acids 1 to 176, 177, 178, 179, 180, 181, 182, 183, 184, 185,
186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198,
199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211,
212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224,
225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237,
238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250,
251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263,
264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276,
277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289,
290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302,
303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315,
316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328,
329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341,
342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,
355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367,
368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380,
381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393,
394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406,
407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419,
420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432,
433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445,
446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458,
459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471,
472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484,
485, or 486 of SEQ ID NO: 27 or fragments thereof.
[0088] In one embodiment, said fragments comprises or consists of
amino acids 21 to 176, 177, 178, 179, 180, 181, 182, 183, 184, 185,
186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198,
199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211,
212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224,
225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237,
238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250,
251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263,
264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276,
277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289,
290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302,
303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315,
316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328,
329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341,
342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354,
355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367,
368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380,
381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393,
394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406,
407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419,
420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432,
433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445,
446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458,
459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471,
472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484,
485, or 486 of SEQ ID NO: 27 or fragments thereof.
[0089] In another embodiment, said fragments comprise or consist of
amino acids 1 to 175 of SEQ ID NO: 27. In another embodiment, said
fragments comprise or consist of amino acids 21 to 175 of SEQ ID
NO: 27.
[0090] In another embodiment, said fragments comprise or consist of
SEQ ID NO: 27, encoded by the DNA sequence SEQ ID NO: 26.
[0091] In one embodiment, the soluble receptor binding domain
ligand is isolated from the glycoprotein of Simian T Leukemia
Virus-2, and is herein referred as STLV3.RBD. In one embodiment,
said STLV3.RBD comprises or consists of the amino acid sequence SEQ
ID NO: 55 or fragments thereof.
[0092] In one embodiment, said fragments comprises or consists of
amino acids 1 to 182, 183, 184, 185, 186, 187, 188, 189, 190, 191,
192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204,
205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217,
218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230,
231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243,
244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,
257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269,
270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282,
283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295,
296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308,
309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321,
322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334,
335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347,
348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360,
361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373,
374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386,
387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399,
400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412,
413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425,
426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438,
439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451,
452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464,
465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477,
478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 489, 490, or 491
of SEQ ID NO: 55 or fragments thereof.
[0093] In one embodiment, said fragments comprises or consists of
amino acids 22 to 182, 183, 184, 185, 186, 187, 188, 189, 190, 191,
192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204,
205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217,
218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230,
231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243,
244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256,
257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269,
270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282,
283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295,
296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308,
309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321,
322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334,
335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347,
348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360,
361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373,
374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386,
387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399,
400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412,
413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425,
426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438,
439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451,
452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464,
465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477,
478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 489, 490, or 491
of SEQ ID NO: 55 or fragments thereof.
[0094] In another embodiment, said fragments comprise or consist of
amino acids 1 to 181 of SEQ ID NO: 55. In another embodiment, said
fragments comprise or consist of amino acids 22 to 181 of SEQ ID
NO: 55.
[0095] In another embodiment, said fragments comprise or consist of
SEQ ID NO: 55, encoded by the DNA sequence SEQ ID NO: 54.
[0096] In one embodiment, the soluble receptor binding domain
ligand is isolated from the glycoprotein of Simian T Leukemia
Virus-3, and is herein referred as STLV3.RBD. In one embodiment,
said STLV3.RBD comprises or consists of the amino acid sequence SEQ
ID NO: 29 or fragments thereof.
[0097] In another embodiment, said fragments comprise or consist of
SEQ ID NO: 29, encoded by the DNA sequence SEQ ID NO: 28.
[0098] In one embodiment, the isolated polypeptides of the
invention are selected from the group comprising the sequences SEQ
ID NO: 4, 5, 7, 9, 10, 11, 13, 15, 17, 19, 21, 22, 23, 25, 27, 29,
43, 51, 53, and 55 fragments and variants thereof. According to
another embodiment, the isolated polypeptides of the invention are
encoded by a DNA sequence selected from the group comprising the
sequences SEQ ID NO: 3, 6, 8, 12, 14, 16, 18, 20, 24, 26, 28, 50,
52, and 54.
[0099] In one embodiment, the isolated polypeptide of the invention
comprises or consists of a sequence presenting a sequence identity
of at least 70% with one of the sequences SEQ ID NO: 4, 5, 7, 9,
10, 11, 13, 15, 17, 19, 21, 22, 23, 25, 27, 29, 43, 51, 53, and 55,
preferably a sequence identity of at least about 75, 80, 85, 90,
91, 92, 93, 94, 95, 96, 97, 98, 99% or more with one of the
sequences SEQ ID NO: 4, 5, 7, 9, 10, 11, 13, 15, 17, 19, 21, 22,
23, 25, 27, 29, 43, 51, 53, and 55.
[0100] In another embodiment, the isolated polypeptide of the
invention is encoded by a DNA sequence presenting a sequence
identity of at least 70% with one of the sequences 3, 6, 8, 12, 14,
16, 18, 20, 24, 26, 28, 50, 52 and 54 preferably a sequence
identity of at least about 75, 80, 85, 90, 91, 92, 93, 94, 95, 96,
97, 98, 99% or more with one of the sequences SEQ ID NO: 3, 6, 8,
12, 14, 16, 18, 20, 24, 26 28, 50, 52 and 54.
[0101] In one embodiment, the isolated polypeptide of the invention
is a variant of one of the polypeptide having the sequences SEQ ID
NO: 4, 5, 7, 9, 10, 11, 13, 15, 17, 19, 21, 22, 23, 25, 27, 29, 43,
51, 53, and 55.
[0102] A polypeptide "variant" as the term is used herein, is a
polypeptide that typically differs from a polypeptide specifically
disclosed herein in one or more substitutions, deletions, additions
and/or insertions. Such variants may be naturally occurring or may
be synthetically generated, for example, by modifying one or more
of the above polypeptide sequences and evaluating one or more
biological activities of the polypeptide as described herein and/or
using any of a number of techniques well known in the art.
Modifications may be made in the structure of polypeptides and
still obtain a functional molecule that encodes a variant or
derivative polypeptide with desirable characteristics.
[0103] When it is desired to alter the amino acid sequence of a
polypeptide to create an equivalent, or even an improved, variant
or portion of a ligand of the invention, one skilled in the art
will typically change one or more of the codons of the encoding DNA
sequence. For example, certain amino acids may be substituted by
other amino acids in a protein structure without appreciable loss
of its ability to bind cell surface nutrient transporters. Since it
is the binding capacity and nature of a protein that defines that
protein's biological functional activity, certain amino acid
sequence substitutions can be made in a protein sequence, and, of
course, its underlying DNA coding sequence, and nevertheless obtain
a protein with similar properties. It is thus contemplated that
various changes may be made in the peptide sequences, or
corresponding DNA sequences that encode said peptides without
appreciable loss of their biological utility or activity, In many
instances, a polypeptide variant will contain one or more
conservative substitutions. A "conservative substitution" is one in
which an amino acid is substituted by another amino acid that has
similar properties, such that one skilled in the art of peptide
chemistry would expect the secondary structure and hydropathic
nature of the polypeptide to be substantially unchanged. As
outlined above, amino acid substitutions are generally therefore
based on the relative similarity of the amino acid side-chain
substituents, for example, their hydrophobicity, hydrophilicity,
charge, size, and the like. Exemplary substitutions that take
various of the foregoing characteristics into consideration are
well known to those of skill in the art and include: arginine and
lysine; glutamate and aspartate; serine and threonine; glutamine
and asparagine; and valine, leucine and isoleucine. Amino acid
substitutions may further be made on the basis of similarity in
polarity, charge, solubility, hydrophobicity, hydrophilicity and/or
the amphipathic nature of the residues. For example, negatively
charged amino acids include aspartic acid and glutamic acid;
positively charged amino acids include lysine and arginine; and
amino acids with uncharged polar head groups having similar
hydrophilicity values include leucine, isoleucine and valine;
glycine and alanine; asparagine and glutamine; and serine,
threonine, phenylalanine and tyrosine. Other groups of amino acids
that may represent conservative changes include: (1) ala, pro, gly,
glu, asp, gln, asn, ser, thr; (2) cys, ser, tyr, thr; (3) val, ile,
leu, met, ala, phe; (4) lys, arg, his; and (5) phe, tyr, trp, his.
A variant may also, or alternatively, contain nonconservative
changes. In a preferred embodiment, variant polypeptides differ
from a native sequence by substitution, deletion or addition of 1,
2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids. Variants may also (or
alternatively) be modified by, for example, the deletion or
addition of amino acids that have minimal influence on the
immunogenicity, secondary structure and hydropathic nature of the
polypeptide.
[0104] In one embodiment, the isolated polypeptide of the invention
is a fusion protein comprising a part or the totality of a receptor
binding domain fused to a detection tag, such as, for example, a Fc
fragment or a fluorescent protein such as GFP. Examples of Fc
fragments include, but are not limited to, rabbit Fc fragment
(amino acid sequence SEQ ID NO: 30, encoded by SEQ ID NO: 31), and
mouse Pc fragment (amino acid sequence SEQ ID NO: 32, encoded by
SEQ ID NO: 33).
[0105] In one embodiment, the isolated polypeptide of the invention
is HTLV2.RBD fused to a mouse Fe fragment (encoded by the DNA
sequence SEQ ID NO: 34).
[0106] In one embodiment, the isolated polypeptide of the invention
is obtained by a cloning method, such as, for example, using any
production system known in the art, such as, for example, E. coli,
yeast, baculovirus-insect cell, or mammalian cells such as HEK or
CHO, expression system. In one embodiment, the sequence of the
receptor binding domain ligand is fused in N-terminal to a peptide
signal sequence allowing the secretion of said receptor binding
domain ligand. Examples of peptide signal sequences include, but
are not limited to, human IL-2 peptide signal (SEQ ID NO: 44),
human albumin peptide signal (SEQ ID NO: 45), human
chymotrypsinogen peptide signal (SEQ ID NO: 46), human
trypsinogen-2 peptide signal (SEQ ID NO: 47), gaussia luciferase
peptide signal (SEQ ID NO: 48), and mouse IgM peptide signal (SEQ
ID NO: 49).
[0107] The present invention also relates to a composition
comprising at least one of the isolated polypeptide of the present
invention.
[0108] The present invention also relates to a pharmaceutical
composition comprising at least one of the isolated polypeptide of
the invention and at least one pharmaceutically acceptable
excipient.
[0109] The term "pharmaceutically" or "pharmaceutically acceptable"
refers to molecular entities and compositions that do not produce
an adverse, allergic or other untoward reaction when administered
to a mammal, especially a human, as appropriate. A pharmaceutically
acceptable carrier or excipient refers to a non-toxic solid,
semi-solid or liquid filler, diluent, encapsulating material or
formulation auxiliary of any type.
[0110] The present invention also relates to a medicament,
comprising at least one of the isolated polypeptide of the
invention.
[0111] Preferably, the composition, the pharmaceutical composition
or the medicament of the invention comprises a therapeutically
effective amount of at least one of the isolated polypeptide of the
invention.
[0112] It will be understood that the total daily usage of at least
one of the isolated polypeptide of the invention, composition,
pharmaceutical composition and medicament of the present invention
will be decided by the attending physician within the scope of
sound medical judgment. The specific therapeutically effective dose
level for any particular patient will depend upon a variety of
factors including the disorder being treated and the severity of
the disorder; activity of the specific RBD employed; the specific
composition employed, the age, body weight, general health, sex and
diet of the patient; the time of administration, route of
administration, and rate of excretion of the specific RBD employed;
the duration of the treatment; drugs used in combination or
coincidental with the specific polypeptide employed; and like
factors well known in the medical arts. For example, it is well
within the skill of the art to start doses of the RBD at levels
lower than those required to achieve the desired therapeutic effect
and to gradually increase the dosage until the desired effect is
achieved. However, the daily dosage of the products may be varied
over a wide range from about 10 to about 10,000 mg per adult per
day, preferably 100 to about 5,000, more preferably from about 200
to about 2,000 mg per adult per day. Preferably, the compositions
contain 10, 50, 100, 250, 500, 1000 and 2,000 mg of the active
ingredient for the symptomatic adjustment of the dosage to the
patient to be treated. A medicament typically contains from about
10 to about 10,000 mg of the active ingredient, preferably 100 to
about 5,000, more preferably from about 200 to about 2,000 mg of
the active ingredient. An effective amount of the drug is
ordinarily supplied at a dosage level from 0.1 mg/kg to about 100
mg/kg of body weight per day, preferably from about 1 mg/kg to 40
mg/kg of body weight per day, more preferably from about 2 mg/kg to
20 mg/kg of body weight per day.
[0113] In one embodiment, the composition, pharmaceutical
composition or medicament comprises sustained-release matrices,
such as biodegradable polymers.
[0114] In the pharmaceutical compositions of the present invention,
the polypeptide of the invention, alone or in combination with
another active principle, can be administered in a unit
administration form, as a mixture with conventional pharmaceutical
supports, to animals and human beings. Suitable unit administration
forms comprise oral-route forms such as tablets, gel capsules,
powders, granules and oral suspensions or solutions, sublingual and
buccal administration forms, aerosols, implants, subcutaneous,
transdermal, topical, intraperitoneal, intramuscular, intravenous,
subdermal, transdermal, intrathecal and intranasal administration
forms and rectal administration forms.
[0115] Preferably, the composition, pharmaceutical composition or
medicament contains vehicles which are pharmaceutically acceptable
for a formulation capable of being injected. These may be in
particular isotonic, sterile, saline solutions (monosodium or
disodium phosphate, sodium, potassium, calcium or magnesium
chloride and the like or mixtures of such salts), or dry,
especially freeze-dried compositions which upon addition, depending
on the case, of sterilized water or physiological saline, permit
the constitution of injectable solutions.
[0116] The pharmaceutical forms suitable for injectable use include
sterile aqueous solutions or dispersions; formulations including
sesame oil, peanut oil or aqueous propylene glycol; and sterile
powders for the extemporaneous preparation of sterile injectable
solutions or dispersions. In all cases, the form must be sterile
and must be fluid to the extent that easy syringability exists. It
must be stable under the conditions of manufacture and storage and
must be preserved against the contaminating action of
microorganisms, such as bacteria and fungi.
[0117] Solutions comprising at least one of the isolated
polypeptide of the invention as free base or pharmacologically
acceptable salts can be prepared in water suitably mixed with a
surfactant, such as hydroxypropylcellulose. Dispersions can also be
prepared in glycerol, liquid polyethylene glycols, and mixtures
thereof and in oils. Under ordinary conditions of storage and use,
these preparations contain a preservative to prevent the growth of
microorganisms.
[0118] The polypeptide of the invention can be formulated into a
composition in a neutral or salt form. Pharmaceutically acceptable
salts include the acid addition salts (formed with the free amino
groups of the protein) and which are formed with inorganic acids
such as, for example, hydrochloric or phosphoric acids, or such
organic acids as acetic, oxalic, tartaric, mandelic, and the like.
Salts formed with the free carboxyl groups can also be derived from
inorganic bases such as, for example, sodium, potassium, ammonium,
calcium, or ferric hydroxides, and such organic bases as
isopropylamine, trimethylamine, histidine, procaine and the
like.
[0119] The carrier can also be a solvent or dispersion medium
containing, for example, water, ethanol, polyol (for example,
glycerol, propylene glycol, and liquid polyethylene glycol, and the
like), suitable mixtures thereof, and vegetables oils. The proper
fluidity can be maintained, for example, by the use of a coating,
such as lecithin, by the maintenance of the required particle size
in the case of dispersion and by the use of surfactants. The
prevention of the action of microorganisms can be brought about by
various antibacterial and antifungal agents, for example, parabens,
chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In
many cases, it will be preferable to include isotonic agents, for
example, sugars or sodium chloride. Prolonged absorption of the
injectable compositions can be brought about by the use in the
compositions of agents delaying absorption, for example, aluminium
monostearate and gelatin.
[0120] Sterile injectable solutions are prepared by incorporating
the polypeptides in the required amount in the appropriate solvent
with one or several of the other ingredients enumerated above, as
required, followed by filtered sterilization. Generally,
dispersions are prepared by incorporating the various sterilized
active ingredients into a sterile vehicle which contains the basic
dispersion medium and the required other ingredients from those
enumerated above. In the case of sterile powders for the
preparation of sterile injectable solutions, the preferred methods
of preparation are vacuum-drying and freeze-drying techniques which
yield a powder of the isolated polypeptide plus any additional
desired ingredient from a previously sterile-filtered solution
thereof.
[0121] Upon formulation, solutions will be administered in a manner
compatible with the dosage formulation and in such amount as is
therapeutically effective. The formulations are easily administered
in a variety of dosage forms, such as the type of injectable
solutions described above, but drug release capsules and the like
can also be employed.
[0122] For parenteral administration in an aqueous solution, for
example, the solution should be suitably buffered if necessary and
the liquid diluent first rendered isotonic with sufficient saline
or glucose. These particular aqueous solutions are especially
suitable for intravenous, intramuscular, subcutaneous and
intraperitoneal administration. In this connection, sterile aqueous
media which can be employed will be known to those of skill in the
art in light of the present disclosure. For example, one dosage
could be dissolved in 1 mL of isotonic NaCl solution and either
added to 1000 mL of hypodermoclysis fluid or injected at the
proposed site of infusion. Some variation in dosage will
necessarily occur depending on the condition of the subject being
treated.
[0123] The person responsible for administration will, in any
event, determine the appropriate dose for the individual subject.
The at least one isolated polypeptide of the invention may be
formulated within a therapeutic mixture to comprise about 10 to
10,000 milligrams, preferably from about 100 to 4,000 milligrams,
more preferably from about 200 to 2,000 per dose or so. Multiple
doses can also be administered.
[0124] In addition, the at least one isolated polypeptide of the
invention formulated for parenteral administration, such as
intravenous or intramuscular injection, other pharmaceutically
acceptable forms include, e.g. tablets or other solids for oral
administration; liposomal formulations; time release capsules; and
any other form currently used.
[0125] In one embodiment, the at least one isolated polypeptide of
the invention is topically administered. Examples of formulations
adapted to topical administration include, but are not limited to,
drops, solutions or topical gels.
[0126] In a preferred embodiment, the at least one isolated
polypeptide of the invention is systemically administered, such as,
for example, orally administered, intranasally administered or
injected (including, for example, intraperitoneal, intravenously or
intramuscularly injected).
[0127] The invention relates to the use of the ubiquitous
vertebrate glucose transporter GLUT1 represented by SEQ ID NO: 2,
or of fragments or sequences derived thereof, for the in vitro
diagnosis of GLUT1 related diseases, such as, for example, cancers
(when used as a tumor marker) or GLUT1 deficiency syndrome, or for
the screening of compounds useful for the preparation of drugs for
the prevention or the treatment of pathologies linked to an
infection of an individual with a primate T-lymphotropic virus
(PTLV), or pathologies linked to an overexpression or
down-expression of GLUT1 on cell surfaces, or the in vitro
detection and/or quantification of GLUT1 on cell surfaces.
[0128] The present application relates to a method for diagnosing
GLUT1 related diseases comprising: [0129] a) collecting sample from
a subject, [0130] b) determining the level of GLUT1 expression at a
cell surface using the polypeptide of the invention, [0131] c)
comparing said level to a reference value.
[0132] Examples of sample include, but are not limited to, blood,
plasma, serum, cerebrospinal fluid, saliva, lymph, ascetic fluid,
cystic fluid, urine, bile, nipple exudate, synovial fluid,
bronchoalveolar lavage fluid, sputum, amniotic fluid, chorionic
villi, peritoneal fluid, pleural fluid, pericardial fluid, semen,
saliva, sweat and alveolar macrophages.
[0133] In one embodiment, the sample collected comprises red blood
cells, preferably peripheral red blood cells.
[0134] In one embodiment, the sample collected is a drop of
blood.
[0135] Methods for determining a protein expression in a sample are
well-known in the art. Examples of such methods include, but are
not limited to, Multiplex methods (Luminex), western blot,
enzyme-linked immunosorbent assay (ELISA), flow cytometry, sandwich
ELISA, fluorescent-linked immunosorbent assay (FLISA), enzyme
immunoassay (EIA), radioimmunoassay (RIA) and the like.
[0136] As used herein, the term "reference" broadly encompasses any
suitable reference expression level which may be used as a basis
for comparison with respect to the measured expression level.
[0137] In one embodiment, the reference value is a personalized
reference, determined earlier in a sample provided by the same
subject.
[0138] In one embodiment, a reference value can be relative to an
expression value derived from population studies, including without
limitation, such subjects having similar age range, subjects in the
same or similar ethnic group, condition history and the like.
[0139] In one embodiment, the reference value is constructed using
algorithms and other methods of statistical and structural
classification.
[0140] In one embodiment of the invention, the reference value is
derived from the measurement of the expression value in a control
sample derived from one or more substantially healthy subjects,
wherein substantially healthy subjects are not affected and/or
diagnosed with the GLUT1 related disease.
[0141] In another embodiment of the invention, the reference value
is derived from the measurement of the expression value of the
GLUT1 expression in a reference sample, preferably a reference
sample, derived from a reference population.
[0142] In one embodiment, the reference population comprises
substantially healthy subjects, preferably at least 100, more
preferably at least 250, more preferably at least 500 substantially
healthy subjects.
[0143] In another embodiment, the reference population comprises
subjects having a GLUT1 related disease, preferably at least 10,
more preferably at least 20, more preferably at least 50, more
preferably at least 100, more preferably at least 250, more
preferably at least 500 subjects having a GLUT1 related
disease.
[0144] Examples of GLUT1 related diseases include but are not
limited to: Glucose transporter type 1 (GLUT1) deficiency syndrome
(DS), and cancer (such as, for example, breast cancer,
Adenocarcinoma, Squamous cell carcinoma, Hepatocellular carcinoma,
Glioblastoma, Rhabdomyosarcoma, tumor cells, lung cancer, vulvar
squamous cell carcinoma, gastric cancer, and esophageal
cancer).
[0145] Glucose transporter type 1 (GLUT1) deficiency syndrome (DS)
is characterized by an encephalopathy marked by childhood epilepsy
that is refractory to treatment, deceleration of cranial growth
leading to microcephaly, psychomotor retardation, spasticity,
ataxia, dysarthria and other paroxysmal neurological phenomena
often occurring before meals, Symptoms appear between the age of 1
and 4 months, following a normal birth and gestation. The
prevalence is unknown.
[0146] Diagnosis is based on the clinical picture and biochemical
analysis of the cerebrospinal fluid (CSF). In the majority of cases
the disease is associated with de novo mutations in the SLC2A1
gene. GLUT1 DS is transmitted as an autosomal dominant trait and in
these cases the affected parent presents with a mild form of the
disease.
[0147] The biochemical signature of GLUT1 DS is the presence of low
glucose level and low lactate concentration in the cerebrospinal
fluid (CSF) absence of hypoglycemia.
[0148] Other diseases were originally given other names and are now
recognized as variants of GLUT1 DS. These include, but are not
limited to, mitochondrial diseases, intracranial infection and
subarachnoid hemorrhage neuroblastoma because of the
opsoclonus-like eye movement abnormalities in early infancy,
infantile-onset metabolic encephalopathies, infantile-onset
seizures, developmental delay and deceleration of head growth,
including chronic hypoglycemic syndromes and disorders of amino
acid and organic acid metabolism, Rett syndrome, Angelman syndrome,
cerebral palsy.
[0149] In one embodiment of the invention, the subject is a male.
In another embodiment of the invention, the subject is a
female.
[0150] In one embodiment, the subject of the invention is a human
embryo. In another embodiment, the subject of the invention is a
human fetus. In another embodiment, the subject of the invention is
a new born child.
[0151] In one embodiment of the invention, the subject is a young
child. As used herein, the term "young child" refers to a child
from 0; 1; 2; 3; 4; 5; 6; 7; 8; 9; 10; 11 months old; 1 year old; 1
year and 3 months old; 1 year and 6 months old; 1 year and 9 months
old; 2 years; 2 years and 3 months old; 2 years and 6 months old; 2
years and 9 months old; 3 years old.
[0152] In one embodiment of the invention, the subject is a child.
The term "child" may refer to subjects aged from 0 to 12,
preferably from 3 to 12. More generally, the term child refers to a
subject which is not yet an adolescent.
[0153] In another embodiment of the invention, the subject is an
adolescent. In one embodiment, the term "adolescent" may refer to
subjects aged from about 12 to 17, but the skilled artisan will
appreciate that the length of adolescence may vary from one
individual to another.
[0154] In another embodiment, the subject is an adult. In one
embodiment, the term "adult" may refer to subjects of more than 17
years old. More generally, the term adult refers to a subject which
is no more an adolescent.
[0155] In another embodiment, the subject of the invention has risk
of developing a cancer described here above. In another embodiment,
the subject of the invention has a predisposition of developing a
cancer described here above.
[0156] In another embodiment, the subject of the invention has risk
of developing a GLUT1 DS. In another embodiment, the subject of the
invention has a predisposition of developing a GLUT1 DS. In one
embodiment, said subject presents a familial history of GLUT1
DS.
[0157] The expression "determining and/or detecting and/or
quantifying the binding of a ligand, such as, for example, a
receptor binding domain ligand, to GLUT1" means that when GLUT1 is
present a complex is formed between GLUTI and the ligand. This
complex can be detected if the ligand has been for example, but not
limited to, covalently coupled with a detectable molecule such as
an antibody constant fragment (Fc) or a fluorescent ligand (e.g.
Cyanine dye, Alexa dye, Quantum dye, etc). The complex can also be
detected if the ligand has been tagged with different means well
known to the person skilled in the art. For example, but without
limitation, a tag used with the invention can be a tag selected
from the group comprising or consisting of fluorescent proteins
such as GFP, Hemaglutinin Tag, Poly Arginine Tag, Poly Histidine
Tage, Myc Tag, Strep Tag, S-Tag, HAT Tag, 3.times. Flag Tag,
Calmodulin-binding peptide Tag, SBP Tag, Chitin binding domain Tag,
GST Tag, Maltose-Binding protein Tag, Fluorescent Protein Tag, T7
Tag, V5 Tag and Xpress Tag.
[0158] In one embodiment, determining and/or detecting and/or
quantifying binding is conducted by flow cytometry,
immunofluorescence or image analysis, for example high content
analysis.
[0159] For illustration purpose, the polypeptide of the invention
can be selected for its ability to bind specifically to said GLUT1,
or fragments of GLUT1, according to the following method using a
EGFP-tagged. GLUT1-binding component derived from PTLV RBD
(receptor binding domain) as an example of such polypeptide that is
able to bind to GLUT1.
[0160] A EGFP-tagged Glut 1-binding component derived from PTLV RBD
is applied onto live or fixed suspension or attached cells. After
washes with appropriate buffer, cells are incubated for 30 min at
RT, washed and analyzed or quantified as attached on an appropriate
support on a fluorescent microscope or as individual cell
suspension on a fluorescent analysis cell sorter (FACS).
Alternatively, a non-fluorescent GLUT1-binding component derived
from PTLV RBD is applied as described above and revealed with a
secondary fluorochrome-tagged reagent such as a fluorochrome-tagged
secondary antibody directed against the PTLV RBD or against a non
fluorochrome tag attached to the said PTLV RBD component.
[0161] The invention relates more particularly to the use as
defined above, of fragments of GLUT1 chosen among the
followings:
TABLE-US-00001 SEQ ID NO: 35 NAPQKVIEEFY SEQ ID NO: 36
NQTWVHRYGESILPTTLTTLWS SEQ ID NO: 37 KSFEMLILGR SEQ ID NO: 38
DSIMGNKDL SEQ ID NO: 39 YSTSIFEKAGVQQP SEQ ID NO: 40 EQLPWMSYLS SEQ
ID NO: 41 QYVEQLC SEQ ID NO: 42 IVGMCFQYVEQLC
[0162] These fragments of GLUT1 correspond to the predicted
extracellular loops of human GLUT1 as described by Mueckler, M.,
and C. Makepeace. 1997. Identification of an amino acid residue
that lies between the exofacial vestibule and exofacial
substrate-binding site of the GLUT1 sugar permeation pathway. J
Biol Chem. 272(48):30141-6.
[0163] The invention also relates to the use of an isolated
polypeptide of the invention, for the preparation of drugs for the
prevention or the treatment of pathologies linked to an
overexpression of GLUT1 on cell surfaces, such as: [0164] cancers,
such as: [0165] squamous cell carcinoma (Kunkel M, Reichert T E,
Benz P, Lehr H A, Jeong J H, Wieand S, Bartenstein P, Wagner W,
Whiteside T L. Cancer. 2003 Feb. 15; 97(4):1015-24), [0166]
hypopharyngeal carcinoma (Mineta, Miura K, Takebayashi S, Misawa K,
Araki K, Misawa Y, Ueda. Y. Anticancer Res. 2002 November-December;
22(6B):3489-94), [0167] breast cancer (Brown R S, Wahl R L.
Overexpression of Glut-1 glucose transporter in human breast
cancer. An immunohistochemical study. Cancer. 1993 Nov. 15;
72(10):2979-85), [0168] cervical carcinoma (Mendez L E, Manci N,
Cantuaria G, Gomez-Marin O, Penalver M, Braunschweiger P, Nadji M.
Expression of glucose transporter-1 in cervical cancer and its
precursors. Gynecol Oncol. 2002 August; 86(2):138-43), [0169]
ovarian carcinoma (Cantuaria G, Fagotti A, Ferrandina G, Magalhaes
A, Nadji N I, Angioli R, Penalver M, Mancuso S, Scambia G. GLUT-1
expression in ovarian carcinoma: association with survival and
response to chemotherapy. Cancer. 2001 Sep. 1; 92(5): 1144-50),
[0170] lung cancer (Ito T, Noguchi Y, Satoh S., Hayashi H, Inayama
Y, Kitamura H. Expression of facilitative glucose transporter
isoforms in lung carcinomas: its relation to histologic type,
differentiation grade, and tumor stage. Mod Pathol. 1998 May;
11(5):437-43. Younes M, Brown R W, Stephenson M, Gondo M, Cagle P
T. Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung
carcinoma is associated with poor survival. Cancer. 1997 Sep. 15;
80(6):1046-51), [0171] pancreatic cancer (Reske S N, Grillenberger
K G, Glatting G, Port M, Hildebrandt M, Gansauge F, Beger H G.
Overexpression of glucose transporter 1 and increased FDG uptake in
pancreatic carcinoma. J Nucl Med. 1997 September; 38(9):1344-8),
[0172] insulinoma (1: Boden G, Murer E, Mozzoli M. Glucose
transporter proteins in human insulinoma. Ann Intern Med. 1994 Jul.
15 ;121(2):109-12, [0173] inflammatory conditions, [0174] immune or
auto-immune diseases, such as: [0175] autoimmune myocarditis
(Tokita N, Hasegawa S, Tsujimura E, Yutani K, Izumi T, Nishimura T.
Serial changes in 14C-deoxyglucose and 201T1 uptake in autoimmune
myocarditis in rats. J Nucl Med. 2001 February; 42(2):285-91),
[0176] in the frame of CD28 T-cell activation (Frauwirth K A, Riley
J L, Harris M H, Parry R V, Rathmell J C, Plas D R, Elstrom R L,
June C H, Thompson C B. The CD28 signaling pathway regulates
glucose metabolism. Immunity. 2002 June; 16(6):769-77), [0177] in
the frame of immunomodulation (Moriguchi S, Kato M, Sakai K,
Yamamoto S, Shimizu E. Decreased mitogen response of splenic
lymphocytes in obese Zucker rats is associated with the decreased
expression of glucose transporter 1 (GLUT-1). Am J Clin Nutr. 1998
June; 67(6):1124-9), [0178] Disorders of the central nervous
system, such as facilitated glucose transporter protein type 1
(GLUT1) deficiency syndrome (review in Keppler J, Voit T, Eur J
Pediatr. 2002 June; 161(6):295-304.)
[0179] The invention relates more particularly to the use for the
preparation of drugs for the prevention or the treatment of
pathologies linked to an overexpression of GLUT1 on cell surfaces,
of compounds chosen among the followings: [0180] polypeptides
compounds corresponding to the envelope proteins of PTLV, or
fragments or sequences derived thereof, said fragments or derived
sequences being able to bind to GLUT1. [0181] glucose or
derivatives such as galactose, 2-fluorodeoxyglucose,
2-deoxyglucose, 3-O-methylglucose [0182] androgenic steroids,
cytochalasin B, forskolin, dipyridamole, isobutylmethylxanthine,
ethanol, genistein, cadmium, barbiturate, dehydroascorbic acid,
tricyclic antidepressants, oestradiol, anti-oestrogens, faslodex
(ICI 182780), tamoxifen, gamma agonists of peroxisome
proliferator-activated receptors (PPAR) such as thiazolidinedione,
troglitazone, pioglitazone, rosiglitazone, as mentioned above.
[0183] The invention relates more particularly to the use of
polypeptides corresponding to the envelope proteins of PTLV, or
fragments or sequences derived thereof, said polypeptides being
selected for their ability to bind specifically to the ubiquitous
vertebrate glucose transporter GLUT1 represented by SEQ ID NO: 2,
or of nucleotide sequences encoding said polypeptides, for the
preparation of drugs for the prevention or the treatment of
pathologies linked to an overexpression of GLUT1 on cell surfaces,
and the in vitro diagnosis of said pathologies.
[0184] The invention relates more particularly to the use as
defined above, of polypeptides able to bind to at least one of the
above mentioned fragments of GLUT1 corresponding to SEQ ID NO: 35,
SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID
NO: 40, SEQ ID NO: 41, and SEQ ID NO: 42.
[0185] The invention relates more particularly to the use as
defined above, of polypeptides able to bind to at least the
fragment of GLUT1 corresponding to SEQ ID NO: 42.
[0186] The invention relates more particularly to the use as
defined above, of GLUT1 binding polypeptides mentioned above chosen
among the followings: [0187] the envelope protein of HTLV-1 set
forth by SEQ ID NO: 9, or of HTLV-2 forth by SEQ ID NO: 43, or of
HTLV-3 forth by SEQ ID NO: 53, or of HTLV-4 forth by SEQ ID NO: 22,
or of HTLV-4 forth by SEQ ID NO: 51 or of STLV-1 forth by SEQ ID
NO: 25, or of STLV-2 forth by SEQ ID NO: 27, or of STLV-3 forth by
SEQ ID NO: 29, or of STLV-3 forth by SEQ ID NO: 55, [0188]
fragments of the envelope proteins of PTLV, said fragments being
polypeptides delimited in their N-terminal extremity by the amino
acid located in position 1 to 90, or in position 75 to 90, and in
their C-terminal extremity by the amino acid located in position
135 to 245, or in position 135 to 150, of said envelope proteins of
PTLV, forth by SEQ ID NO: 43, 9, 25, 27, 29, 23, [0189] sequences
of HTLV-1.RBD set forth by SEQ ID NO: 9, 10, 11, 13, 15, 17, 19 or
21, or of HTLV-2.RBD set forth by SEQ ID NO: 4, 5, 7, 9 or 43, or
of HTLV-3.RBD set forth by SEQ ID NO: 53, or of HTLV-4.RBD set
forth by SEQ ID NO: 22 or 51, or of STLV-set forth by SEQ ID NO:
25, or of STLV-2.RBD set forth by SEQ ID NO: 27, or of STLV-3.RBD
forth by SEQ ID NO: 29 or 55, [0190] fragments of the envelope
proteins of PTLV, said fragments corresponding to the following
polypeptides [0191] the polypeptide delimited in its N-terminal
extremity by the amino acid located in position 83 to 89, and in
its C-terminal extremity by the amino acid located in position 139
to 145, of the envelope protein of the strain MT-2 of HTLV-1 forth
by SEQ ID NO: 9, [0192] the polypeptide delimited in its N-terminal
extremity by the amino acid located in position 79 to 85, and in
its C-terminal extremity by the amino acid located in position 135
to 141, of the envelope protein of the strain NRA of HTLV-2 forth
by SEQ ID NO: 43, [0193] the polypeptide delimited in its
N-terminal extremity by the amino acid located in position 83 to
89, and in its C-terminal extremity by the amino acid located in
position 139 to 145, of the envelope protein of STLV-1 forth by SEQ
ID NO: 25, [0194] the polypeptide delimited in its N-terminal
extremity by the amino acid located in position 79 to 85, and in
its C-terminal extremity by the amino acid located in position 135
to 141, of the envelope protein of STLV-2 forth by SEQ ID NO: 27,
[0195] the polypeptide delimited in its N-terminal extremity by the
amino acid located in position 82 to 88, and in its C-terminal
extremity by the amino acid located in position 138 to 144, of the
envelope protein of STLV-3 forth by SEQ ID NO: 29, [0196] the
polypeptide corresponding to the envelope protein of a variant of
HTLV-1, said polypeptide having the following sequence SEQ ID NO:
13,
TABLE-US-00002 [0196] I K K P N P N G G G Y Y L A S Y S D P C S L K
C P Y L G C Q S W T C P Y T G A V S S P Y K F Q Q D V
the polypeptide corresponding to the envelope protein of a variant
of HTLV-1, said polypeptide having the following sequence SEQ ID
NO: 15,
TABLE-US-00003 V K K P N R N G G G Y Y L A S Y S D P C S L K C P Y
L G C Q S W T C P Y T G A V S S P Y W K F Q Q D V
the polypeptide corresponding to the envelope protein of a variant
of HTLV-1, said polypeptide having the following sequence SEQ ID
NO: 17,
TABLE-US-00004 I K K P N R N G G G Y Y L A S Y S D P C S L K C P Y
L G C Q S W T C P Y T G A V S S P Y W K F Q Q D V
the polypeptide corresponding to the envelope protein of a variant
of HTLV-1, said polypeptide having the following sequence SEQ ID
NO: 19,
TABLE-US-00005 I K K P N R N G G G Y Y L A S Y S D P C S L K C P Y
L G C Q S W T C P Y T G P V S S P Y W K F Q Q D V
the polypeptide corresponding to the envelope protein of a variant
of HTLV-1, said polypeptide having the following sequence SEQ ID
NO: 21,
TABLE-US-00006 I K K P N R N G G G Y H S A S Y S D P C S L K C P Y
L G C Q S W T C P Y A G A V S S P Y W K F Q Q D V N F T Q E V
the polypeptide corresponding to the envelope protein of a variant
of HTLV-2, said polypeptide having the following sequence SEQ ID
NO: 7,
TABLE-US-00007 I R K P N R Q G L G Y Y S P S Y N D P C S L Q C P Y
L G S Q S W T C P Y T A P V S T P S W N F H S D V.
[0197] The invention relates more particularly to the use of
mentioned above of GLUT1 binding polypeptides as defined above,
characterized in that the treated or detected pathologies are the
followings: [0198] solid tumors, such as brain tumors, squamous
cell carcinoma, hypopharyngeal carcinoma, breast cancer, cervical
carcinoma, ovarian carcinoma, pancreatic cancer, insulinoma, [0199]
inflammatory conditions, such as multiple sclerosis, rhumatoid
arthritis, [0200] immune or auto-immune diseases, such as
autoimmune myocarditis, or in the frame of CD28 T-cell activation,
or in the frame of immunomodulation, or systemic lupus
erythematous, [0201] disorders of the central nervous system, such
as facilitated glucose transporter protein type 1 (GLUT1)
deficiency syndrome.
[0202] The invention relates more particularly to the use of
polypeptides selected for their ability to bind specifically to
GLUT1 as mentioned above, and more particularly GLUT1 binding
polypeptides as defined above, for the in vitro detection of GLUT1
on cell surfaces in the frame of processes for the in vitro
diagnosis of pathologies linked to an overexpression or
down-expression of GLUT1 on cell surfaces, such as pathologies
defined above, said processes comprising the following steps:
[0203] contacting a biological sample (such as biopsies or cells or
tissue manifesting or with a suspected aberrant GLUT1 expression
profile) from an individual with at least one polypeptide of the
invention, said at least one polypeptide being optionally labeled,
or susceptible to be recognized by a labeled molecule, [0204]
determining the level of said at least one polypeptide hound to the
cells contained in the biological sample and comparison with the
level of binding of said compound to cells contained in the
biological sample from an healthy individual.
[0205] The invention relates more particularly to the use of
polypeptides as defined above for the in vitro diagnosis of cancers
or of GLUT1 DS, characterized in that the polypeptides used are
chosen among the polypeptides defined above selected for their
ability to bind specifically to GLUT1.
[0206] The invention relates more particularly to the use as
defined above, of GLUT1 binding polypeptides, or of nucleotide
sequences encoding said polypeptides, for the preparation of drug
vectors containing at their surface said polypeptides, said vectors
being useful for targeting GLUT1 overexpressing cells for the
prevention or the treatment of pathologies linked to an
overexpression of GLUT1 on cell surfaces, said vectors containing
molecules active against said pathologies, or containing genes in
the frame of gene therapy of these pathologies.
[0207] The invention relates more particularly to the use as
defined above, of GLUT1 binding polypeptides, or of nucleotide
sequences encoding said polypeptides, for the preparation of drug
vectors containing at their surface GLUT1 binding polypeptides,
said vectors being useful for targeting GLUT1 overexpressing tumor
cells, or cells involved in the inflammatory mechanism, or
activated cells of the immune system, or cells of the central
nervous system, for the prevention or the treatment of related
pathologies as defined above.
[0208] The invention concerns more particularly the use of GLUT1
binding polypeptides, or of nucleotide sequences encoding said
polypeptides, for the preparation of drug vectors as defined above,
wherein the molecules active against the pathologies are antitumor
molecules, or molecules against inflammatory conditions, immune or
auto-immune diseases, or disorders of the central nervous
system.
[0209] The invention also relates to the use of nucleotide
sequences encoding polypeptides compounds selected for their
ability to bind specifically to GLUT1 as defined above, such as
nucleotide sequences encoding the polypeptides defined above, or
fragments thereof, for the preparation, by substitution of one or
several nucleotides of said nucleotide sequences, of mutant
nucleotide sequences encoding corresponding mutant polypeptides
unable to bind to GLUT1.
[0210] The invention also relates to the use of mutant polypeptides
unable to bind to GLUT1 as defined above: [0211] as a negative
control in the frame of the screening of compounds able to bind
specifically to the non mutated corresponding polypeptides, and
thus liable to be used in the frame of the preparation of drugs for
the prevention or the treatment of pathologies linked to an
infection of an individual with a PTLV, [0212] for the preparation
of drugs for the prevention or the treatment of pathologies linked
to an infection of an individual with a PTLV.
[0213] The invention relates more particularly to the use as
defined above, of mutant polypeptides corresponding to the
polypeptides defined above, wherein: [0214] D in position 106
and/or Y in position 114 of the envelope protein of HTLV-1
corresponding to SEQ ID NO: 9, [0215] D in position 102 and/or Y in
position 110 or of HTLV-2 corresponding to SEQ ID NO: 43, [0216] D
in position 106 and/or Y in position 114 or of STLV-1 corresponding
to SEQ ID NO: 25, [0217] D in position 102 and/or Y in position 110
or of STLV-2 corresponding to SEQ ID NO: 27, [0218] D in position
105 and/or Y in position 113 or of STLV-3 corresponding to SEQ ID
NO: 29, [0219] D in position 18 and/or Y in position 26 of the
polypeptides corresponding to SEQ ID NO: 13, 15, 17, 19, 21, and 7,
are substituted by another amino acid, natural or not, such as
mutant polypeptides corresponding to the polypeptides mentioned
above wherein said D and/or A residues are substituted by A.
[0220] The invention also relates to the use of mutant nucleotide
sequences encoding corresponding mutant polypeptides unable to bind
to GLUT1 as defined above, for the preparation of transgenic mammal
cells expressing said mutant polypeptides, said cells having a
negative transdominant effect with regard to PTLV, thus preventing
infection and dissemination of this latter in the organism.
[0221] The invention also relates to pharmaceutical compositions
containing GLUT1 represented by SEQ ID NO: 2, or fragments or
sequences derived thereof, said fragments or derived sequences
being able to bind to the envelope proteins of the primate T-cell
leukemia viruses (PTLV), in association with a pharmaceutically
acceptable carrier.
[0222] The invention relates more particularly to pharmaceutical
compositions containing mutant polypeptides corresponding to the
polypeptides defined above, wherein: [0223] D in position 106
and/or Y in position 114 of the envelope protein of HTLV-1
corresponding to SEQ ID NO: 9, [0224] D in position 102 and/or Y in
position 110 or of HTLV-2 corresponding to SEQ ID NO: 7, [0225] D
in position 105 and/or Y in position 113 or of STLV-3 corresponding
to SEQ ID NO: 29, [0226] D in position 18 and/or Y in position 26,
of the polypeptides corresponding to SEQ ID NO: 13, 15, 17, 19, 21,
and 7, are substituted by another amino acid, natural or not, such
as mutant polypeptides corresponding to the polypeptides mentioned
above wherein said D and/or A residues are substituted by A, in
association with a pharmaceutically acceptable carrier.
[0227] The invention also relates to transgenic mammal cells
expressing mutant polypeptides unable to bind to GLUT1 as defined
above, said cells having a negative transdominant effect with
regard to PTLV, thus preventing infection and dissemination of this
latter in the organism.
[0228] The invention relates more particularly to pharmaceutical
compositions containing transgenic mammal cells as defined above,
in association with a pharmaceutically acceptable carrier.
[0229] The invention also relates to therapeutic vectors useful for
targeting GLUT1 overexpressing cells in pathologies linked to an
overexpression of GLUT1 on cell surfaces, such as defined above,
said vectors containing at their surface GLUT1 binding polypeptides
chosen among those defined above, and containing molecules active
against said pathologies, as defined above, or containing genes in
the frame of gene therapy.
[0230] The invention relates more particularly to pharmaceutical
compositions containing therapeutic vectors as described above, in
association with a pharmaceutically acceptable carrier.
[0231] The invention also relates to a method for the screening of
compounds useful for: [0232] the preparation of drugs for the
prevention or the treatment of pathologies linked to an infection
of an individual with a PTLV, [0233] the preparation of drugs for
the prevention or the treatment of pathologies linked to an
overexpression or to a down-expression of GLUTI on cell surfaces,
[0234] the in vitro detection of GLUT1 on cell surfaces, said
method comprising: the contacting of GLUT1 represented by SEQ ID
NO: 2, or of fragments or sequences derived thereof, said fragments
or derived sequences being able to bind to the envelope proteins of
the primate T-cell leukemia viruses (PTLV), or of cells expressing
GLUT1, with compounds to be tested, the selection of compounds able
to bind specifically to GLUT1, or fragments or sequences derived
thereof, as for example according to the method mentioned
above.
[0235] The invention relates more particularly to a method for the
screening of compounds useful for the prevention or the treatment
of pathologies linked to an overexpression of GLUT1 on cell
surfaces, and the in vitro diagnosis of said pathologies,
comprising the steps described above:
[0236] The invention also relates to a method for the in vitro
diagnosis pathologies linked to an overexpression of GLUT1 on cell
surfaces, characterized in that it comprises: [0237] contacting a
biological sample (such as biopsies or cells or tissue manifesting
or with a suspected aberrant GLUT1 expression profile) from an
individual with at least one polypeptide of the invention, said at
least one polypeptide being optionally labeled, or susceptible to
be recognized by a labeled molecule, [0238] determining the level
of said at least one polypeptide bound to the cells contained in
the biological sample and comparison with the level of binding of
said at least one polypeptide to cells contained in the biological
sample from an healthy individual.
[0239] The invention also relates to a method for the in vitro
diagnosis pathologies linked to a down-expression of GLUT1 on cell
surfaces (such as, for example, GLUT1 DS), characterized in that it
comprises: [0240] contacting a biological sample (such as biopsies
or cells or tissue manifesting or with a suspected aberrant GLUT1
expression profile) from an individual with at least one
polypeptide of the invention, said at least one polypeptide being
optionally labeled, or susceptible to be recognized by a labeled
molecule, [0241] determining the level of said at least one
polypeptide hound to the cells contained in the biological sample
and comparison with the level of binding of said at least one
polypeptide to cells contained in the sample from an healthy
individual.
[0242] The invention relates more particularly to a method as
defined above for the in vitro diagnosis of pathologies mentioned
above.
[0243] The invention also relates to a kit for research use or for
in vitro diagnosis, such as for example in vitro diagnosis of
pathologies linked to an overexpression of GLUT1 on cell surfaces
as described above, comprising at least one polypeptide of the
invention as defined above, said at least one polypeptide being
optionally labeled, and, if necessary reagents for the detection of
the binding of said at least one polypeptide to GLUT1 initially
present on cell surfaces in the biological sample.
[0244] The invention also relates to a kit for the in vitro
diagnosis of pathologies linked to an down-expression of GLUT1 on
cell surfaces as described above, comprising at least one
polypeptide of the invention as defined above, said at least one
polypeptide being optionally labeled, and, if necessary reagents
for the detection of the binding of said at least one polypeptide
to GLUT1 initially present on cell surfaces in the biological
sample.
[0245] The present invention also relates to a kit of parts for
detecting and/or determining the expression level of GLUT1 nutrient
transporter on the cell surface, comprising at least one
polypeptide of the invention.
[0246] The present invention also relates to a kit of parts for
detecting and/or quantifying the binding of the RBD ligand of the
present invention to GLUT1 nutrient transporter, comprising at
least one polypeptide of the invention.
[0247] In one embodiment, the expression level of GLUT1 nutrient
transporter is assessed at the protein level, and the kit of the
invention may further comprises means for detecting the expression
level of at least one normalization protein.
[0248] The present invention also relates to a kit of parts for
diagnosing a disease related to GLUT1, comprising at least one
polypeptide of the invention or a composition comprising at least
one polypeptide of the invention.
[0249] In one embodiment, the kit comprises other elements, such
as, for example, instructions for use; vials, containers or other
storage vessels containing each of the unit doses; delivery devices
such as needles, catheters, syringes, tubing and the like; and/or
packaging suitable for safely and conveniently storing and/or
transporting the kit. Preferably the instructions for use are a
label or package insert, wherein the label or package insert
indicates that the composition of the invention.
[0250] A "package insert" refers to instructions included in
commercial packages of the compositions, that contains information
about the indications, usage, dosage, administration,
contraindications and/or warnings concerning the use of such
compositions.
[0251] For the purposes herein, a "vial" refers to a container
which holds the composition of the invention. The vial may be
sealed by a stopper pierceable by a syringe. Generally, the vial is
formed from a glass material.
[0252] The composition in the vial can be in various states
including liquid, lyophilized, frozen etc. The fixed dosage
composition is preferably stable as a liquid. Stability may be
measured by any means known in the art, although turbidity is a
preferred measure. Turbidity level of below about 10, 15, 20, or 30
Nephelometric Turbidity Unit (NTU) can generally be considered a
stable fixed dosage composition. Turbidity measurements can be
taken by incubating the fixed dosage compositions over time periods
such as 0 h, 2 h, 4h, 6 h, 12 h, 18 h, 24 h, 36 h, 72 h, 7 days and
14 days at storage temperatures such as room temperature or
37.degree. C. Preferably the fixed dosage composition is considered
to be stable as a liquid when it is stored for 14 days at room
temperature and exhibits a turbidity of less than about 15 NTU.
[0253] The invention is further illustrated with the detailed
description hereafter of the determination of GLUT1 as a specific
receptor for PTLV RBD.
[0254] The human T-cell leukemia virus (HTLV) type 1 and 2 are
present in all areas of the world as endemic or sporadic infectious
agents [Slattery, 1999]. The etiological role of HTLV-1 in adult T
cell leukemia (ATL) and tropical spastic
paraparesis/HTLV-associated myelopathy (TSP/HAM) has been well
established [Poiesz, 1980; Yoshida, 1982; Gessain, 1985; Osame,
1986]. The apparently restricted tropism of HTLV to T lymphocytes
in infected patients [Cavrois, 1996; Hanon, 2000] contrasts with
the ability of the viral-encoded envelope glycoprotein (Env) to
bind to and direct entry into all vertebrate cell types tested in
vitro [Sutton, 1996; Trejo, 2000; Kim, 2003]. Retroviral infections
depend on early interactions between Env and cellular receptors.
Identification of cellular receptors and coreceptors for other
retroviral envelopes have helped to elucidate certain aspects of
retrovirus physiopathology as well as their transmission and
spreading within organisms and populations [Berger, 1999; Clapham,
2001; Weiss, 2002]. However, no clear association between HTLV Env
and HTLV-associated diseases has been established and the identity
of the receptor(s) for HTLV-1 and HTLV-2 Env has remained
elusive.
[0255] Numerous cell surface components have been shown to play a
role in HTLV Env-mediated syncytia formation [Niyogi, 2001; Daenke,
1999; Hildreth, 1997]. Nevertheless, HTLV Env-dependent cell
membrane fusion and syncytia formation appear to be distinct from
receptor binding per se [Denesvre, 1996; Daenke, 2000; Kim, 2000;
Kim, 2003]. The search for HTLV Env receptor has been hindered in
part by its ubiquitous presence [Sutton, 1996; Trejo, 2000; Jassal,
2001; Kim, 2003]. Additionally, the induction of rampant syncytium
formation in cell culture upon expression of HTLV Env [Hoshino,
1983; Nagy, 1983] has prevented efficient and persistent Env
expression. Based on our observation that the HTLV Env amino
terminal domain shares striking structural and functional homology
with that of murine leukemia viruses (MLV), we defined HTLV Env
receptor-binding domain (RBD) and derived HTLV Env-based tools that
overcome the problem of syncytia formation [Kim, 2000; Kim, 2003].
We were thus able to follow specific interactions between the Env
RBD and a primary HTLV receptor. Using these tools, we have
previously shown that the HTLV receptor is expressed on the surface
on T lymphocytes, the major HTLV reservoir in vivo, only following
T cell receptor activation [Manel, 2003].
[0256] Here we describe striking metabolic alterations in cell
cultures following expression of HTLV envelopes as well as HTLV
receptor binding domains. These alterations are characterized by a
defect in the acidification of the cell culture medium associated
with a decreased lactate production and a decline in glucose
consumption and uptake. These observations as well as the knowledge
that Env receptors for the related MLV and most of the
gammaretrovirus belong to the family of multiple-membrane spanning
transporters [Overbaugh, 2001] prompted us to test ubiquitous
lactate and glucose transport-associated molecules as receptors for
HTLV Env. We show that the ubiquitous GLUT-1 glucose transporter,
present in all vertebrates, is an essential and specific component
of the receptor for HTLV. Moreover, interaction of GLUT-1 with the
entire HTLV-1 and HTLV-2 envelopes as well as the truncated HTLV-1
and HTLV-2 RBDs alters glucose metabolism.
BRIEF DESCRIPTION OF THE DRAWINGS
[0257] FIGS. 1a-1d Expression of the HTLV receptor-binding domain
alters cellular metabolism.
[0258] FIG. 1a, Medium acidification and syncytia formation in 293T
cells one day post-transfection with control DNA or Env expression
vectors, including syncytial wild-type HTLV-1 Env and HTLV-2 Env, a
non-syncytial chimeric H.sub.183FEnv, and syncytial A-MLV .DELTA.R
Env.
[0259] FIG. 1b, Extracellular lactate and glucose in the culture
medium of 293T cells were measured two days following transfection
with an irrelevant DNA (control), F-MLV Env, H.sub.183FEnv, HTLV-1
RBD (H1.sub.RBD) or amphotropic MLV RBD (A.sub.RBD) expression
vectors. Lactate and glucose concentrations were normalized to
cellular protein content.
[0260] FIG. 1c, 2-deoxyglucose and fructose uptake following
transfection of 293T with an irrelevant DNA (control), H1.sub.RBD,
H2.sub.RBD or A.sub.RBD expression vectors. Control cells were also
incubated with glucose transporter inhibitors cytochalasin and
phloretin. Data are the means of triplicate measures and are
representative of two to three independent experiments.
[0261] FIG. 1d, Expression of the HTLV and amphotropic-MLV
receptors on 293T (1) and Jurkat T (2) cells cultured overnight in
the presence or absence of glucose was monitored by binding of
H1.sub.RBD and A.sub.RBD, respectively.
[0262] FIGS. 2a and 2b HTLV receptor properties correlate with
GLUT1 properties.
[0263] FIG. 2a, Expression of the HTLV and amphotropic-MLV
receptors at the surface of human and murine erythrocytes, as well
as human primary hepatocytes.
[0264] FIG. 2b, H1.sub.RBD and A.sub.RBD binding to Jurkat cells in
the absence or presence of the Glut-1 inhibitor cytochalasin B.
[0265] FIGS. 3a-3c HTLV receptor-binding correlates with altered
lactate metabolism.
[0266] FIG. 3a, Expression of H1.sub.RBD and the derived mutants
D106A and Y114A was monitored by Western blot analysis of the
supernatants of 293T cells following transfection with the various
expression plasmids.
[0267] FIG. 3b, Binding of H1.sub.RBD and the D106A and Y114A
mutants to the HTLV receptor on HeLa cells.
[0268] FIG. 3c, Extracellular lactate in the medium of 293T cells
one day post transfection with an irrelevant DNA (control),
H1.sub.RBD or the H1.sub.RBD D106A and Y114A mutants. Data are
representative of three independent experiments.
[0269] FIGS. 4a-4c GLUT-1 is a receptor for HTLV envelopes.
[0270] FIG. 4a, Binding of H1.sub.RBD, H2.sub.RBD, H2.sub.RBD D102A
mutant, and A.sub.RBD to control 293T cells or 293T cells
overexpressing either GLUT-1 or PiT2.
[0271] FIG. 4b, Binding of H2.sub.RBD-EGFP to cells overexpressing
GLUT-1-HA or GLUT-3-HA, and corresponding immunoblots using an
anti-HA antibody.
[0272] FIG. 4c, Immunoprecipitation of GLUT-1-HA from 293T cells
transfected with either an irrelevant construct, GLUT-1 alone,
H1RBD alone, H1RBD Y114A alone, GLUT-1 with H1.sub.RBD or GLUT-1
with H1.sub.RBD Y114A expression vectors. Immunoprecipitation was
performed using anti-rabbit-Pc beads and probed with an anti-HA
antibody. Total cell extracts were blotted using an anti-rabbit Fc
or an anti-HA antibody.
[0273] FIG. 5 GLUT-1 is an entry receptor for HTLV. Infections
titer of MLV particles pseudotypes with HTLV-2 or A-MLV envelopes
on 293T cells following transfection of an irrelevant or
interfering H2.sub.RBD expression vectors alone or in addition to
GLUT-1, GLUT-3 or Pit2 expression vectors.
[0274] FIG. 6 represents a schematic diagram of the HTLV-1 envelope
glycoprotein (Env). Mature Env is constituted of two subunits
formed after cleavage of the amino terminal signal peptide (SP) and
cleavage of the Env polyprotein precursor into the extracellular SU
and the membrane-anchored TM. SU comprises three distinct
subdomains: an amino terminal receptor-binding domain (RBD), a
central proline-rich region (PRR) and a carboxy terminal domain
(C-term).
EXAMPLES
[0275] The present invention is further illustrated by the
following examples.
Example 1
HTLV Envelopes Alter Lactate Metabolism
[0276] Cell proliferation in standard culture media is accompanied
by acidification of the milieu that translates into a color change
from red to yellow tones in the presence of the phenol-red pH
indicator. Upon transfection of either highly syncytial HTLV-1 and
HTLV-2 envelopes, or a non-syncytial chimeric envelope that harbors
the HTLV-1 RBD in a MLV Env backbone (H.sub.183FEnv), culture
medium did not readily acidify, and harbored red tones for several
days post-transfection (FIG. 1a). Moreover, expression of truncated
soluble HTLV RBD proteins fused with either GFP, -HA, or -rFc tags
also inhibited medium acidification. In contrast, no envelope
construct that lacked HTLV RBD, including different MLV group
envelopes, feline, porcine, lentiviral and Jaagsiekte retroviral
Envs, as well as VSV-G and Ebola glycoproteins, had this effect.
The lack of acidification associated with HTLV-1 or HTLV-2 Env
expression was not an indirect consequence of their syncytial
activity, since (i) medium acidification was observed in cells
expressing a syncytial amphotropic-MLV Env (A-MLV devoid of the R
peptide) (FIG. 1a) and (ii) medium acidification was blocked when
HTLV Env was expressed in cells that are resistant to HTLV-Env
mediated syncytia formation (NIH3T3 TK.sup.- cells)[Kim, 2003].
[0277] Decrease of pH in cell culture is primarily due to
extracellular accumulation of lactate [Warburg, 1956]. Lactate is
the major byproduct of anaerobic glycolysis in vitro and its
excretion is mediated by an H+/lactate symporter [Halestrap, 1999],
We monitored lactate content in culture supernatants following
transfection of various retroviral envelopes and RBD. Lactate
accumulation was consistently 3-fold lower in H.sub.183FEnv- and
HTLV RBD-transfected cells than in control- or MLV Env-transfected
cells (FIG. 1b). This decrease in extracellular glucose and
fructose accumulation after HTLV RBD transfection was DNA
dose-dependent. Moreover, we found that the decrease in glucose and
fructose accumulation following transfection of HTLV RBD was
apparent as early as 4 hours after the addition of fresh media
(FIG. 1e).
Example 2
Receptor Binding and Lactate Metabolism
[0278] To examine whether a direct relationship exists between
binding of the HTLV envelope receptor and diminished extracellular
acidification and lactate accumulation, we attempted to generate
HTLV-1 RBD (H1.sub.RBD) mutants with impaired receptor binding
capacities. To this end, mutations resulting in single alanine
substitutions were introduced at two different positions in
H1.sub.RBD, D106 and Y114 which are highly conserved among primate
T-lymphotropic viruses. Although both D106A and Y114A RBD mutants
were expressed and secreted as efficiently as the wild-type
H1.sub.RBD (FIG. 3a), they exhibited significantly reduced (D106A)
or non-detectable (Y114A) binding to the HTLV receptor as detected
by FACS analysis (FIG. 3b). Moreover, perturbations in lactate
metabolism correlated with binding to the HTLV receptor: lactate
accumulation was not reduced in cells expressing the non-binding
Y114A RBD mutant and was minimally reduced in cells harboring the
D106 RBD (FIG. 3c). Similar results were obtained with H2.sub.RBD
harboring the same allelic mutations. These data favor a direct
association between lactate-related metabolic alterations and HTLV
Env receptor binding.
[0279] Extracellular lactate accumulates in cell cultures following
its transport across cellular membranes by the MCT1 monocarboxylate
transporter [Garcia, 1994]. Because HTLV and MLV share a common
organization of the extracellular envelope [Kim, 2000]and the
receptors for MLV Env are multispanning metabolite transporters
[Overbaugh, 2001], we assessed whether the HTLV RBD bound to MCT1.
Moreover, similar to our previous data concerning expression of the
HTLV receptor on T cells [Manel, 2003], expression of MCT1
chaperone CD147 [Kirk, 2000] increases during T cell activation
[Kasinrerk, 1992]. However, separate and combined overexpression of
MCT1 and CD147 did not result in increased H1.sub.RBD binding,
arguing against a role for these molecules as receptors for HTLV
Env.
Example 3
HTLV Receptor and Glucose Metabolism
[0280] In addition to a decrease in extracellular lactate
accumulation, expression of the HTLV RBD also led to decreased
intracellular lactate content, indicative of metabolic alterations
upstream of lactate transport. In cell cultures, lactate
accumulation results from the degradation of glucose during
anaerobic glycolysis. Therefore, we assessed whether the decreased
accumulation of lactate observed upon expression of HTLV RBD was
linked to glucose metabolism. We measured glucose consumption as
normalized to cellular protein content. Glucose consumption of
cells expressing an HTLV RBD within the context of the
H.sub.183FEnv entire envelope or the H1.sub.RBD was significantly
decreased as compared to control cells (FIG. 1b) and this defect
was detectable as early as 8 hours post transfection. To determine
if this decrease in glucose consumption corresponded to a decrease
in glucose transport across cellular membrane, we measured
2-deoxyglucose and fructose uptake in control cells and cells
expressing HTLV RBD (FIG. 1c). We observed that expression of
either HTLV-1 or HTLV-2 RBD induced an approximatively 4-fold
decrease in 2-deoxyglucose uptake, while A-MLV RBD had only a minor
effect. Inhibitors of glucose uptake, cytochalasin B and phloterin,
also inhibited glucose uptake. These results were also true for
3-O-methylglucose transport. Fructose uptake in the same cells was
not altered by the presence of HTLV-1 nor HTLV-2 RBD however A-MLV
RBD induced a slight decreased. We next evaluated the effect of
glucose deprivation on the availability of the HTLV receptor in
both adherent human 293T cells and suspension Jurkat T cells. After
overnight culture of cells in the absence of glucose, binding of
H1.sub.RBD was consistently increased by 2-fold in both cell types
(FIG. 1d). This effect of glucose deprivation was specific to HTLV
as amphotropic MLV RBD (A.sub.RBD) binding was only marginally
affected (FIG. 1d). This phenomenon is reminiscent of a general
metabolite transport feedback loop, whereby transporter
availability at the cell surface increases upon substrate
starvation [Martineau, 1972].
Example 4
HTLV Envelopes Bind Glucose Transporter-1
[0281] A simple model whereby the HTLV envelope inhibits glucose
consumption via direct binding to a glucose transporter can explain
the metabolic effects described above. Upon evaluation of the
different glucose transporter candidates, GLUT-1 appears to be the
only one encompassing all the known properties of the HTLV
receptor. Indeed, GLUT-1 expression is increased upon glucose
deprivation and is transports glucose in all vertebrate cells
[Mueckler, 1985], while fructose is transported by GLUT-5.
Furthermore, GLUT-1 is not expressed on resting primary T cells and
its expression is induced upon T cell activation [Rathmell, 2000;
Chakrabarti, 1994] with kinetics that are strikingly similar to
what we have reported for the HTLV receptor [Manel, 2003]. Since
human but not murine erythrocytes have been described to be the
cells exhibiting the highest concentration of GLUT-1 [Mueckler,
1994], we evaluated HTLV receptor availability on freshly isolated
red blood cells. Binding of H1.sub.RBD on human erythrocytes was
strikingly efficient, reaching levels higher than those observed on
any other tested cell type, whereas A.sub.RBD binding to
erythrocytes was minimal (FIG. 2a). On murine erythrocytes however,
no significant H1.sub.RBD binding could be detected, despite a
similar A.sub.RBD binding on murine and human erythrocytes.
Furthermore, primary human hepatocytes do not express GLUT-1.
Accordingly, we were unable to detect H1.sub.RBD binding to human
primary hepatocytes, while A.sub.RBD binding could be readily
detected.
[0282] In order to directly test the ability of HTLV envelopes to
bind GLUT-1, we derived a tagged GLUT-1 expression vector and
overexpressed this protein in HeLa cells. Both H1.sub.RBD and
H2.sub.RBD binding was dramatically increased upon GLUT-1
overexpression (FIG. 4a). This interaction was specific as the
HTLV-2 binding-defective mutant, D102A, as well as its HTLV-1
counterpart, D106A, did not bind GLUT-1 (FIG. 4a). Furthermore,
H1.sub.RBD and H2.sub.RBD binding remained at background levels
upon overexpression of the amphotropic MLV envelope receptor, the
inorganic phosphate transporter PiT2 [Miller, 1994]. Conversely,
binding of A.sub.RBD was not increased after GLUT-1 overexpression
but as expected, this interaction was increased upon transfection
of PiT2 (FIG. 4b). GLUT-3 is the closest isoform to GLUT-1, and
transports glucose with kinetics similar to that of GLUT-1. Thus,
we derived a tagged. GLUT-3 expression vector. Albeit similar
overexpression levels of GLUT-1 and GLUT-3 in 293T cells, GLUT-3
did not induce any increase in H1.sub.RBD binding (FIG. 4b),
suggesting that increase H1.sub.RBD binding in cells overexpressing
GLUT-1 is not an indirect consequence of increased glucose uptake.
To determine if GLUT-1 transfected cells were directly responsible
for the observed increased in H1.sub.RBD binding, we derived
fluorescent tagged GLUT-1 and GLUT-3 to uniquevocally identity
GLUT-overexpressing cells in the course of our FACS analysis. In
this context, only cells overexpressing GLUT-1-DsRed2 displayed a
significant increase in H1.sub.RBD binding, while overexpressing
GLUT-3-DsRed2 had no effect on H1.sub.RBD binding. Consequently, we
tested if HTLV glycoproteins directly interact with GLUT-1
proteins. To this end, we evaluated the ability of H1.sub.RBD to
immunoprecipitate GLUT-1. As shown on FIG. 4e, GLUT-1 could be
readily detected upon immunoprecipitation with anti-rabbit-Fc-beads
when it was co-expressed with H1.sub.RBD, but could not be detected
when expressed alone or with the H1.sub.RBD Y114A mutant. Moreover,
a GFP-tagged HTLV-2 RBD colocalized with GLUT-1 but not with PiT2
as assessed by fluorescence microscopy. Therefore, the GLUT-1
glucose transporter is an essential component of the HTLV envelope
receptor.
[0283] Interaction of GLUT-1 with its ligand cytochalasin B
inhibits glucose transport [Kasahara, 1977]. Since we showed that
binding of HTLV envelopes to GLUT-1 inhibits glucose consumption
and uptake, we tested whether cytochalasin B would abrogate HTLV
RBD binding. Indeed, cytochalasin B treatment of Jurkat T cells
dramatically inhibited binding of H1.sub.RBD, whereas binding of
A.sub.RBD was not affected (FIG. 5). Thus, GLUT-1 directed glucose
transport as well as binding of HTLV envelopes to GLUT-1 are
similarly inhibited by the cytochalasin B ligand. Altogether, these
data demonstrate that GLUT-1 is a receptor for HTLV envelopes.
[0284] Viral receptor permits entry and thus infection. No cellular
system currently exists that lacks GLUT-1 expression. Thus, we
developed a system in which HTLV infection is specifically
inhibited at the level of envelope-receptor interaction. In this
system, over-expression of HTLV-2 RBD interferes with infecting
incoming HTLV particles and specifically decreases HTLV titers by
at least 2 logs, while no effect is detected on control A-MLV
titers. To determine if GLUT-1 is an entry receptor for HTLV, we
overexpressed GLUT-1, GLUT-3 or Pit2 in addition to the interfering
H2.sub.RBD. While Pit2 and GLUT-3 had no effect on HTLV titers,
GLUT-1 completely alleviated the interference to infection induced
by H2.sub.RBD (FIG. 5). Interestingly, both GLUT-1 and GLUT-3, but
not Pit2, alleviated the alteration of glucose metabolism induced
by the HTLV RBD. Thus, GLUT-1 is an entry receptor for HTLV.
Discussion
[0285] Here we show that HTLV-1 and -2 envelopes interact with
GLUT-1 through their receptor binding domains. This interaction
strongly inhibits glucose consumption and glucose uptake, leading
to decreased lactate production and a block in extracellular milieu
acidification. Mutations that specifically altered receptor binding
of both HTLV-1 and 2 envelopes released the block in glucose
consumption, indicative of a direct correlation between receptor
binding determinants in the HTLV envelopes and glucose transport.
Glucose starvation was rapidly followed by increased binding of
HTLV envelopes, highlighting a nutrient-sensing negative feedback
loop between glucose availability and cell surface HTLV receptor
expression. Further evidence converged to identify GLUT-1 as the
receptor, including increased binding of HTLV RBD upon
overexpression of GLUT-1 but not GLUT-3, immunoprecipitation of
GLUT-1 by H1.sub.RBD but not the receptor-binding mutant H1.sub.RBD
Y114A, uppermost binding of HTLV RBD on human erythrocytes, where
GLUT-1 is the major glucose transporter isoform, and no binding of
HTLV RBD on human primary hepatocytes and murine erythrocytes,
where GLUT-1 is minimally expressed. Finally, GLUT-1 could
specifically alleviate interference to infection induced by HTLV
RBD. GLUT-1 fits all other known properties of the HTLV receptor.
Indeed, as previously demonstrated for the HTLV receptor [Manel,
2003], GLUT-1, but not the GLUT 2-4 isoforms, is not expressed on
resting T lymphocytes [Chakrabarti, 1994; Korgun, 2002] and is
induced upon immunological [Frauwirth, 2002; Yu, 2003] or
pharmacological [Chakrabarti, 1994] activation. Moreover, GLUT-1
orthologues are highly conserved among vertebrates, but are highly
divergent between vertebrates and insects [Escher, 1999].
[0286] GLUT-1 is thus a new member of the multimembrane spanning
metabolite transporters that serve as receptors for retroviral
envelopes. Interestingly, until now, all envelopes that recognize
these receptors have been encoded by retroviruses that have a
so-called simple genetic organization, such as MLV, feline leukemia
viruses, porcine endogenous retrovirus and the gibbon ape leukemia
virus [Overbaugh, 2001], whereas HTLV belongs to the so-called
complex retroviruses which code for several additional regulatory
proteins. However, we have shown that in contrast to the wide
phylogenetic divergence of their genomic RNA, the envelopes of HTLV
and MLV share a similar modular organization with some highly
conserved amino acid motifs in their respective receptor binding
domains [Kim, 2000].
[0287] Cell-to-cell contact appears to be required for HTLV
transmission, and the cytoskeleton appears to play a major role in
this process [Igakura, 2003]. Indeed, we observed that the HTLV
receptor, despite pancellular expression, is specifically
concentrated to mobile membrane regions and cell-to-cell contact
areas. It should therefore be expected that the HTLV envelope
receptor is associated to the cytoskeleton. Importantly, a
cytoplasmic-binding partner of GLUT-1, GLUT1CBP, which encodes a
PDZ domain, has been reported to link GLUT-1 to the cytoskeleton
[Bunn, 1999]. It will therefore be interesting to evaluate the
respective roles of the HTLV envelope, its cytoskeleton-associated
cellular partners, such as GLUT-1, GLUT1CBP and their immediate
interacting cell components.
[0288] Because expression of the HTLV receptor is induced upon
glucose starvation, transmission of HTLV may be more efficient in
cells that are locally starved for glucose, such as lymphocytes in
lymph nodes [Yu, 2003]. Furthermore, the ability of circulating
erythrocytes to dock HTLV, as shown here, might provide a means to
distribute HTLV to such tissues.
[0289] The identification of GLUT-1 as a receptor for HTLV
envelopes provides additional clues as to the ubiquitous in vitro
expression of the receptor on cell lines and the paradoxical
restriction of HTLV tropism to T lymphocytes in vivo. Rapid and
dramatic metabolic alterations associated with the blockade of
glucose consumption are likely to take place upon expression of the
HTLV envelope in vivo, early after infection. Therefore, we propose
that in vivo, HTLV infection initially spreads with a large
tropism, however early after infection the vast majority of cells
that are highly dependent on GLUT-1 activity are rapidly
eliminated. In contrast, resting T lymphocytes that have an
extremely low metabolic rate and as such are much less dependent on
glucose uptake, can tolerate this effect and are therefore
maintained in vivo. Furthermore, local imbalances in the access to
glucose following HTLV infection may lead to specific physiological
alterations [Akaoka, 2001]. In this regard, it will be of interest
to study the potential relationship between HTLV-associated
neuropathologies and the specific dependence of neurons on GLUT-1
mediated glucose consumption [Siegel, 1998].
Materials and Methods
[0290] Cell culture, 293T human embryonic kidney and HeLa cervical
carcinoma cells were grown in Dulbecco's modified Eagle medium
(DMEM) with high glucose (4.5 g/l) and Jurkat T-cells were grown in
RPMI supplemented with 10% fetal bovine serum (FBS) at 37.degree.
C. in a 5% CO2-95% air atmosphere. For glucose starvation
experiments, cells were grown in either glucose-free DMEM (Life
Technologies) or glucose-free RPMI (Dutscher) with 10% dialyzed FBS
(Life Technologies) and glucose (1 g/l) was supplemented when
indicated.
[0291] Expression vectors. Full length envelope expression vectors
for HTLV-1 (pCEL/2[Denesvre, 1995]) and Friend ecotropic MLV
(pCEL/F [Denesvre, 1995]), have been previously described. For the
HTLV-2 envelope, a fragment from pHTE2 [Rosenberg, 1998]
encompassing the tax, rex and env genes and the 3' LTR was inserted
in the pCSI [Battini, 1999] vector (pCSIX.H2). Full length envelope
expression vectors for amphotropic MLV (pCSI.A), or devoid of its R
peptide (pCSI.A.DELTA.R), and H.sub.183FEnv that contains the
N-terminal 183 amino acids of the HTLV-1 receptor-binding domain in
the F-MLV envelope background, as well as truncated envelope
expression vectors, derived from pCSI and encoding either of the
first 215 residues of HTLV-1 SU (H1.sub.RBD), the first 178
residues of HTLV2-SU (H2.sub.RBD) or the first 397 residues of the
amphotropic marine leukemia virus (MLV) SU (A.sub.RBD), fused to a
C-terminal rabbit IgG Fc tag (rFc) or to EGFP (H2 All point
mutations introduced in HTLV-1 and -2 RBD constructs were generated
using the quickchange site-directed mutagenesis method and
mutations were verified by sequencing. Human Glut-1 and Glut-3 cDNA
were amplified by PCR from the pLib HeLa cDNA library (Clontech),
and inserted into pCHIX, a modified version of the pCSI vector that
contains a cassette comprising a factor Xa cleavage site, two
copies of the hemagglutinin (HA) tag, and a histidine tag. The
resulting construct (pCHIX.hGLUT1) encodes a GLUT-1 protein with a
HA-His tag at the C-terminal end. GLUT-1 and GLUT-3 were also
inserted in a modified pCSI vector containing a DsRed2 C-terminal
tag. Similarly, human CD147 was amplified from 293T total RNA by
RT-PCR and inserted into the pCHIX backbone in frame with the
HA-His tag (pCHIX.hCD147).
[0292] Envelope expression and metabolic measurements. 293T cells
were transfected with the various envelope expression vectors using
a modified version of the calcium phosphate method. After an
overnight transfection, cells were washed in phosphate-buffered
saline (PBS) and fresh medium was added. Media were harvested at
the indicated time points, filtered through a 0.45 .mu.m pore-size
filter, and lactate and glucose were measured with enzymatic
diagnostic kits (Sigma). Values were normalized to cellular protein
content using the Bradford assay (Sigma) after solubilization of
cells in lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1%
sodium dodecyl sulfate, 1.0% Nonidet P-40, 0.5% deoxycholate) and
clarification by centrifugation,
[0293] Assay of hexose uptake. 2-deoxy-D[1-.sup.3H]glucose,
D[U-.sup.14C] fructose and 3-O-[.sup.14C]methyl-D-glucose were
obtained from Amersham. Hexose uptake assay were adapted from
Harrison et al. 1991). After transfection, approximatively 250,000
were seeded/well in 24-well plates. The next day, cells were washed
two times in PBS, incubated in serum-free DMEM, washed one time in
serum-free glucose-free DMEM, and incubated for 20' in 500 .mu.l
serum-free glucose-free DMEM modulo inhibitors (20 .mu.M
cytochalasin B, 300 .mu.M phloretin; SIGMA). Uptake was initiated
by adding labeled hexoses to a final concentration of 0.1 mM (2
.mu.Ci/ml for 2-2-deoxy-D[1-.sup.3H]glucose and 0.2 .mu.Ci/ml for
D[U-.sup.14C] fructose and 3-O-[.sup.14C]methyl-D-glucose) and
cells were incubated for 5' additional minutes. Cells were then
resuspended in 500 .mu.l cold serum-free glucose-free DMEM, wash
one time in serum-free glucose-free DMEM, and solubilized in 400
.mu.l of 0.1% SDS. 3 .mu.l was used for Bradford normalization,
while the rest was used for detection of either .sup.3H or .sup.14C
by liquid scintillation in a Beckman counter.
[0294] Western blots. Culture media (10 .mu.l) from 293T cells
expressing wild type or mutant HTLV-1 RBDs, and/or GLUT-1 for
GLUT-3 expression vector. were subjected to electrophoresis on
SDS-15% acrylamide gels, transferred onto nitrocellulose (Protran;
Schleicher & Schuell), blocked in PBS containing 5% powdered
milk and 0.5% Tween 20, probed with either a 1:5000 dilution of
horseradish peroxidase-conjugated anti-rabbit immunoglobulin or
1:2000 dilution of anti-HA 12CA5 (Roche) monoclonal antibody
followed by a 1:5000 dilution of horseradish peroxidase-conjugated
anti-mouse immunoglobulin, and visualized using an enhanced
chemiluminescence kit (Amersham).
[0295] Binding assays. Binding assays were carried out as
previously described [Manel, 2003]. Briefly, 5.times.10.sup.5 cells
(293T, HeLa, Jurkat or freshly isolated human erythrocytes) were
incubated with 500 .mu.l of H2.sub.RBD, H2.sub.RBD or A.sub.RBD
supernatants for 30 min at 37.degree. C., washed with PBA (1% BSA,
0.1% sodium azide in PBS), and incubated with a sheep anti-rabbit
IgG antibody conjugated to fluorescein isothiocyanate (Sigma). When
indicated, cytochalasin. B (20 .mu.M; Sigma) was added to cells for
1 hour prior to binding analyses. Binding was analyzed on a
FACSCalibur (Becton Dickinson) and data analysis was performed
using CellQuest (Becton Dickinson) and WinMDI (Scripps)
softwares.
[0296] Infections. 293T cells were transfected in 6-wells plate,
and one day after transfection, medium was replaced by high glucose
DMEM supplemented with fructose (5 g/l) and non-essential amino
acids. The next day, infection was initiated by adding supernatants
containing MLV particles pseudotyped with either HTLV-2 or A-MLV
envelopes. The following day, fresh medium was added, and 24 hours
later cells were fixed and stained for alkaline phosphatase
activity and dark focus of infection were counted. Viral particles
were obtained by transfecting 293T cells with pLAPSN, pGagPol and
either pCSIX.H2 or pCSI.A, and harvesting the 0.45 .mu.m-filtered
supernatants 24 hours later.
Sequence CWU 1 SEQUENCE LISTING <160> NUMBER OF SEQ ID
NOS: 55 <210> SEQ ID NO 1 <211> LENGTH: 3687
<212> TYPE: DNA <213> ORGANISM: Homo sapiens
<220> FEATURE: <221> NAME/KEY: source <222>
LOCATION: (1)..(3687) <223> OTHER INFORMATION:
/mol_type="unassigned DNA" /note="Nucleic acid sequence of GLUT1"
/organism="Homo sapiens" <400> SEQUENCE: 1 tccaccattt
tgctagagaa ggccgcggag gctcagagag gtgcgcacac ttgccctgag 60
tcacacagcg aatgccctcc gcggtcccaa cgcagagaga acgagccgat cggcagcctg
120 agcgaggcag tggttagggg gggccccggc cccggccact cccctcaccc
cctccccgca 180 gagcgccgcc caggacaggc tgggccccag gccccgcccc
gaggtcctgc ccacacaccc 240 ctgacacacc ggcgtcgcca gccaatggcc
ggggtcctat aaacgctacg gtccgcgcgc 300 tctctggcaa gaggcaagag
gtagcaacag cgagcgtgcc ggtcgctagt cgcgggtccc 360 cgagtgagca
cgccagggag caggagacca aacgacgggg gtcggagtca gagtcgcagt 420
gggagtcccc ggaccggagc acgagcctga gcgggagagc gccgctcgca cgcccgtcgc
480 cacccgcgta cccggcgcag ccagagccac cagcgcagcg ctgccatgga
gcccagcagc 540 aagaagctga cgggtcgcct catgctggcc gtgggaggag
cagtgcttgg ctccctgcag 600 tttggctaca acactggagt catcaatgcc
ccccagaagg tgatcgagga gttctacaac 660 cagacatggg tccaccgcta
tggggagagc atcctgccca ccacgctcac cacgctctgg 720 tccctctcag
tggccatctt ttctgttggg ggcatgattg gctccttctc tgtgggcctt 780
ttcgttaacc gctttggccg gcggaattca atgctgatga tgaacctgct ggccttcgtg
840 tccgccgtgc tcatgggctt ctcgaaactg ggcaagtcct ttgagatgct
gatcctgggc 900 cgcttcatca tcggtgtgta ctgcggcctg accacaggct
tcgtgcccat gtatgtgggt 960 gaagtgtcac ccacagccct tcgtggggcc
ctgggcaccc tgcaccagct gggcatcgtc 1020 gtcggcatcc tcatcgccca
ggtgttcggc ctggactcca tcatgggcaa caaggacctg 1080 tggcccctgc
tgctgagcat catcttcatc ccggccctgc tgcagtgcat cgtgctgccc 1140
ttctgccccg agagtccccg cttcctgctc atcaaccgca acgaggagaa ccgggccaag
1200 agtgtgctaa agaagctgcg cgggacagct gacgtgaccc atgacctgca
ggagatgaag 1260 gaagagagtc ggcagatgat gcgggagaag aaggtcacca
tcctggagct gttccgctcc 1320 cccgcctacc gccagcccat cctcatcgct
gtggtgctgc agctgtccca gcagctgtct 1380 ggcatcaacg ctgtcttcta
ttactccacg agcatcttcg agaaggcggg ggtgcagcag 1440 cctgtgtatg
ccaccattgg ctccggtatc gtcaacacgg ccttcactgt cgtgtcgctg 1500
tttgtggtgg agcgagcagg ccggcggacc ctgcacctca taggcctcgc tggcatggcg
1560 ggttgtgcca tactcatgac catcgcgcta gcactgctgg agcagctacc
ctggatgtcc 1620 tatctgagca tcgtggccat ctttggcttt gtggccttct
ttgaagtggg tcctggcccc 1680 atcccatggt tcatcgtggc tgaactcttc
agccagggtc cacgtccagc tgccattgcc 1740 gttgcaggct tctccaactg
gacctcaaat ttcattgtgg gcatgtgctt ccagtatgtg 1800 gagcaactgt
gtggtcccta cgtcttcatc atcttcactg tgctcctggt tctgttcttc 1860
atcttcacct acttcaaagt tcctgagact aaaggccgga ccttcgatga gatcgcttcc
1920 ggcttccggc aggggggagc cagccaaagt gacaagacac ccgaggagct
gttccatccc 1980 ctgggggctg attcccaagt gtgagtcgcc ccagatcacc
agcccggcct gctcccagca 2040 gccctaagga tctctcagga gcacaggcag
ctggatgaga cttccaaacc tgacagatgt 2100 cagccgagcc gggcctgggg
ctcctttctc cagccagcaa tgatgtccag aagaatattc 2160 aggacttaac
ggctccagga ttttaacaaa agcaagactg ttgctcaaat ctattcagac 2220
aagcaacagg ttttataatt tttttattac tgattttgtt atttttatat cagcctgagt
2280 ctcctgtgcc cacatcccag gcttcaccct gaatggttcc atgcctgagg
gtggagacta 2340 agccctgtcg agacacttgc cttcttcacc cagctaatct
gtagggctgg acctatgtcc 2400 taaggacaca ctaatcgaac tatgaactac
aaagcttcta tcccaggagg tggctatggc 2460 cacccgttct gctggcctgg
atctccccac tctaggggtc aggctccatt aggatttgcc 2520 ccttcccatc
tcttcctacc caaccactca aattaatctt tctttacctg agaccagttg 2580
ggagcactgg agtgcaggga ggagagggga agggccagtc tgggctgccg ggttctagtc
2640 tcctttgcac tgagggccac actattacca tgagaagagg gcctgtggga
gcctgcaaac 2700 tcactgctca agaagacatg gagactcctg ccctgttgtg
tatagatgca agatatttat 2760 atatattttt ggttgtcaat attaaataca
gacactaagt tatagtatat ctggacaagc 2820 caacttgtaa atacaccacc
tcactcctgt tacttaccta aacagatata aatggctggt 2880 ttttagaaac
atggttttga aatgcttgtg gattgagggt aggaggtttg gatgggagtg 2940
agacagaagt aagtggggtt gcaaccactg caacggctta gacttcgact caggatccag
3000 tcccttacac gtacctctca tcagtgtcct cttgctcaaa aatctgtttg
atccctgtta 3060 cccagagaat atatacattc tttatcttga cattcaaggc
atttctatca catatttgat 3120 agttggtgtt caaaaaaaca ctagttttgt
gccagccgtg atgctcaggc ttgaaatgca 3180 ttattttgaa tgtgaagtaa
atactgtacc tttattggac aggctcaaag aggttatgtg 3240 cctgaagtcg
cacagtgaat aagctaaaac acctgctttt aacaatggta ccatacaacc 3300
actactccat taactccacc cacctcctgc acccctcccc acacacacaa aatgaaccac
3360 gttctttgta tgggcccaat gagctgtcaa gctgccctgt gttcatttca
tttggaattg 3420 ccccctctgg ttcctctgta tactactgct tcatctctaa
agacagctca tcctcctcct 3480 tcacccctga atttccagag cacttcatct
gctccttcat cacaagtcca gttttctgcc 3540 actagtctga atttcatgag
aagatgccga tttggttcct gtgggtcctc agcactattc 3600 agtacagtgc
ttgatgcaca gcaggcactc agaaaatact ggaggaaata aaacaccaaa 3660
gatatttgtc aaaaaaaaaa aaaaaaa 3687 <210> SEQ ID NO 2
<211> LENGTH: 492 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 2 Met Glu Pro Ser Ser Lys Lys
Leu Thr Gly Arg Leu Met Leu Ala Val 1 5 10 15 Gly Gly Ala Val Leu
Gly Ser Leu Gln Phe Gly Tyr Asn Thr Gly Val 20 25 30 Ile Asn Ala
Pro Gln Lys Val Ile Glu Glu Phe Tyr Asn Gln Thr Trp 35 40 45 Val
His Arg Tyr Gly Glu Ser Ile Leu Pro Thr Thr Leu Thr Thr Leu 50 55
60 Trp Ser Leu Ser Val Ala Ile Phe Ser Val Gly Gly Met Ile Gly Ser
65 70 75 80 Phe Ser Val Gly Leu Phe Val Asn Arg Phe Gly Arg Arg Asn
Ser Met 85 90 95 Leu Met Met Asn Leu Leu Ala Phe Val Ser Ala Val
Leu Met Gly Phe 100 105 110 Ser Lys Leu Gly Lys Ser Phe Glu Met Leu
Ile Leu Gly Arg Phe Ile 115 120 125 Ile Gly Val Tyr Cys Gly Leu Thr
Thr Gly Phe Val Pro Met Tyr Val 130 135 140 Gly Glu Val Ser Pro Thr
Ala Leu Arg Gly Ala Leu Gly Thr Leu His 145 150 155 160 Gln Leu Gly
Ile Val Val Gly Ile Leu Ile Ala Gln Val Phe Gly Leu 165 170 175 Asp
Ser Ile Met Gly Asn Lys Asp Leu Trp Pro Leu Leu Leu Ser Ile 180 185
190 Ile Phe Ile Pro Ala Leu Leu Gln Cys Ile Val Leu Pro Phe Cys Pro
195 200 205 Glu Ser Pro Arg Phe Leu Leu Ile Asn Arg Asn Glu Glu Asn
Arg Ala 210 215 220 Lys Ser Val Leu Lys Lys Leu Arg Gly Thr Ala Asp
Val Thr His Asp 225 230 235 240 Leu Gln Glu Met Lys Glu Glu Ser Arg
Gln Met Met Arg Glu Lys Lys 245 250 255 Val Thr Ile Leu Glu Leu Phe
Arg Ser Pro Ala Tyr Arg Gln Pro Ile 260 265 270 Leu Ile Ala Val Val
Leu Gln Leu Ser Gln Gln Leu Ser Gly Ile Asn 275 280 285 Ala Val Phe
Tyr Tyr Ser Thr Ser Ile Phe Glu Lys Ala Gly Val Gln 290 295 300 Gln
Pro Val Tyr Ala Thr Ile Gly Ser Gly Ile Val Asn Thr Ala Phe 305 310
315 320 Thr Val Val Ser Leu Phe Val Val Glu Arg Ala Gly Arg Arg Thr
Leu 325 330 335 His Leu Ile Gly Leu Ala Gly Met Ala Gly Cys Ala Ile
Leu Met Thr 340 345 350 Ile Ala Leu Ala Leu Leu Glu Gln Leu Pro Trp
Met Ser Tyr Leu Ser 355 360 365 Ile Val Ala Ile Phe Gly Phe Val Ala
Phe Phe Glu Val Gly Pro Gly 370 375 380 Pro Ile Pro Trp Phe Ile Val
Ala Glu Leu Phe Ser Gln Gly Pro Arg 385 390 395 400 Pro Ala Ala Ile
Ala Val Ala Gly Phe Ser Asn Trp Thr Ser Asn Phe 405 410 415 Ile Val
Gly Met Cys Phe Gln Tyr Val Glu Gln Leu Cys Gly Pro Tyr 420 425 430
Val Phe Ile Ile Phe Thr Val Leu Leu Val Leu Phe Phe Ile Phe Thr 435
440 445 Tyr Phe Lys Val Pro Glu Thr Lys Gly Arg Thr Phe Asp Glu Ile
Ala 450 455 460 Ser Gly Phe Arg Gln Gly Gly Ala Ser Gln Ser Asp Lys
Thr Pro Glu 465 470 475 480 Glu Leu Phe His Pro Leu Gly Ala Asp Ser
Gln Val 485 490 <210> SEQ ID NO 3 <211> LENGTH: 534
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: HTLV2.RBD
<400> SEQUENCE: 3 atgggtaatg ttttcttcct acttttattc agtctcacac
attttccact agcccagcag 60 agccgatgca cactcacagt tggtatctcc
tcctaccact ccagcccctg tagcccaacc 120 caacccgtct gcacgtggaa
cctcgacctt aattccctaa caacggacca acgactacac 180 cccccctgcc
ctaacctaat tacttactct ggcttccata agacttattc cttatactta 240
ttcccacatt ggataaaaaa gccaaacaga cagggcctag ggtactactc gccttcctac
300 aatgaccctt gctcgctaca atgcccctac ttgggctgcc aatcatggac
atgcccatac 360 acgggccccg tctccagtcc atcctggaag tttcattcag
atgtaaattt cacccaggaa 420 gtcagccaag tgtcccttcg actacacttc
tctaagtgcg gctcctccat gaccctccta 480 gtagatgccc ctggatatga
tcctttatgg ttcatcacct cagaacccac tcag 534 <210> SEQ ID NO 4
<211> LENGTH: 224 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: HTLV-2.RBD <400> SEQUENCE: 4 Met Gly Asn Val Phe
Phe Leu Leu Leu Phe Ser Leu Thr His Phe Pro 1 5 10 15 Leu Ala Gln
Gln Ser Arg Cys Thr Leu Thr Val Gly Ile Ser Ser Tyr 20 25 30 His
Ser Ser Pro Cys Ser Pro Thr Gln Pro Val Cys Thr Trp Asn Leu 35 40
45 Asp Leu Asn Ser Leu Thr Thr Asp Gln Arg Leu His Pro Pro Cys Pro
50 55 60 Asn Leu Ile Thr Tyr Ser Gly Phe His Lys Thr Tyr Ser Leu
Tyr Leu 65 70 75 80 Phe Pro His Trp Ile Lys Lys Pro Asn Arg Gln Gly
Leu Gly Tyr Tyr 85 90 95 Ser Pro Ser Tyr Asn Asp Pro Cys Ser Leu
Gln Cys Pro Tyr Leu Gly 100 105 110 Cys Gln Ser Trp Thr Cys Pro Tyr
Thr Gly Pro Val Ser Ser Pro Ser 115 120 125 Trp Lys Phe His Ser Asp
Val Asn Phe Thr Gln Glu Val Ser Gln Val 130 135 140 Ser Leu Arg Leu
His Phe Ser Lys Cys Gly Ser Ser Met Thr Leu Leu 145 150 155 160 Val
Asp Ala Pro Gly Tyr Asp Pro Leu Trp Phe Ile Thr Ser Glu Pro 165 170
175 Thr Gln Pro Pro Pro Thr Ser Pro Pro Leu Val His Asp Ser Asp Leu
180 185 190 Glu His Val Leu Thr Pro Ser Thr Ser Trp Thr Thr Lys Ile
Leu Lys 195 200 205 Phe Ile Gln Leu Thr Leu Gln Ser Thr Asn Tyr Ser
Cys Met Val Cys 210 215 220 <210> SEQ ID NO 5 <211>
LENGTH: 178 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
HTLV2.RBD <400> SEQUENCE: 5 Met Gly Asn Val Phe Phe Leu Leu
Leu Phe Ser Leu Thr His Phe Pro 1 5 10 15 Leu Ala Gln Gln Ser Arg
Cys Thr Leu Thr Val Gly Ile Ser Ser Tyr 20 25 30 His Ser Ser Pro
Cys Ser Pro Thr Gln Pro Val Cys Thr Trp Asn Leu 35 40 45 Asp Leu
Asn Ser Leu Thr Thr Asp Gln Arg Leu His Pro Pro Cys Pro 50 55 60
Asn Leu Ile Thr Tyr Ser Gly Phe His Lys Thr Tyr Ser Leu Tyr Leu 65
70 75 80 Phe Pro His Trp Ile Lys Lys Pro Asn Arg Gln Gly Leu Gly
Tyr Tyr 85 90 95 Ser Pro Ser Tyr Asn Asp Pro Cys Ser Leu Gln Cys
Pro Tyr Leu Gly 100 105 110 Cys Gln Ser Trp Thr Cys Pro Tyr Thr Gly
Pro Val Ser Ser Pro Ser 115 120 125 Trp Lys Phe His Ser Asp Val Asn
Phe Thr Gln Glu Val Ser Gln Val 130 135 140 Ser Leu Arg Leu His Phe
Ser Lys Cys Gly Ser Ser Met Thr Leu Leu 145 150 155 160 Val Asp Ala
Pro Gly Tyr Asp Pro Leu Trp Phe Ile Thr Ser Glu Pro 165 170 175 Thr
Gln <210> SEQ ID NO 6 <211> LENGTH: 153 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: HTLV2.RBD <400>
SEQUENCE: 6 ataagaaagc caaacagaca gggcctaggg tactactcgc cttcctacaa
tgacccttgc 60 tcgctacaat gcccctactt gggctcccaa tcatggacat
gcccatacac ggcccccgtc 120 tccactccat cctggaattt tcattcagat gta 153
<210> SEQ ID NO 7 <211> LENGTH: 51 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: HTLV2.RBD <400> SEQUENCE: 7
Ile Arg Lys Pro Asn Arg Gln Gly Leu Gly Tyr Tyr Ser Pro Ser Tyr 1 5
10 15 Asn Asp Pro Cys Ser Leu Gln Cys Pro Tyr Leu Gly Ser Gln Ser
Trp 20 25 30 Thr Cys Pro Tyr Thr Ala Pro Val Ser Thr Pro Ser Trp
Asn Phe His 35 40 45 Ser Asp Val 50 <210> SEQ ID NO 8
<211> LENGTH: 924 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: HTLV1.RBD <400> SEQUENCE: 8 atgggtaagt
ttctcgccac tttgatttta ttcttccagt tctgccccct catcctcggt 60
gattacagcc ccagctgctg tactctcaca attggagtct cctcatacca ctctaaaccc
120 tgcaatcctg cccagccagt ttgttcgtgg accctcgacc tgctggccct
ttcagcggat 180 caggccctac agcccccctg ccctaatcta gtaagttact
ccagctacca tgccacctat 240 tccctatatc tattccctca ttggattaaa
aagccaaacc gaaatggcgg aggctattat 300 tcagcctctt attcagaccc
ttgttcctta aagtgcccat acctggggtg ccaatcatgg 360 acctgcccct
atacaggagc cgtctccagc ccctactgga agtttcagca agatgtcaat 420
tttactcaag aagtttcacg cctcaatatt aatctccatt tttcaaaatg cggttttccc
480 ttctcccttc tagtcgacgc tccaggatat gaccccatct ggttccttaa
taccgaaccc 540 agccaactgc ctcccaccgc ccctcctcta ctcccccact
ctaacctaga ccacatcctc 600 gagccctcta taccatggaa atcaaaactc
ctgacccttg tccagttaac cctacaaagc 660 actaattata cttgcattgt
ctgtatcgat cgtgccagcc tatccacttg gcacgtccta 720 tactctccca
acgtctctgt tccatcctct tcttctaccc ccctccttta cccatcgtta 780
gcgcttccag ccccccacct gacgttacca tttaactgga cccactgctt tgacccccag
840 attcaagcta tagtctcctc cccctgtcat aactccctca tcctgccccc
cttttccttg 900 tcacctgttc ccaccctagg atcc 924 <210> SEQ ID NO
9 <211> LENGTH: 308 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV1.RBD <400> SEQUENCE: 9 Met Gly Lys
Phe Leu Ala Thr Leu Ile Leu Phe Phe Gln Phe Cys Pro 1 5 10 15 Leu
Ile Leu Gly Asp Tyr Ser Pro Ser Cys Cys Thr Leu Thr Ile Gly 20 25
30 Val Ser Ser Tyr His Ser Lys Pro Cys Asn Pro Ala Gln Pro Val Cys
35 40 45 Ser Trp Thr Leu Asp Leu Leu Ala Leu Ser Ala Asp Gln Ala
Leu Gln 50 55 60 Pro Pro Cys Pro Asn Leu Val Ser Tyr Ser Ser Tyr
His Ala Thr Tyr 65 70 75 80 Ser Leu Tyr Leu Phe Pro His Trp Ile Lys
Lys Pro Asn Arg Asn Gly 85 90 95 Gly Gly Tyr Tyr Ser Ala Ser Tyr
Ser Asp Pro Cys Ser Leu Lys Cys 100 105 110 Pro Tyr Leu Gly Cys Gln
Ser Trp Thr Cys Pro Tyr Thr Gly Ala Val 115 120 125 Ser Ser Pro Tyr
Trp Lys Phe Gln Gln Asp Val Asn Phe Thr Gln Glu 130 135 140 Val Ser
Arg Leu Asn Ile Asn Leu His Phe Ser Lys Cys Gly Phe Pro 145 150 155
160 Phe Ser Leu Leu Val Asp Ala Pro Gly Tyr Asp Pro Ile Trp Phe Leu
165 170 175 Asn Thr Glu Pro Ser Gln Leu Pro Pro Thr Ala Pro Pro Leu
Leu Pro 180 185 190 His Ser Asn Leu Asp His Ile Leu Glu Pro Ser Ile
Pro Trp Lys Ser 195 200 205 Lys Leu Leu Thr Leu Val Gln Leu Thr Leu
Gln Ser Thr Asn Tyr Thr 210 215 220 Cys Ile Val Cys Ile Asp Arg Ala
Ser Leu Ser Thr Trp His Val Leu 225 230 235 240 Tyr Ser Pro Asn Val
Ser Val Pro Ser Ser Ser Ser Thr Pro Leu Leu 245 250 255 Tyr Pro Ser
Leu Ala Leu Pro Ala Pro His Leu Thr Leu Pro Phe Asn 260 265 270 Trp
Thr His Cys Phe Asp Pro Gln Ile Gln Ala Ile Val Ser Ser Pro 275 280
285 Cys His Asn Ser Leu Ile Leu Pro Pro Phe Ser Leu Ser Pro Val Pro
290 295 300 Thr Leu Gly Ser 305 <210> SEQ ID NO 10
<211> LENGTH: 228 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: HTLV1.RBD <400> SEQUENCE: 10 Met Gly Lys Phe Leu
Ala Thr Leu Ile Leu Phe Phe Gln Phe Cys Pro 1 5 10 15 Leu Ile Phe
Gly Asp Tyr Ser Pro Ser Cys Cys Thr Leu Thr Ile Gly 20 25 30 Val
Ser Ser Tyr His Ser Lys Pro Cys Asn Pro Ala Gln Pro Val Cys 35 40
45 Ser Trp Thr Leu Asp Leu Leu Ala Leu Ser Ala Asp Gln Ala Leu Gln
50 55 60 Pro Pro Cys Pro Asn Leu Val Ser Tyr Ser Ser Tyr His Ala
Thr Tyr 65 70 75 80 Ser Leu Tyr Leu Phe Pro His Trp Thr Lys Lys Pro
Asn Arg Asn Gly 85 90 95 Gly Gly Tyr Tyr Ser Ala Ser Tyr Ser Asp
Pro Cys Ser Leu Lys Cys 100 105 110 Pro Tyr Leu Gly Cys Gln Ser Trp
Thr Cys Pro Tyr Thr Gly Ala Val 115 120 125 Ser Ser Pro Tyr Trp Lys
Phe Gln His Asp Val Asn Phe Thr Gln Glu 130 135 140 Val Ser Arg Leu
Asn Ile Asn Leu His Phe Ser Lys Cys Gly Phe Pro 145 150 155 160 Phe
Ser Leu Leu Val Asp Ala Pro Gly Tyr Asp Pro Ile Trp Phe Leu 165 170
175 Asn Thr Glu Pro Ser Gln Leu Pro Pro Thr Ala Pro Pro Leu Leu Pro
180 185 190 His Ser Asn Leu Asp His Ile Leu Glu Pro Ser Ile Pro Trp
Lys Ser 195 200 205 Lys Leu Leu Thr Leu Val Gln Leu Thr Leu Gln Ser
Thr Asn Tyr Thr 210 215 220 Cys Ile Val Cys 225 <210> SEQ ID
NO 11 <211> LENGTH: 182 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV1.RBD <400> SEQUENCE: 11 Met Gly Lys
Phe Leu Ala Thr Leu Ile Leu Phe Phe Gln Phe Cys Pro 1 5 10 15 Leu
Ile Phe Gly Asp Tyr Ser Pro Ser Cys Cys Thr Leu Thr Ile Gly 20 25
30 Val Ser Ser Tyr His Ser Lys Pro Cys Asn Pro Ala Gln Pro Val Cys
35 40 45 Ser Trp Thr Leu Asp Leu Leu Ala Leu Ser Ala Asp Gln Ala
Leu Gln 50 55 60 Pro Pro Cys Pro Asn Leu Val Ser Tyr Ser Ser Tyr
His Ala Thr Tyr 65 70 75 80 Ser Leu Tyr Leu Phe Pro His Trp Thr Lys
Lys Pro Asn Arg Asn Gly 85 90 95 Gly Gly Tyr Tyr Ser Ala Ser Tyr
Ser Asp Pro Cys Ser Leu Lys Cys 100 105 110 Pro Tyr Leu Gly Cys Gln
Ser Trp Thr Cys Pro Tyr Thr Gly Ala Val 115 120 125 Ser Ser Pro Tyr
Trp Lys Phe Gln His Asp Val Asn Phe Thr Gln Glu 130 135 140 Val Ser
Arg Leu Asn Ile Asn Leu His Phe Ser Lys Cys Gly Phe Pro 145 150 155
160 Phe Ser Leu Leu Val Asp Ala Pro Gly Tyr Asp Pro Ile Trp Phe Leu
165 170 175 Asn Thr Glu Pro Ser Gln 180 <210> SEQ ID NO 12
<211> LENGTH: 153 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: HTLV1.RBD <400> SEQUENCE: 12 attaaaaagc
caaacccaaa tggcggaggc tattatttag cctcttattc agacccttgt 60
tccttaaaat gcccatacct ggggtgccaa tcatggacct gcccctatac aggagccgtc
120 tccagcccct actggaagtt tcagcaagat gtc 153 <210> SEQ ID NO
13 <211> LENGTH: 51 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV1.RBD <400> SEQUENCE: 13 Ile Lys Lys
Pro Asn Pro Asn Gly Gly Gly Tyr Tyr Leu Ala Ser Tyr 1 5 10 15 Ser
Asp Pro Cys Ser Leu Lys Cys Pro Tyr Leu Gly Cys Gln Ser Trp 20 25
30 Thr Cys Pro Tyr Thr Gly Ala Val Ser Ser Pro Tyr Trp Lys Phe Gln
35 40 45 Gln Asp Val 50 <210> SEQ ID NO 14 <211>
LENGTH: 153 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
HTLV1.RBD <400> SEQUENCE: 14 gttaaaaagc caaaccgaaa tggcggaggc
tattatttag cctcttattc agacccttgt 60 tccttaaaat gcccatacct
ggggtgccaa tcatggacct gcccctatac aggagccgtc 120 tccagcccct
actggaagtt tcagcaagat gtc 153 <210> SEQ ID NO 15 <211>
LENGTH: 51 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
HTLV1.RBD <400> SEQUENCE: 15 Val Lys Lys Pro Asn Arg Asn Gly
Gly Gly Tyr Tyr Leu Ala Ser Tyr 1 5 10 15 Ser Asp Pro Cys Ser Leu
Lys Cys Pro Tyr Leu Gly Cys Gln Ser Trp 20 25 30 Thr Cys Pro Tyr
Thr Gly Ala Val Ser Ser Pro Tyr Trp Lys Phe Gln 35 40 45 Gln Asp
Val 50 <210> SEQ ID NO 16 <211> LENGTH: 51 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: HTLV1.RBD <400>
SEQUENCE: 16 Ile Lys Lys Pro Asn Arg Asn Gly Gly Gly Tyr Tyr Leu
Ala Ser Tyr 1 5 10 15 Ser Asp Pro Cys Ser Leu Lys Cys Pro Tyr Leu
Gly Cys Gln Ser Trp 20 25 30 Thr Cys Pro Tyr Thr Gly Ala Val Ser
Ser Pro Tyr Trp Lys Phe Gln 35 40 45 Gln Asp Val 50 <210> SEQ
ID NO 17 <211> LENGTH: 153 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV1.RBD <400> SEQUENCE: 17 attaaaaagc
caaaccgaaa tggcggaggc tattatttag cctcttattc agacccttgt 60
tccttaaaat gcccatacct ggggtgccaa tcatggacct gcccctatac aggacccgtc
120 tccagcccct actggaagtt tcagcaagat gtc 153 <210> SEQ ID NO
18 <211> LENGTH: 51 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV1.RBD <400> SEQUENCE: 18 Ile Lys Lys
Pro Asn Arg Asn Gly Gly Gly Tyr Tyr Leu Ala Ser Tyr 1 5 10 15 Ser
Asp Pro Cys Ser Leu Lys Cys Pro Tyr Leu Gly Cys Gln Ser Trp 20 25
30 Thr Cys Pro Tyr Thr Gly Pro Val Ser Ser Pro Tyr Trp Lys Phe Gln
35 40 45 Gln Asp Val 50 <210> SEQ ID NO 19 <211>
LENGTH: 171 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
HTLV1.RBD <400> SEQUENCE: 19 attaaaaagc caaaccgaaa tggcggaggc
tatcattcag cctcttattc agacccttgt 60 tccttaaagt gcccatacct
ggggtgccaa tcatggacct gcccctatgc aggagccgtc 120 tccagcccct
actggaagtt tcagcaagat gtcaatttta cccaggaagt a 171 <210> SEQ
ID NO 20 <211> LENGTH: 57 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV1.RBD <400> SEQUENCE: 20 Ile Lys Lys
Pro Asn Arg Asn Gly Gly Gly Tyr His Ser Ala Ser Tyr 1 5 10 15 Ser
Asp Pro Cys Ser Leu Lys Cys Pro Tyr Leu Gly Cys Gln Ser Trp 20 25
30 Thr Cys Pro Tyr Ala Gly Ala Val Ser Ser Pro Tyr Trp Lys Phe Gln
35 40 45 Gln Asp Val Asn Phe Thr Gln Glu Val 50 55 <210> SEQ
ID NO 21 <211> LENGTH: 224 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV4.RBD <400> SEQUENCE: 21 Met Gly Asn
Val Leu Phe Leu Thr Leu Leu Ala Thr Leu Gly Ile Pro 1 5 10 15 Val
Leu Gln Ala Ser Arg Cys Thr Ile Thr Val Gly Ile Ser Ser Tyr 20 25
30 His Ser Ser Pro Cys Ser Pro Ala Gln Pro Leu Cys Thr Trp Ala Leu
35 40 45 Asp Leu Val Ser Ile Thr Lys Asp Gln Leu Leu Tyr Pro Pro
Cys Gln 50 55 60 Asn Leu Ile Thr Tyr Ser Asn Tyr His Lys Thr Tyr
Ser Leu Tyr Leu 65 70 75 80 Phe Pro His Trp Val Gln Lys Pro Leu Arg
Arg Gly Leu Gly Tyr Tyr 85 90 95 Ser Ala Ser Tyr Ser Asp Pro Cys
Ser Leu Gln Cys Pro Tyr Leu Gly 100 105 110 Ser Gln Ser Trp Thr Cys
Pro Tyr Thr Gly Pro Val Ser Ser Pro Thr 115 120 125 Trp Arg Phe Ser
Thr Asp Val Asn Phe Thr Gln Glu Val Ser Arg Val 130 135 140 Ser Leu
Lys Leu His Phe Ser Lys Cys Gly Ser Ser Leu Thr Leu Leu 145 150 155
160 Ile Asp Ala Pro Gly Tyr Asp Pro Leu Trp Tyr Leu Thr Ser Glu Pro
165 170 175 Thr Gln Glu Pro Pro Thr Pro Pro Pro Leu Val Ser Asp Ser
Asp Leu 180 185 190 Glu His Val Leu Thr Pro Ser Ala Ser Trp Ala Ser
Lys Met Leu Thr 195 200 205 Leu Ile His Leu Thr Leu Gln Ser Thr Asn
Tyr Ser Cys Met Val Cys 210 215 220 <210> SEQ ID NO 22
<211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: HTLV4.RBD <400> SEQUENCE: 22 Met Gly Asn Val Leu
Phe Leu Thr Leu Leu Ala Thr Leu Gly Ile Pro 1 5 10 15 Val Leu Gln
Ala Ser Arg Cys Thr Ile Thr Val Gly Ile Ser Ser Tyr 20 25 30 His
Ser Ser Pro Cys Ser Pro Ala Gln Pro Leu Cys Thr Trp Ala Leu 35 40
45 Asp Leu Val Ser Ile Thr Lys Asp Gln Leu Leu Tyr Pro Pro Cys Gln
50 55 60 Asn Leu Ile Thr Tyr Ser Asn Tyr His Lys Thr Tyr Ser Leu
Tyr Leu 65 70 75 80 Phe Pro His Trp Val Gln Lys Pro Leu Arg Arg Gly
Leu Gly Tyr Tyr 85 90 95 Ser Ala Ser Tyr Ser Asp Pro Cys Ser Leu
Gln Cys Pro Tyr Leu Gly 100 105 110 Ser Gln Ser Trp Thr Cys Pro Tyr
Thr Gly Pro Val Ser Ser Pro Thr 115 120 125 Trp Arg Phe Ser Thr Asp
Val Asn Phe Thr Gln Glu Val Ser Arg Val 130 135 140 Ser Leu Lys Leu
His Phe Ser Lys Cys Gly Ser Ser Leu Thr Leu Leu 145 150 155 160 Ile
Asp Ala Pro Gly Tyr Asp Pro Leu Trp Tyr Leu Thr Ser Glu Pro 165 170
175 Thr Gln <210> SEQ ID NO 23 <211> LENGTH: 1467
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: STLV1.RBD
<400> SEQUENCE: 23 atgggtaagt ttctcgccac tttgatttta
ttcttccagt tctgccccct cattctcggt 60 gattacagcc ccagctgctg
tactctcaca attggagtct cctcatacct ctctaaaccc 120 tgcaatcctg
cccagccagt ttgttcatgg accctcgacc tactggccct ttcagcagac 180
caagccctac agcccccctg ccctaatcta gtaagttact ccagctacca tgccacctat
240 tccctatatc tattccctca ttggattaaa aagccaaacc gaaatggcgg
aggctattat 300 tcggcctctt attcagaccc atgttcttta aagtgcccat
acttagggtg ccaatcatgg 360 acctgcccct atacaggagt cgtctccagc
ccctattgga aatttcagca agatgtcaat 420 tttactcaag aagtttcaca
cctcaatatt aatctccatt tctcaaaatg cggttttccc 480 ttctcccttc
taatcgacgc tccaggatat gaccccatct ggttccttaa taccgaaccc 540
agccaactgc ctcccaccgc ccctcctcta ctcccccact ctaacctgga ccacatcctc
600 gagccctcta taccatggaa atcaaaactt ctgactcttg tccagctaac
cctacaaagc 660 actaattaca cttgcatcgt ctgtatagac cgtgccagcc
tctctacttg gcatgtcctg 720 tactctccca acgtctctgt tccgtcctct
tcttctaccc ccctccttta cccgtcgtta 780 gcgcttccag ctccccacct
gacgctacca tttaactgga cccactgctt tgacccccag 840 attcaagcta
tagtctcctc cccctgtcat aactccctca tcctgccccc cttttccttg 900
tcacctgttc ccaccctagg atcccgctcc cgccgagcgg taccggtggc ggtctggctt
960 gtctccgccc tggccatggg agccggaatt gctggcggga ttaccggctc
catgtccctc 1020 gcctcaggaa agagcctcct acatgaggtg gacaaagata
tttcccaatt aactcaagca 1080 atagtcaaaa accacaaaaa tctactcaaa
attgcacagt atgctgccca gaacaggcga 1140 ggccttgatc tcctgttctg
ggagcaagga ggattatgca aagcattaca agaacagtgc 1200 tgttttctaa
atattaccaa ttcccatgtc tcaatactac aagaaagacc cccccttgag 1260
aatcgagtcc tcactggctg gggccttaac tgggaccttg gcctctcaca gtgggctcga
1320 gaggccttac aaactgggat cacccttgtt gcactactcc ttctcgttat
ccttgcagga 1380 ccatgcatcc tccgtcagct gcgacacctc ccctcgcgcg
tcagataccc ccattattct 1440 cttataaacc ctgagtcatc cctgtaa 1467
<210> SEQ ID NO 24 <211> LENGTH: 488 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: STLV1.RBD <400> SEQUENCE: 24
Met Gly Lys Phe Leu Ala Thr Leu Ile Leu Phe Phe Gln Phe Cys Pro 1 5
10 15 Leu Ile Leu Gly Asp Tyr Ser Pro Ser Cys Cys Thr Leu Thr Ile
Gly 20 25 30 Val Ser Ser Tyr Leu Ser Lys Pro Cys Asn Pro Ala Gln
Pro Val Cys 35 40 45 Ser Trp Thr Leu Asp Leu Leu Ala Leu Ser Ala
Asp Gln Ala Leu Gln 50 55 60 Pro Pro Cys Pro Asn Leu Val Ser Tyr
Ser Ser Tyr His Ala Thr Tyr 65 70 75 80 Ser Leu Tyr Leu Phe Pro His
Trp Ile Lys Lys Pro Asn Arg Asn Gly 85 90 95 Gly Gly Tyr Tyr Ser
Ala Ser Tyr Ser Asp Pro Cys Ser Leu Lys Cys 100 105 110 Pro Tyr Leu
Gly Cys Gln Ser Trp Thr Cys Pro Tyr Thr Gly Val Val 115 120 125 Ser
Ser Pro Tyr Trp Lys Phe Gln Gln Asp Val Asn Phe Thr Gln Glu 130 135
140 Val Ser His Leu Asn Ile Asn Leu His Phe Ser Lys Cys Gly Phe Pro
145 150 155 160 Phe Ser Leu Leu Ile Asp Ala Pro Gly Tyr Asp Pro Ile
Trp Phe Leu 165 170 175 Asn Thr Glu Pro Ser Gln Leu Pro Pro Thr Ala
Pro Pro Leu Leu Pro 180 185 190 His Ser Asn Leu Asp His Ile Leu Glu
Pro Ser Ile Pro Trp Lys Ser 195 200 205 Lys Leu Leu Thr Leu Val Gln
Leu Thr Leu Gln Ser Thr Asn Tyr Thr 210 215 220 Cys Ile Val Cys Ile
Asp Arg Ala Ser Leu Ser Thr Trp His Val Leu 225 230 235 240 Tyr Ser
Pro Asn Val Ser Val Pro Ser Ser Ser Ser Thr Pro Leu Leu 245 250 255
Tyr Pro Ser Leu Ala Leu Pro Ala Pro His Leu Thr Leu Pro Phe Asn 260
265 270 Trp Thr His Cys Phe Asp Pro Gln Ile Gln Ala Ile Val Ser Ser
Pro 275 280 285 Cys His Asn Ser Leu Ile Leu Pro Pro Phe Ser Leu Ser
Pro Val Pro 290 295 300 Thr Leu Gly Ser Arg Ser Arg Arg Ala Val Pro
Val Ala Val Trp Leu 305 310 315 320 Val Ser Ala Leu Ala Met Gly Ala
Gly Ile Ala Gly Gly Ile Thr Gly 325 330 335 Ser Met Ser Leu Ala Ser
Gly Lys Ser Leu Leu His Glu Val Asp Lys 340 345 350 Asp Ile Ser Gln
Leu Thr Gln Ala Ile Val Lys Asn His Lys Asn Leu 355 360 365 Leu Lys
Ile Ala Gln Tyr Ala Ala Gln Asn Arg Arg Gly Leu Asp Leu 370 375 380
Leu Phe Trp Glu Gln Gly Gly Leu Cys Lys Ala Leu Gln Glu Gln Cys 385
390 395 400 Cys Phe Leu Asn Ile Thr Asn Ser His Val Ser Ile Leu Gln
Glu Arg 405 410 415 Pro Pro Leu Glu Asn Arg Val Leu Thr Gly Trp Gly
Leu Asn Trp Asp 420 425 430 Leu Gly Leu Ser Gln Trp Ala Arg Glu Ala
Leu Gln Thr Gly Ile Thr 435 440 445 Leu Val Ala Leu Leu Leu Leu Val
Ile Leu Ala Gly Pro Cys Ile Leu 450 455 460 Arg Gln Leu Arg His Leu
Pro Ser Arg Val Arg Tyr Pro His Tyr Ser 465 470 475 480 Leu Ile Asn
Pro Glu Ser Ser Leu 485 <210> SEQ ID NO 25 <211>
LENGTH: 486 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
STV2.RBD <400> SEQUENCE: 25 Met Gly Lys Ile Ile Ala Phe Leu
Leu Phe His Leu Thr Cys Ile Thr 1 5 10 15 Ile Thr Lys Gln Ser Arg
Cys Thr Leu Thr Val Gly Val Ser Ser Tyr 20 25 30 His Ser Ser Pro
Cys Ser Leu Ala Gln Pro Ile Cys Thr Trp Asp Leu 35 40 45 Asp Leu
His Ser Leu Thr Thr Asp Gln Arg Leu Tyr Pro Pro Cys Pro 50 55 60
Asn Leu Val Ser Tyr Ser Asn Phe His Lys Ser Tyr Ser Leu Tyr Leu 65
70 75 80 Phe Pro His Trp Val Lys Lys Pro Asn Arg Gln Gly Leu Gly
Tyr Tyr 85 90 95 Ser Ala Ser Tyr Ser Asp Pro Cys Ser Leu Gln Cys
Pro Tyr Leu Gly 100 105 110 Ser Gln Ser Trp Thr Cys Pro Tyr Thr Gly
Pro Ile Ser Ser Pro Ser 115 120 125 Trp Arg Phe His Arg Asp Val Asn
Phe Thr Gln Glu Val Asn His Val 130 135 140 Thr Leu Arg Leu His Phe
Ser Arg Cys Gly Ser Ser Met Thr Leu Leu 145 150 155 160 Ile Asp Ala
Pro Gly Tyr Asp Pro Leu Trp Phe Ile Ser Ser Glu Pro 165 170 175 Thr
Gln Pro Pro Pro Thr Ser Pro Pro Leu Val Arg Asp Ser Asp Leu 180 185
190 Glu His Ile Leu Thr Pro Ser Ser Ser Trp Ala Thr Arg Met Leu Thr
195 200 205 Leu Ile Gln Leu Thr Leu Gln Ser Thr Asn Tyr Ser Cys Met
Val Cys 210 215 220 Ile Asp Arg Thr Ser Leu Ser Ser Trp His Val Leu
Tyr Thr Pro Asn 225 230 235 240 Ile Ser Ala Ser Pro Gly Gly Asp Ser
Leu Pro Ile Leu Tyr Pro Ser 245 250 255 Leu Ala Leu Pro Ala Pro Gln
Pro Gln Pro Phe Ser Trp Ser His Cys 260 265 270 Tyr Gln Pro His Leu
Gln Ala Val Thr Thr Ala Asn Cys Asn Asn Ser 275 280 285 Ile Val Leu
Pro Pro Phe Ser Leu Thr Pro Val Pro Ser Pro Gly Thr 290 295 300 Arg
Ser Arg Arg Ala Ile Pro Val Ala Val Trp Leu Val Ser Ala Leu 305 310
315 320 Ala Ala Gly Thr Gly Ile Ala Gly Gly Ile Thr Gly Ser Leu Ser
Leu 325 330 335 Ala Ser Ser Arg Ser Leu Leu Phe Glu Val Asp Lys Asp
Ile Ser His 340 345 350 Leu Thr Gln Ala Ile Val Lys Asn His Gln Asn
Ile Leu Arg Val Ala 355 360 365 Gln Tyr Ala Ala Gln Asn Arg Arg Gly
Leu Asp Leu Leu Phe Trp Glu 370 375 380 Gln Gly Gly Leu Cys Lys Ala
Ile Gln Glu Gln Cys Cys Phe Leu Asn 385 390 395 400 Ile Ser Asn Thr
His Val Ser Val Leu Gln Glu Arg Pro Pro Leu Glu 405 410 415 Lys Arg
Val Ile Thr Gly Trp Gly Leu Asn Trp Asp Leu Gly Leu Ser 420 425 430
Gln Trp Ala Arg Glu Ala Leu Gln Thr Gly Ile Thr Ile Leu Ala Leu 435
440 445 Leu Leu Leu Val Ile Leu Phe Gly Pro Cys Ile Leu Arg Gln Leu
Gln 450 455 460 Ser Leu Pro His Arg Leu Gln Asn Arg His Asn Gln Tyr
Ser Leu Ile 465 470 475 480 Asn Gln Glu Thr Thr Leu 485 <210>
SEQ ID NO 26 <211> LENGTH: 930 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: STLV3.RBD <400> SEQUENCE: 26
atgggtaagt ttggccttta ttgtcttgtt cacctttaca tacttctccc tgcctcctct
60 ggcaatccca gtcggtgcac cctgttcata ggggcctctt cctaccactc
cagcccttgc 120 gggtccagcc tcccacggtg tacctggaat cttgacctat
tctccctcac gaaagatcaa 180 agcctaagcc ccccatgtcc agacttaatt
acttactcac aataccacaa gccctactcc 240 ctgtatgtat tccctcattg
gataactaaa cctaaccgcc ggggcttagg ttactattcc 300 gcttcctact
cagacccctg tgccatacag tgcccttacc tgggatgcca gtcgtggaca 360
tgcccctata cgggcccggt gtccagtccg cattggagat acacctatga tcttaacttt
420 acccaggagg tatcatccgt ctccttacac ttgcatttct ccaaatgcgg
atcctcgttc 480 tcctttctac tagacgcacc aggatatgac ccagtgtggt
tcctctcctc ccaggccaca 540 caggctccac ccacacctgc ccctctcata
cgggactcag atctccagta cattctagaa 600 ccgcccattc cgtggagctc
taagattctt aaccttatcc tcctcaccct aaaaagcact 660 aactattctt
gcatggtctg tgttgaccgc tccagcctat cctcatggca tgtcctgtat 720
ggacccactc aagtccccag tccacccgac ccccaagccc ggtctatcct gcgacctgcc
780 ttagctattc ccgccagtaa tatcaccccc ccgtttcctt ggacccattg
ctatcgccct 840 cctccgcaag ccatctcctc ggagaattgt aacaactctg
tagtgctgcc ccccttttct 900 ctgtctccaa ttcctaacgt ctccagaccc 930
<210> SEQ ID NO 27 <211> LENGTH: 310 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: STLV3.RBD <400> SEQUENCE: 27
Met Gly Lys Phe Gly Leu Tyr Cys Leu Val His Leu Tyr Ile Leu Leu 1 5
10 15 Pro Ala Ser Ser Gly Asn Pro Ser Arg Cys Thr Leu Phe Ile Gly
Ala 20 25 30 Ser Ser Tyr His Ser Ser Pro Cys Gly Ser Ser Leu Pro
Arg Cys Thr 35 40 45 Trp Asn Leu Asp Leu Phe Ser Leu Thr Lys Asp
Gln Ser Leu Ser Pro 50 55 60 Pro Cys Pro Asp Leu Ile Thr Tyr Ser
Gln Tyr His Lys Pro Tyr Ser 65 70 75 80 Leu Tyr Val Phe Pro His Trp
Ile Thr Lys Pro Asn Arg Arg Gly Leu 85 90 95 Gly Tyr Tyr Ser Ala
Ser Tyr Ser Asp Pro Cys Ala Ile Gln Cys Pro 100 105 110 Tyr Leu Gly
Cys Gln Ser Trp Thr Cys Pro Tyr Thr Gly Pro Val Ser 115 120 125 Ser
Pro His Trp Arg Tyr Thr Tyr Asp Leu Asn Phe Thr Gln Glu Val 130 135
140 Ser Ser Val Ser Leu His Leu His Phe Ser Lys Cys Gly Ser Ser Phe
145 150 155 160 Ser Phe Leu Leu Asp Ala Pro Gly Tyr Asp Pro Val Trp
Phe Leu Ser 165 170 175 Ser Gln Ala Thr Gln Ala Pro Pro Thr Pro Ala
Pro Leu Ile Arg Asp 180 185 190 Ser Asp Leu Gln Tyr Ile Leu Glu Pro
Pro Ile Pro Trp Ser Ser Lys 195 200 205 Ile Leu Asn Leu Ile Leu Leu
Thr Leu Lys Ser Thr Asn Tyr Ser Cys 210 215 220 Met Val Cys Val Asp
Arg Ser Ser Leu Ser Ser Trp His Val Leu Tyr 225 230 235 240 Gly Pro
Thr Gln Val Pro Ser Pro Pro Asp Pro Gln Ala Arg Ser Ile 245 250 255
Leu Arg Pro Ala Leu Ala Ile Pro Ala Ser Asn Ile Thr Pro Pro Phe 260
265 270 Pro Trp Thr His Cys Tyr Arg Pro Pro Pro Gln Ala Ile Ser Ser
Glu 275 280 285 Asn Cys Asn Asn Ser Val Val Leu Pro Pro Phe Ser Leu
Ser Pro Ile 290 295 300 Pro Asn Val Ser Arg Pro 305 310 <210>
SEQ ID NO 28 <211> LENGTH: 228 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Rabbit Fc fragment <400>
SEQUENCE: 28 Ala Pro Ser Thr Cys Ser Lys Pro Thr Cys Pro Pro Pro
Glu Leu Leu 1 5 10 15 Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys
Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu Val Thr
Cys Val Val Val Asp Val Ser 35 40 45 Gln Asp Asp Pro Glu Val Gln
Phe Thr Trp Tyr Ile Asn Asn Glu Gln 50 55 60 Val Arg Thr Ala Arg
Pro Pro Leu Arg Glu Gln Gln Phe Asp Cys Thr 65 70 75 80 Ile Arg Val
Val Ser Thr Leu Pro Ile Ala His Gln Asp Trp Leu Arg 85 90 95 Gly
Lys Glu Phe Lys Cys Lys Val His Asn Lys Ala Leu Pro Ala Pro 100 105
110 Ile Glu Lys Thr Ile Ser Lys Ala Arg Gly Gln Pro Leu Glu Pro Lys
115 120 125 Val Tyr Thr Met Gly Pro Pro Arg Glu Glu Leu Ser Ser Arg
Ser Val 130 135 140 Ser Leu Thr Cys Met Ile Asn Gly Phe Tyr Pro Ser
Asp Ile Ser Val 145 150 155 160 Glu Trp Glu Lys Asn Gly Lys Ala Glu
Asp Asn Tyr Lys Thr Thr Pro 165 170 175 Ala Val Leu Asp Ser Asp Gly
Ser Tyr Phe Leu Tyr Ser Lys Leu Ser 180 185 190 Val Pro Thr Ser Glu
Trp Gln Arg Gly Asp Val Phe Thr Cys Ser Val 195 200 205 Met His Glu
Ala Leu His Asn His Tyr Thr Gln Lys Ser Ile Ser Arg 210 215 220 Ser
Pro Gly Lys 225 <210> SEQ ID NO 29 <211> LENGTH: 687
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Rabbit Fc
fragment <400> SEQUENCE: 29 gcaccctcga catgcagcaa gcccacgtgc
ccaccccctg aactcctggg gggaccgtct 60 gtcttcatct tccccccaaa
acccaaggac accctcatga tctcacgcac ccccgaggtc 120 acatgcgtgg
tggtggacgt gagccaggat gaccccgagg tgcagttcac atggtacata 180
aacaacgagc aggtgcgcac cgcccggccg ccgctacggg agcagcagtt caacagcacg
240 atccgcgtgg tcagcaccct ccccatcacg caccaggact ggctgagggg
caaggagttc 300 aagtgcaaag tccacaacaa ggcactcccg gcccccatcg
agaaaaccat ctccaaagcc 360 agagggcagc ccctggagcc gaaggtctac
accatgggcc ctccccggga ggagctgagc 420 agcaggtcgg tcagcctgac
ctgcatgatc aacggcttct acccttccga catctcggtg 480 gagtgggaga
agaacgggaa ggcagaggac aactacaaga ccacgccggc cgtgctggac 540
agcgacggct cctacttcct ctacaacaag ctctcagtgc ccacgagtga gtggcagcgg
600 ggcgacgtct tcacctgctc cgtgatgcac gaggccttgc acaaccacta
cacgcagaag 660 tccatctccc gctctccggg taaatga 687 <210> SEQ ID
NO 30 <211> LENGTH: 229 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Mouse Fc fragment <400> SEQUENCE: 30 Val
Asp Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val 1 5 10
15 Pro Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val
20 25 30 Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val
Asp Ile 35 40 45 Ser Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe
Val Asp Asp Val 50 55 60 Glu Val His Thr Ala Gln Thr Gln Pro Arg
Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Phe Arg Ser Val Ser Glu Leu
Pro Ile Met His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Phe Lys
Cys Arg Val Asn Ser Ala Ala Phe Pro Ala 100 105 110 Pro Ile Glu Lys
Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro 115 120 125 Gln Val
Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys 130 135 140
Val Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr 145
150 155 160 Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys
Asn Thr 165 170 175 Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val
Tyr Ser Lys Leu 180 185 190 Asn Val Gln Lys Ser Asn Trp Glu Ala Gly
Asn Thr Phe Thr Cys Ser 195 200 205 Val Leu His Glu Gly Leu His Asn
His His Thr Glu Lys Ser Leu Ser 210 215 220 His Ser Pro Gly Lys 225
<210> SEQ ID NO 31 <211> LENGTH: 690 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Mouse Fc fragment <400>
SEQUENCE: 31 gtcgacgtgc ccagggattg tggttgtaag ccttgcatat gtacagtccc
agaagtatca 60 tctgtcttca tcttcccccc aaagcccaag gatgtgctca
ccattactct gactcctaag 120 gtcacgtgtg ttgtggtaga catcagcaag
gatgatcccg aggtccagtt cagctggttt 180 gtagatgatg tggaggtgca
cacagctcag acgcaacccc gggaggagca gttcaacagc 240 actttccgct
cagtcagtga acttcccatc atgcaccagg actggctcaa tggcaaggag 300
ttcaaatgca gggtcaacag tgcagctttc cctgccccca tcgagaaaac catctccaaa
360 accaaaggca gaccgaaggc tccacaggtg tacaccattc cacctcccaa
ggagcagatg 420 gccaaggata aagtcagtct gacctgcatg ataacagact
tcttccctga agacattact 480 gtggagtggc agtggaatgg gcagccagcg
gagaactaca agaacactca gcccatcatg 540 gacacagatg gctcttactt
cgtctacagc aagctcaatg tgcagaagag caactgggag 600 gcaggaaata
ctttcacctg ctctgtgtta catgagggcc tgcacaacca ccatactgag 660
aagagcctct cccactctcc tggtaaatga 690 <210> SEQ ID NO 32
<211> LENGTH: 1230 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV2.RBD fused to a mouse Fc fragment
<400> SEQUENCE: 32 atgggtaatg ttttcttcct acttttattc
agtctcacac attttccact agcccagcag 60 agccgatgca cactcacagt
tggtatctcc tcctaccact ccagcccctg tagcccaacc 120 caacccgtct
gcacgtggaa cctcgacctt aattccctaa caacggacca acgactacac 180
cccccctgcc ctaacctaat tacttactct ggcttccata agacttattc cttatactta
240 ttcccacatt ggataaaaaa gccaaacaga cagggcctag ggtactactc
gccttcctac 300 aatgaccctt gctcgctaca atgcccctac ttgggctgcc
aatcatggac atgcccatac 360 acgggccccg tctccagtcc atcctggaag
tttcattcag atgtaaattt cacccaggaa 420 gtcagccaag tgtcccttcg
actacacttc tctaagtgcg gctcctccat gaccctccta 480 gtagatgccc
ctggatatga tcctttatgg ttcatcacct cagaacccac tcagggatcc 540
gtcgacgtgc ccagggattg tggttgtaag ccttgcatat gtacagtccc agaagtatca
600 tctgtcttca tcttcccccc aaagcccaag gatgtgctca ccattactct
gactcctaag 660 gtcacgtgtg ttgtggtaga catcagcaag gatgatcccg
aggtccagtt cagctggttt 720 gtagatgatg tggaggtgca cacagctcag
acgcaacccc gggaggagca gttcaacagc 780 actttccgct cagtcagtga
acttcccatc atgcaccagg actggctcaa tggcaaggag 840 ttcaaatgca
gggtcaacag tgcagctttc cctgccccca tcgagaaaac catctccaaa 900
accaaaggca gaccgaaggc tccacaggtg tacaccattc cacctcccaa ggagcagatg
960 gccaaggata aagtcagtct gacctgcatg ataacagact tcttccctga
agacattact 1020 gtggagtggc agtggaatgg gcagccagcg gagaactaca
agaacactca gcccatcatg 1080 gacacagatg gctcttactt cgtctacagc
aagctcaatg tgcagaagag caactgggag 1140 gcaggaaata ctttcacctg
ctctgtgtta catgagggcc tgcacaacca ccatactgag 1200 aagagcctct
cccactctcc tggtaaatga 1230 <210> SEQ ID NO 33 <211>
LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: GLUT1
fragment <400> SEQUENCE: 33 Asn Ala Pro Gln Lys Val Ile Glu
Glu Phe Tyr 1 5 10 <210> SEQ ID NO 34 <211> LENGTH: 22
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: GLUT1 fragment
<400> SEQUENCE: 34 Asn Gln Thr Trp Val His Arg Tyr Gly Glu
Ser Ile Leu Pro Thr Thr 1 5 10 15 Leu Thr Thr Leu Trp Ser 20
<210> SEQ ID NO 35 <211> LENGTH: 10 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: GLUT1 fragment <400> SEQUENCE:
35 Lys Ser Phe Glu Met Leu Ile Leu Gly Arg 1 5 10 <210> SEQ
ID NO 36 <211> LENGTH: 9 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: GLUT1 fragment <400> SEQUENCE: 36 Asp Ser
Ile Met Gly Asn Lys Asp Leu 1 5 <210> SEQ ID NO 37
<211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: GLUT1 fragment <400> SEQUENCE: 37 Tyr Ser Thr
Ser Ile Phe Glu Lys Ala Gly Val Gln Gln Pro 1 5 10 <210> SEQ
ID NO 38 <211> LENGTH: 10 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: GLUT1 fragment <400> SEQUENCE: 38 Glu Gln
Leu Pro Trp Met Ser Tyr Leu Ser 1 5 10 <210> SEQ ID NO 39
<211> LENGTH: 7 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: GLUT1 fragment <400> SEQUENCE: 39 Gln Tyr Val
Glu Gln Leu Cys 1 5 <210> SEQ ID NO 40 <211> LENGTH: 13
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: GLUT1 fragment
<400> SEQUENCE: 40 Ile Val Gly Met Cys Phe Gln Tyr Val Glu
Gln Leu Cys 1 5 10 <210> SEQ ID NO 41 <211> LENGTH: 304
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: HTLV2.RBD
<400> SEQUENCE: 41 Met Gly Asn Val Phe Phe Leu Leu Leu Phe
Ser Leu Thr His Phe Pro 1 5 10 15 Pro Val Gln Gln Ser Arg Cys Thr
Leu Thr Val Gly Ile Ser Ser Tyr 20 25 30 His Ser Ser Pro Cys Ser
Pro Thr Gln Pro Val Cys Thr Trp Asn Leu 35 40 45 Asp Leu Asn Ser
Leu Thr Thr Asp Gln Arg Leu His Pro Pro Cys Pro 50 55 60 Asn Leu
Ile Thr Tyr Ser Gly Phe His Lys Thr Tyr Ser Leu Tyr Leu 65 70 75 80
Phe Pro His Trp Ile Lys Lys Pro Asn Arg Gln Gly Leu Gly Tyr Tyr 85
90 95 Ser Pro Ser Tyr Asn Asp Pro Cys Ser Leu Gln Cys Pro Tyr Leu
Gly 100 105 110 Cys Gln Ser Trp Thr Cys Pro Tyr Thr Gly Pro Val Ser
Ser Pro Ser 115 120 125 Trp Lys Phe His Ser Asp Val Asn Phe Thr Gln
Glu Val Ser Gln Val 130 135 140 Ser Leu Arg Leu His Phe Ser Lys Cys
Gly Ser Ser Met Thr Leu Leu 145 150 155 160 Val Asp Ala Pro Gly Tyr
Asp Pro Leu Trp Phe Ile Thr Ser Glu Pro 165 170 175 Thr Gln Pro Pro
Pro Thr Pro Pro Pro Leu Val His Asp Ser Asp Leu 180 185 190 Glu His
Val Leu Thr Pro Ser Thr Ser Trp Thr Thr Lys Met Leu Lys 195 200 205
Phe Ile Gln Leu Thr Leu Gln Ser Thr Asn Tyr Ser Cys Met Val Cys 210
215 220 Val Asp Arg Ser Ser Leu Ser Ser Trp His Val Leu Tyr Thr Pro
Asn 225 230 235 240 Ile Ser Ile Pro Gln Gln Thr Ser Ser Arg Thr Ile
Leu Phe Pro Ser 245 250 255 Leu Ala Leu Pro Ala Pro Pro Phe Gln Pro
Phe Pro Trp Thr His Cys 260 265 270 Tyr Gln Pro Arg Leu Gln Ala Ile
Thr Thr Asp Asp Cys Asn Asn Ser 275 280 285 Ile Ile Leu Pro Pro Phe
Ser Leu Ala Pro Val Pro Pro Pro Ala Thr 290 295 300 <210> SEQ
ID NO 42 <211> LENGTH: 20 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: human IL-2 peptide signal <400> SEQUENCE:
42 Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu
1 5 10 15 Val Thr Asn Ser 20 <210> SEQ ID NO 43 <211>
LENGTH: 18 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: human
albumine peptide signal <400> SEQUENCE: 43 Met Lys Trp Val
Thr Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala 1 5 10 15 Tyr Ser
<210> SEQ ID NO 44 <211> LENGTH: 18 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: human chymotryosinogen peptide
signal <400> SEQUENCE: 44 Met Ala Phe Leu Trp Leu Leu Ser Cys
Trp Ala Leu Leu Gly Thr Thr 1 5 10 15 Phe Gly <210> SEQ ID NO
45 <211> LENGTH: 15 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: human trypsinogen-2 peptide signal <400>
SEQUENCE: 45 Met Asn Leu Leu Leu Ile Leu Thr Phe Val Ala Ala Ala
Val Ala 1 5 10 15 <210> SEQ ID NO 46 <211> LENGTH: 17
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: gaussia
luciferase peptide signal <400> SEQUENCE: 46 Met Gly Val Lys
Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu 1 5 10 15 Ala
<210> SEQ ID NO 47 <211> LENGTH: 21 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Mouse IgM peptide signal <400>
SEQUENCE: 47 Met Lys Phe Ser Trp Val Met Phe Phe Leu Met Ala Val
Val Thr Gly 1 5 10 15 Val Asn Ser Glu Phe 20 <210> SEQ ID NO
48 <211> LENGTH: 2208 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Nucleic acid HTLV4 <400> SEQUENCE: 48
atgggatgtc ttgggaatca gctgcttatc gccatcttgc ttttaagtgt ctatgggatc
60 tattgtactc aatatgtcac agtcttttat ggtgtaccag cttggaggaa
tgcgacaatt 120 cccctcttct gtgcaaccaa gaatagggat acttggggaa
caactcagtg cctaccagat 180 aatggtgatt attcagaatt ggcccttaat
gttacagaaa gctttgatgc ttgggagaat 240 acagtcacag aacaggcaat
agaggacgta tggcaactct ttgagacctc aataaagcct 300 tgtgtaaaat
tatccccatt atgcattact atgagatgca ataaaagtga gacagataga 360
tggggattga caaaatcatc aacaacaata acaacagcag caccaacatc agcaccagta
420 tcagaaaaaa tagacatggt caatgagact agttcttgta tagctcagaa
taattgcaca 480 ggcttggaac aagagcaaat gataagctgt aaattcacca
tgacagggtt aaaaagagac 540 aagacaaagg agtacaatga aacttggtac
tctacagatt tggtttgtga acaagggaat 600 agcactgata atgaaagcag
atgctacata aatcactgta acacttctgt tatccaagag 660 tcttgtgaca
aacattattg ggatactatt agatttaggt attgtgcacc tccaggttat 720
gctttgctta gatgtaatga cacaaattat tcaggcttta tgcctaaatg ttctaaggtg
780 gtggtctctt catgcacaag gatgatggag acacagactt ctacttggtt
tggctttaat 840 ggaactagag cagaaaatag aacttatatt tactggcatg
gtagggataa taggactata 900 attagtttaa ataagtatta taatctaaca
atgaaatgta gaagaccagg aaataagaca 960 gttttaccag tcaccattat
gtctggattg gttttccact cacaaccaat caatgatagg 1020 ccaaagcagg
catggtgttg gtttggagga aaatggaagg atgcaataaa agaggtgaaa 1080
cagaccattg tcaaacatcc caggtatact ggaactaaca atactgataa aatcaattta
1140 acggctcctg gaggaggaga tccagaagtt accttcatgt ggacaaattg
cagaggagag 1200 ttcctctact gtaaaatgaa ttggtttcta aattgggtag
aggataggga tgtaactacc 1260 cagaggccaa aggaacggca tagaaggaat
tacgtgccgt gtcatattag acaagtaatc 1320 aacacttggc ataaagtagg
caaaaatgtt tatttgcctc caagagaggg agacctcacg 1380 tgtaactcca
cagtgaccag tctcatagca aacatagatt ggactgatgg aaaccaaact 1440
aatatcacca tgagtgcaga ggtggcagaa ctgtatcgat tggagttggg agattataaa
1500 ttagtagaga tcactccgat cggcttggcc cccacagatg tgaagaggta
cactactggt 1560 ggcacctcaa gaaataaaag aggggtcttt gtgctagggt
tcttgggttt tctcgcaacg 1620 gcaggttctg caatgggcgc ggcgtcgttg
acgctgaccg ctcagtcccg gactttattg 1680 gctgggatag tgcagcaaca
gcaacagctg ttggacgtgg tcaagagaca acaagaattg 1740 ttgcgactga
ccgtctgggg aacaaagaac ctccagacta gggtcactgc catcgagaag 1800
tacttaaagg accaggcgca gctgaatact tggggatgtg cgtttagaca agtctgccac
1860 actactgtac catggccaaa tgcaagtcta acaccagact ggaacaatga
tacttggcaa 1920 gagtgggagc gaaaggttga cttcttggag gaaaatataa
cagccctcct agaagaggca 1980 caaattcaac aagagaagaa catgtatgaa
ttacaaaagt taaatagctg ggatgtgttt 2040 ggcaattggt ttgaccttgc
ttcttggata aagtatatac aatatggaat ttatgtagtt 2100 gtaggagtaa
tactgttaag aatagtgatc tatatagtac aaatgctagc taagttaagg 2160
caggggtata ggccagtgtt ctcttcccca ccctcttatt tccagtag 2208
<210> SEQ ID NO 49 <211> LENGTH: 735 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Amino acid HTLV4 <400>
SEQUENCE: 49 Met Gly Cys Leu Gly Asn Gln Leu Leu Ile Ala Ile Leu
Leu Leu Ser 1 5 10 15 Val Tyr Gly Ile Tyr Cys Thr Gln Tyr Val Thr
Val Phe Tyr Gly Val 20 25 30 Pro Ala Trp Arg Asn Ala Thr Ile Pro
Leu Phe Cys Ala Thr Lys Asn 35 40 45 Arg Asp Thr Trp Gly Thr Thr
Gln Cys Leu Pro Asp Asn Gly Asp Tyr 50 55 60 Ser Glu Leu Ala Leu
Asn Val Thr Glu Ser Phe Asp Ala Trp Glu Asn 65 70 75 80 Thr Val Thr
Glu Gln Ala Ile Glu Asp Val Trp Gln Leu Phe Glu Thr 85 90 95 Ser
Ile Lys Pro Cys Val Lys Leu Ser Pro Leu Cys Ile Thr Met Arg 100 105
110 Cys Asn Lys Ser Glu Thr Asp Arg Trp Gly Leu Thr Lys Ser Ser Thr
115 120 125 Thr Ile Thr Thr Ala Ala Pro Thr Ser Ala Pro Val Ser Glu
Lys Ile 130 135 140 Asp Met Val Asn Glu Thr Ser Ser Cys Ile Ala Gln
Asn Asn Cys Thr 145 150 155 160 Gly Leu Glu Gln Glu Gln Met Ile Ser
Cys Lys Phe Thr Met Thr Gly 165 170 175 Leu Lys Arg Asp Lys Thr Lys
Glu Tyr Asn Glu Thr Trp Tyr Ser Thr 180 185 190 Asp Leu Val Cys Glu
Gln Gly Asn Ser Thr Asp Asn Glu Ser Arg Cys 195 200 205 Tyr Ile Asn
His Cys Asn Thr Ser Val Ile Gln Glu Ser Cys Asp Lys 210 215 220 His
Tyr Trp Asp Thr Ile Arg Phe Arg Tyr Cys Ala Pro Pro Gly Tyr 225 230
235 240 Ala Leu Leu Arg Cys Asn Asp Thr Asn Tyr Ser Gly Phe Met Pro
Lys 245 250 255 Cys Ser Lys Val Val Val Ser Ser Cys Thr Arg Met Met
Glu Thr Gln 260 265 270 Thr Ser Thr Trp Phe Gly Phe Asn Gly Thr Arg
Ala Glu Asn Arg Thr 275 280 285 Tyr Ile Tyr Trp His Gly Arg Asp Asn
Arg Thr Ile Ile Ser Leu Asn 290 295 300 Lys Tyr Tyr Asn Leu Thr Met
Lys Cys Arg Arg Pro Gly Asn Lys Thr 305 310 315 320 Val Leu Pro Val
Thr Ile Met Ser Gly Leu Val Phe His Ser Gln Pro 325 330 335 Ile Asn
Asp Arg Pro Lys Gln Ala Trp Cys Trp Phe Gly Gly Lys Trp 340 345 350
Lys Asp Ala Ile Lys Glu Val Lys Gln Thr Ile Val Lys His Pro Arg 355
360 365 Tyr Thr Gly Thr Asn Asn Thr Asp Lys Ile Asn Leu Thr Ala Pro
Gly 370 375 380 Gly Gly Asp Pro Glu Val Thr Phe Met Trp Thr Asn Cys
Arg Gly Glu 385 390 395 400 Phe Leu Tyr Cys Lys Met Asn Trp Phe Leu
Asn Trp Val Glu Asp Arg 405 410 415 Asp Val Thr Thr Gln Arg Pro Lys
Glu Arg His Arg Arg Asn Tyr Val 420 425 430 Pro Cys His Ile Arg Gln
Val Ile Asn Thr Trp His Lys Val Gly Lys 435 440 445 Asn Val Tyr Leu
Pro Pro Arg Glu Gly Asp Leu Thr Cys Asn Ser Thr 450 455 460 Val Thr
Ser Leu Ile Ala Asn Ile Asp Trp Thr Asp Gly Asn Gln Thr 465 470 475
480 Asn Ile Thr Met Ser Ala Glu Val Ala Glu Leu Tyr Arg Leu Glu Leu
485 490 495 Gly Asp Tyr Lys Leu Val Glu Ile Thr Pro Ile Gly Leu Ala
Pro Thr 500 505 510 Asp Val Lys Arg Tyr Thr Thr Gly Gly Thr Ser Arg
Asn Lys Arg Gly 515 520 525 Val Phe Val Leu Gly Phe Leu Gly Phe Leu
Ala Thr Ala Gly Ser Ala 530 535 540 Met Gly Ala Ala Ser Leu Thr Leu
Thr Ala Gln Ser Arg Thr Leu Leu 545 550 555 560 Ala Gly Ile Val Gln
Gln Gln Gln Gln Leu Leu Asp Val Val Lys Arg 565 570 575 Gln Gln Glu
Leu Leu Arg Leu Thr Val Trp Gly Thr Lys Asn Leu Gln 580 585 590 Thr
Arg Val Thr Ala Ile Glu Lys Tyr Leu Lys Asp Gln Ala Gln Leu 595 600
605 Asn Thr Trp Gly Cys Ala Phe Arg Gln Val Cys His Thr Thr Val Pro
610 615 620 Trp Pro Asn Ala Ser Leu Thr Pro Asp Trp Asn Asn Asp Thr
Trp Gln 625 630 635 640 Glu Trp Glu Arg Lys Val Asp Phe Leu Glu Glu
Asn Ile Thr Ala Leu 645 650 655 Leu Glu Glu Ala Gln Ile Gln Gln Glu
Lys Asn Met Tyr Glu Leu Gln 660 665 670 Lys Leu Asn Ser Trp Asp Val
Phe Gly Asn Trp Phe Asp Leu Ala Ser 675 680 685 Trp Ile Lys Tyr Ile
Gln Tyr Gly Ile Tyr Val Val Val Gly Val Ile 690 695 700 Leu Leu Arg
Ile Val Ile Tyr Ile Val Gln Met Leu Ala Lys Leu Arg 705 710 715 720
Gln Gly Tyr Arg Pro Val Phe Ser Ser Pro Pro Ser Tyr Phe Gln 725 730
735 <210> SEQ ID NO 50 <211> LENGTH: 1485 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Nucleic acid HTLV3
<400> SEQUENCE: 50 atgggtaagt ccggtcttta tttcagtctc
atttgttttt acacactctt cccttcctct 60 tttggcaatc ccagccgatg
caccctgttc ataggagctt cctcctacca ctctgacccc 120 tgtgggtcca
accacccacg atgtacctgg agacttgacc tcttttccct cacaaaggat 180
caaagcctaa gccccccatg tccaggctta gttacttact cacagtacca taaaccctac
240 tccctatatg tatttcctca ttggatagcc aaacctgacc gtcgaggcct
aggttactat 300 tctgcttcct actcggaccc ctgcgctata caatgccctt
acctaggatg ccagtcatgg 360 acgtgcccct atacaggtcc ggtgtccaac
ccacattgga aatacacctc tgatcttaac 420 ttcacccaag aagtatcatc
catttcccta cacttgcact tttccaaatg tgggtcctca 480 ttctcctttc
tattagatgc gccaggatat gacccagtgt ggctcctctc atcccaggcc 540
acccaaattc cacccacgcc cgcccctctc atacaggact cagatctcca acatatcctg
600 gaaccttcta tcccatggag ttctaaaatc cttaacctta tcctccttgc
tttaaagagc 660 actaattatt cttgcatggt ctgtgtcgat cgctccagcc
tctcttcatg gcatgttctg 720 tacgacccac tcaaagcccc cagttcaccc
gacccccaag cccagtctat cctacggccc 780 tccttagcca ttcccgccag
taacatcacc cctccgtttc cttggaccca ctgctatcgc 840 cctcctctac
aggccatctc ctcagaaaac tgcaataact ctgtaatact gccccccttc 900
tccctgtccc caattcctga tgtctctaga ccccggaagc gccgagcagt ccccatcgct
960 atatggctgg tatccgccct agcggccggc acgggtatag caggcggagt
taccggctcc 1020 ctgtccctgg cgtccagcaa gagtctgttg cgcgaggttg
accaggacat agatcaccta 1080 acccgggcaa ttgtaaagaa ccatgacaac
atccttcggg ttgctcagta cgcagcccaa 1140 aatcgccgcg gcctagacct
gcttttttgg gagcagggag gtctttgtaa ggccatccag 1200 gagcaatgtt
gtttccttaa tatcagcaac acccatgtgt cagtccttca ggaaagacct 1260
cctctagaaa aaagggtaat taccggctgg gggctcaatt gggaccttgg gctctcccaa
1320 tgggcccgag aggccctcca gacaggtata acactcttgg ccctctttct
cctcctcatt 1380 gtcgtagggc cctgtgtcat acgtcagctg cagaccctcc
cctcccgcct gcagcaccgc 1440 agccaaccct actcccttct caattatgaa
accaacttat aataa 1485 <210> SEQ ID NO 51 <211> LENGTH:
493 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Amino acid
HTLV3 <400> SEQUENCE: 51 Met Gly Lys Ser Gly Leu Tyr Phe Ser
Leu Ile Cys Phe Tyr Thr Leu 1 5 10 15 Phe Pro Ser Ser Phe Gly Asn
Pro Ser Arg Cys Thr Leu Phe Ile Gly 20 25 30 Ala Ser Ser Tyr His
Ser Asp Pro Cys Gly Ser Asn His Pro Arg Cys 35 40 45 Thr Trp Arg
Leu Asp Leu Phe Ser Leu Thr Lys Asp Gln Ser Leu Ser 50 55 60 Pro
Pro Cys Pro Gly Leu Val Thr Tyr Ser Gln Tyr His Lys Pro Tyr 65 70
75 80 Ser Leu Tyr Val Phe Pro His Trp Ile Ala Lys Pro Asp Arg Arg
Gly 85 90 95 Leu Gly Tyr Tyr Ser Ala Ser Tyr Ser Asp Pro Cys Ala
Ile Gln Cys 100 105 110 Pro Tyr Leu Gly Cys Gln Ser Trp Thr Cys Pro
Tyr Thr Gly Pro Val 115 120 125 Ser Asn Pro His Trp Lys Tyr Thr Ser
Asp Leu Asn Phe Thr Gln Glu 130 135 140 Val Ser Ser Ile Ser Leu His
Leu His Phe Ser Lys Cys Gly Ser Ser 145 150 155 160 Phe Ser Phe Leu
Leu Asp Ala Pro Gly Tyr Asp Pro Val Trp Leu Leu 165 170 175 Ser Ser
Gln Ala Thr Gln Ile Pro Pro Thr Pro Ala Pro Leu Ile Gln 180 185 190
Asp Ser Asp Leu Gln His Ile Leu Glu Pro Ser Ile Pro Trp Ser Ser 195
200 205 Lys Ile Leu Asn Leu Ile Leu Leu Ala Leu Lys Ser Thr Asn Tyr
Ser 210 215 220 Cys Met Val Cys Val Asp Arg Ser Ser Leu Ser Ser Trp
His Val Leu 225 230 235 240 Tyr Asp Pro Leu Lys Ala Pro Ser Ser Pro
Asp Pro Gln Ala Gln Ser 245 250 255 Ile Leu Arg Pro Ser Leu Ala Ile
Pro Ala Ser Asn Ile Thr Pro Pro 260 265 270 Phe Pro Trp Thr His Cys
Tyr Arg Pro Pro Leu Gln Ala Ile Ser Ser 275 280 285 Glu Asn Cys Asn
Asn Ser Val Ile Leu Pro Pro Phe Ser Leu Ser Pro 290 295 300 Ile Pro
Asp Val Ser Arg Pro Arg Lys Arg Arg Ala Val Pro Ile Ala 305 310 315
320 Ile Trp Leu Val Ser Ala Leu Ala Ala Gly Thr Gly Ile Ala Gly Gly
325 330 335 Val Thr Gly Ser Leu Ser Leu Ala Ser Ser Lys Ser Leu Leu
Arg Glu 340 345 350 Val Asp Gln Asp Ile Asp His Leu Thr Arg Ala Ile
Val Lys Asn His 355 360 365 Asp Asn Ile Leu Arg Val Ala Gln Tyr Ala
Ala Gln Asn Arg Arg Gly 370 375 380 Leu Asp Leu Leu Phe Trp Glu Gln
Gly Gly Leu Cys Lys Ala Ile Gln 385 390 395 400 Glu Gln Cys Cys Phe
Leu Asn Ile Ser Asn Thr His Val Ser Val Leu 405 410 415 Gln Glu Arg
Pro Pro Leu Glu Lys Arg Val Ile Thr Gly Trp Gly Leu 420 425 430 Asn
Trp Asp Leu Gly Leu Ser Gln Trp Ala Arg Glu Ala Leu Gln Thr 435 440
445 Gly Ile Thr Leu Leu Ala Leu Phe Leu Leu Leu Ile Val Val Gly Pro
450 455 460 Cys Val Ile Arg Gln Leu Gln Thr Leu Pro Ser Arg Leu Gln
His Arg 465 470 475 480 Ser Gln Pro Tyr Ser Leu Leu Asn Tyr Glu Thr
Asn Leu 485 490 <210> SEQ ID NO 52 <211> LENGTH: 1476
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Nucleic acid
STLV3 <400> SEQUENCE: 52 atgggtaagt ccggctttta tttctgtttt
atttacactc tcttccctgc ctcctttggc 60 aaccccagtc gatgcaccct
gttcataggg gcctcttcct accactccga cccttgtggg 120 tccaatcacc
cacaatgtac ctggaggctc gacctattct ccctcacaag ggatcaaagc 180
ctgagccccc catgtccaga cttagtcact tactcacagt atcataaacc ctactccctg
240 tatgtatttc cccattggat ggccaaacct aaccgtcaag gcctaggcta
ctattctgct 300 tcctactcag acccttgtgc tatacagtgc ccttacctag
gatgccagtc atggacctgt 360 ccctacacag gcccggtgtc cagcccgcat
tggaaatact cctccgatct taattttacc 420 caagaggtat catctatctc
cctacactta catttttcca aatgcgggtc ttcattctct 480 tttctactag
atgcaccggg gtacgaccct gtgtggttcc tctcctccca ggccacacag 540
gttccaccca cgcccgcccc tctcatacag gactctaatc tccaacatat cctggaaccc
600 tccgtcccgt ggagctccaa aatcctcaat ctcatcctcc tcaccttaaa
aagcactaac 660 tattcttgta tggtctgtgt cgaccgctcc agcctatctt
cgtggcatgt tctatatgac 720 ccactcaaag cccccggtcc acccgacccc
caagcccagt ctatcttgcg accctcctta 780 gccattcccg ccagtaatat
cacccctccg tttccctgga cccattgcta tcgccctctt 840 ctacaggcca
tctcctcaga acactgcaac aactccgtag tgctgccccc cttttccctg 900
tccccacttc ctaacgcctt cagaccccga aagcgccggg cagtccccat cgccatatgg
960 ctagtatccg cccttgcggc cggcaccggt atagctggtg gagttacagg
ctccctgtct 1020 ctggcctccg gcaaaagcct gttacacgaa gtagaccaag
acatagatca cctgacgcgg 1080 gcaattgtaa agaaccatga caatatcctt
cgggtcgctc agtatgcagc ccaaaatcgt 1140 cgcggcctag atctgctttt
ctgggaacaa ggaggccttt gtaaggccat ccaagagcaa 1200 tgttgtttcc
tcaatatcag taacacccat gtgtccgtcc tccaggaaag acccccccta 1260
gaaaaaagag taatcacggg ctgggggctc aattgggacc tcgggctctc ccaatgggcc
1320 cgagaggccc ttcagacagg tataaccctc ttggccctct ttctcctcct
tattgtggtc 1380 gggccctgcg tcatacgcca gctgcaggcc ctcccttccc
gcctgcagcc tcgcagccag 1440 ccctactccc ttctaaatta tgaaaccaac ttataa
1476 <210> SEQ ID NO 53 <211> LENGTH: 491 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Amino acid STLV3
<400> SEQUENCE: 53 Met Gly Lys Ser Gly Phe Tyr Phe Cys Phe
Ile Tyr Thr Leu Phe Pro 1 5 10 15 Ala Ser Phe Gly Asn Pro Ser Arg
Cys Thr Leu Phe Ile Gly Ala Ser 20 25 30 Ser Tyr His Ser Asp Pro
Cys Gly Ser Asn His Pro Gln Cys Thr Trp 35 40 45 Arg Leu Asp Leu
Phe Ser Leu Thr Arg Asp Gln Ser Leu Ser Pro Pro 50 55 60 Cys Pro
Asp Leu Val Thr Tyr Ser Gln Tyr His Lys Pro Tyr Ser Leu 65 70 75 80
Tyr Val Phe Pro His Trp Met Ala Lys Pro Asn Arg Gln Gly Leu Gly 85
90 95 Tyr Tyr Ser Ala Ser Tyr Ser Asp Pro Cys Ala Ile Gln Cys Pro
Tyr 100 105 110 Leu Gly Cys Gln Ser Trp Thr Cys Pro Tyr Thr Gly Pro
Val Ser Ser 115 120 125 Pro His Trp Lys Tyr Ser Ser Asp Leu Asn Phe
Thr Gln Glu Val Ser 130 135 140 Ser Ile Ser Leu His Leu His Phe Ser
Lys Cys Gly Ser Ser Phe Ser 145 150 155 160 Phe Leu Leu Asp Ala Pro
Gly Tyr Asp Pro Val Trp Phe Leu Ser Ser 165 170 175 Gln Ala Thr Gln
Val Pro Pro Thr Pro Ala Pro Leu Ile Gln Asp Ser 180 185 190 Asn Leu
Gln His Ile Leu Glu Pro Ser Val Pro Trp Ser Ser Lys Ile 195 200 205
Leu Asn Leu Ile Leu Leu Thr Leu Lys Ser Thr Asn Tyr Ser Cys Met 210
215 220 Val Cys Val Asp Arg Ser Ser Leu Ser Ser Trp His Val Leu Tyr
Asp 225 230 235 240 Pro Leu Lys Ala Pro Gly Pro Pro Asp Pro Gln Ala
Gln Ser Ile Leu 245 250 255 Arg Pro Ser Leu Ala Ile Pro Ala Ser Asn
Ile Thr Pro Pro Phe Pro 260 265 270 Trp Thr His Cys Tyr Arg Pro Leu
Leu Gln Ala Ile Ser Ser Glu His 275 280 285 Cys Asn Asn Ser Val Val
Leu Pro Pro Phe Ser Leu Ser Pro Leu Pro 290 295 300 Asn Ala Phe Arg
Pro Arg Lys Arg Arg Ala Val Pro Ile Ala Ile Trp 305 310 315 320 Leu
Val Ser Ala Leu Ala Ala Gly Thr Gly Ile Ala Gly Gly Val Thr 325 330
335 Gly Ser Leu Ser Leu Ala Ser Gly Lys Ser Leu Leu His Glu Val Asp
340 345 350 Gln Asp Ile Asp His Leu Thr Arg Ala Ile Val Lys Asn His
Asp Asn 355 360 365 Ile Leu Arg Val Ala Gln Tyr Ala Ala Gln Asn Arg
Arg Gly Leu Asp 370 375 380 Leu Leu Phe Trp Glu Gln Gly Gly Leu Cys
Lys Ala Ile Gln Glu Gln 385 390 395 400 Cys Cys Phe Leu Asn Ile Ser
Asn Thr His Val Ser Val Leu Gln Glu 405 410 415 Arg Pro Pro Leu Glu
Lys Arg Val Ile Thr Gly Trp Gly Leu Asn Trp 420 425 430 Asp Leu Gly
Leu Ser Gln Trp Ala Arg Glu Ala Leu Gln Thr Gly Ile 435 440 445 Thr
Leu Leu Ala Leu Phe Leu Leu Leu Ile Val Val Gly Pro Cys Val 450 455
460 Ile Arg Gln Leu Gln Ala Leu Pro Ser Arg Leu Gln Pro Arg Ser Gln
465 470 475 480 Pro Tyr Ser Leu Leu Asn Tyr Glu Thr Asn Leu 485 490
<210> SEQ ID NO 54 <211> LENGTH: 0 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: HTLV1.RBD <400> SEQUENCE: 54
000 <210> SEQ ID NO 55 <211> LENGTH: 0 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: STLV2.RBD <400>
SEQUENCE: 55 000
1 SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 55 <210>
SEQ ID NO 1 <211> LENGTH: 3687 <212> TYPE: DNA
<213> ORGANISM: Homo sapiens <220> FEATURE: <221>
NAME/KEY: source <222> LOCATION: (1)..(3687) <223>
OTHER INFORMATION: /mol_type="unassigned DNA" /note="Nucleic acid
sequence of GLUT1" /organism="Homo sapiens" <400> SEQUENCE: 1
tccaccattt tgctagagaa ggccgcggag gctcagagag gtgcgcacac ttgccctgag
60 tcacacagcg aatgccctcc gcggtcccaa cgcagagaga acgagccgat
cggcagcctg 120 agcgaggcag tggttagggg gggccccggc cccggccact
cccctcaccc cctccccgca 180 gagcgccgcc caggacaggc tgggccccag
gccccgcccc gaggtcctgc ccacacaccc 240 ctgacacacc ggcgtcgcca
gccaatggcc ggggtcctat aaacgctacg gtccgcgcgc 300 tctctggcaa
gaggcaagag gtagcaacag cgagcgtgcc ggtcgctagt cgcgggtccc 360
cgagtgagca cgccagggag caggagacca aacgacgggg gtcggagtca gagtcgcagt
420 gggagtcccc ggaccggagc acgagcctga gcgggagagc gccgctcgca
cgcccgtcgc 480 cacccgcgta cccggcgcag ccagagccac cagcgcagcg
ctgccatgga gcccagcagc 540 aagaagctga cgggtcgcct catgctggcc
gtgggaggag cagtgcttgg ctccctgcag 600 tttggctaca acactggagt
catcaatgcc ccccagaagg tgatcgagga gttctacaac 660 cagacatggg
tccaccgcta tggggagagc atcctgccca ccacgctcac cacgctctgg 720
tccctctcag tggccatctt ttctgttggg ggcatgattg gctccttctc tgtgggcctt
780 ttcgttaacc gctttggccg gcggaattca atgctgatga tgaacctgct
ggccttcgtg 840 tccgccgtgc tcatgggctt ctcgaaactg ggcaagtcct
ttgagatgct gatcctgggc 900 cgcttcatca tcggtgtgta ctgcggcctg
accacaggct tcgtgcccat gtatgtgggt 960 gaagtgtcac ccacagccct
tcgtggggcc ctgggcaccc tgcaccagct gggcatcgtc 1020 gtcggcatcc
tcatcgccca ggtgttcggc ctggactcca tcatgggcaa caaggacctg 1080
tggcccctgc tgctgagcat catcttcatc ccggccctgc tgcagtgcat cgtgctgccc
1140 ttctgccccg agagtccccg cttcctgctc atcaaccgca acgaggagaa
ccgggccaag 1200 agtgtgctaa agaagctgcg cgggacagct gacgtgaccc
atgacctgca ggagatgaag 1260 gaagagagtc ggcagatgat gcgggagaag
aaggtcacca tcctggagct gttccgctcc 1320 cccgcctacc gccagcccat
cctcatcgct gtggtgctgc agctgtccca gcagctgtct 1380 ggcatcaacg
ctgtcttcta ttactccacg agcatcttcg agaaggcggg ggtgcagcag 1440
cctgtgtatg ccaccattgg ctccggtatc gtcaacacgg ccttcactgt cgtgtcgctg
1500 tttgtggtgg agcgagcagg ccggcggacc ctgcacctca taggcctcgc
tggcatggcg 1560 ggttgtgcca tactcatgac catcgcgcta gcactgctgg
agcagctacc ctggatgtcc 1620 tatctgagca tcgtggccat ctttggcttt
gtggccttct ttgaagtggg tcctggcccc 1680 atcccatggt tcatcgtggc
tgaactcttc agccagggtc cacgtccagc tgccattgcc 1740 gttgcaggct
tctccaactg gacctcaaat ttcattgtgg gcatgtgctt ccagtatgtg 1800
gagcaactgt gtggtcccta cgtcttcatc atcttcactg tgctcctggt tctgttcttc
1860 atcttcacct acttcaaagt tcctgagact aaaggccgga ccttcgatga
gatcgcttcc 1920 ggcttccggc aggggggagc cagccaaagt gacaagacac
ccgaggagct gttccatccc 1980 ctgggggctg attcccaagt gtgagtcgcc
ccagatcacc agcccggcct gctcccagca 2040 gccctaagga tctctcagga
gcacaggcag ctggatgaga cttccaaacc tgacagatgt 2100 cagccgagcc
gggcctgggg ctcctttctc cagccagcaa tgatgtccag aagaatattc 2160
aggacttaac ggctccagga ttttaacaaa agcaagactg ttgctcaaat ctattcagac
2220 aagcaacagg ttttataatt tttttattac tgattttgtt atttttatat
cagcctgagt 2280 ctcctgtgcc cacatcccag gcttcaccct gaatggttcc
atgcctgagg gtggagacta 2340 agccctgtcg agacacttgc cttcttcacc
cagctaatct gtagggctgg acctatgtcc 2400 taaggacaca ctaatcgaac
tatgaactac aaagcttcta tcccaggagg tggctatggc 2460 cacccgttct
gctggcctgg atctccccac tctaggggtc aggctccatt aggatttgcc 2520
ccttcccatc tcttcctacc caaccactca aattaatctt tctttacctg agaccagttg
2580 ggagcactgg agtgcaggga ggagagggga agggccagtc tgggctgccg
ggttctagtc 2640 tcctttgcac tgagggccac actattacca tgagaagagg
gcctgtggga gcctgcaaac 2700 tcactgctca agaagacatg gagactcctg
ccctgttgtg tatagatgca agatatttat 2760 atatattttt ggttgtcaat
attaaataca gacactaagt tatagtatat ctggacaagc 2820 caacttgtaa
atacaccacc tcactcctgt tacttaccta aacagatata aatggctggt 2880
ttttagaaac atggttttga aatgcttgtg gattgagggt aggaggtttg gatgggagtg
2940 agacagaagt aagtggggtt gcaaccactg caacggctta gacttcgact
caggatccag 3000 tcccttacac gtacctctca tcagtgtcct cttgctcaaa
aatctgtttg atccctgtta 3060 cccagagaat atatacattc tttatcttga
cattcaaggc atttctatca catatttgat 3120 agttggtgtt caaaaaaaca
ctagttttgt gccagccgtg atgctcaggc ttgaaatgca 3180 ttattttgaa
tgtgaagtaa atactgtacc tttattggac aggctcaaag aggttatgtg 3240
cctgaagtcg cacagtgaat aagctaaaac acctgctttt aacaatggta ccatacaacc
3300 actactccat taactccacc cacctcctgc acccctcccc acacacacaa
aatgaaccac 3360 gttctttgta tgggcccaat gagctgtcaa gctgccctgt
gttcatttca tttggaattg 3420 ccccctctgg ttcctctgta tactactgct
tcatctctaa agacagctca tcctcctcct 3480 tcacccctga atttccagag
cacttcatct gctccttcat cacaagtcca gttttctgcc 3540 actagtctga
atttcatgag aagatgccga tttggttcct gtgggtcctc agcactattc 3600
agtacagtgc ttgatgcaca gcaggcactc agaaaatact ggaggaaata aaacaccaaa
3660 gatatttgtc aaaaaaaaaa aaaaaaa 3687 <210> SEQ ID NO 2
<211> LENGTH: 492 <212> TYPE: PRT <213> ORGANISM:
Homo sapiens <400> SEQUENCE: 2 Met Glu Pro Ser Ser Lys Lys
Leu Thr Gly Arg Leu Met Leu Ala Val 1 5 10 15 Gly Gly Ala Val Leu
Gly Ser Leu Gln Phe Gly Tyr Asn Thr Gly Val 20 25 30 Ile Asn Ala
Pro Gln Lys Val Ile Glu Glu Phe Tyr Asn Gln Thr Trp 35 40 45 Val
His Arg Tyr Gly Glu Ser Ile Leu Pro Thr Thr Leu Thr Thr Leu 50 55
60 Trp Ser Leu Ser Val Ala Ile Phe Ser Val Gly Gly Met Ile Gly Ser
65 70 75 80 Phe Ser Val Gly Leu Phe Val Asn Arg Phe Gly Arg Arg Asn
Ser Met 85 90 95 Leu Met Met Asn Leu Leu Ala Phe Val Ser Ala Val
Leu Met Gly Phe 100 105 110 Ser Lys Leu Gly Lys Ser Phe Glu Met Leu
Ile Leu Gly Arg Phe Ile 115 120 125 Ile Gly Val Tyr Cys Gly Leu Thr
Thr Gly Phe Val Pro Met Tyr Val 130 135 140 Gly Glu Val Ser Pro Thr
Ala Leu Arg Gly Ala Leu Gly Thr Leu His 145 150 155 160 Gln Leu Gly
Ile Val Val Gly Ile Leu Ile Ala Gln Val Phe Gly Leu 165 170 175 Asp
Ser Ile Met Gly Asn Lys Asp Leu Trp Pro Leu Leu Leu Ser Ile 180 185
190 Ile Phe Ile Pro Ala Leu Leu Gln Cys Ile Val Leu Pro Phe Cys Pro
195 200 205 Glu Ser Pro Arg Phe Leu Leu Ile Asn Arg Asn Glu Glu Asn
Arg Ala 210 215 220 Lys Ser Val Leu Lys Lys Leu Arg Gly Thr Ala Asp
Val Thr His Asp 225 230 235 240 Leu Gln Glu Met Lys Glu Glu Ser Arg
Gln Met Met Arg Glu Lys Lys 245 250 255 Val Thr Ile Leu Glu Leu Phe
Arg Ser Pro Ala Tyr Arg Gln Pro Ile 260 265 270 Leu Ile Ala Val Val
Leu Gln Leu Ser Gln Gln Leu Ser Gly Ile Asn 275 280 285 Ala Val Phe
Tyr Tyr Ser Thr Ser Ile Phe Glu Lys Ala Gly Val Gln 290 295 300 Gln
Pro Val Tyr Ala Thr Ile Gly Ser Gly Ile Val Asn Thr Ala Phe 305 310
315 320 Thr Val Val Ser Leu Phe Val Val Glu Arg Ala Gly Arg Arg Thr
Leu 325 330 335 His Leu Ile Gly Leu Ala Gly Met Ala Gly Cys Ala Ile
Leu Met Thr 340 345 350 Ile Ala Leu Ala Leu Leu Glu Gln Leu Pro Trp
Met Ser Tyr Leu Ser 355 360 365 Ile Val Ala Ile Phe Gly Phe Val Ala
Phe Phe Glu Val Gly Pro Gly 370 375 380 Pro Ile Pro Trp Phe Ile Val
Ala Glu Leu Phe Ser Gln Gly Pro Arg 385 390 395 400 Pro Ala Ala Ile
Ala Val Ala Gly Phe Ser Asn Trp Thr Ser Asn Phe 405 410 415 Ile Val
Gly Met Cys Phe Gln Tyr Val Glu Gln Leu Cys Gly Pro Tyr 420 425 430
Val Phe Ile Ile Phe Thr Val Leu Leu Val Leu Phe Phe Ile Phe Thr 435
440 445 Tyr Phe Lys Val Pro Glu Thr Lys Gly Arg Thr Phe Asp Glu Ile
Ala 450 455 460 Ser Gly Phe Arg Gln Gly Gly Ala Ser Gln Ser Asp Lys
Thr Pro Glu 465 470 475 480 Glu Leu Phe His Pro Leu Gly Ala Asp Ser
Gln Val 485 490 <210> SEQ ID NO 3 <211> LENGTH: 534
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: HTLV2.RBD <400> SEQUENCE: 3
atgggtaatg ttttcttcct acttttattc agtctcacac attttccact agcccagcag
60 agccgatgca cactcacagt tggtatctcc tcctaccact ccagcccctg
tagcccaacc 120 caacccgtct gcacgtggaa cctcgacctt aattccctaa
caacggacca acgactacac 180 cccccctgcc ctaacctaat tacttactct
ggcttccata agacttattc cttatactta 240 ttcccacatt ggataaaaaa
gccaaacaga cagggcctag ggtactactc gccttcctac 300 aatgaccctt
gctcgctaca atgcccctac ttgggctgcc aatcatggac atgcccatac 360
acgggccccg tctccagtcc atcctggaag tttcattcag atgtaaattt cacccaggaa
420 gtcagccaag tgtcccttcg actacacttc tctaagtgcg gctcctccat
gaccctccta 480 gtagatgccc ctggatatga tcctttatgg ttcatcacct
cagaacccac tcag 534 <210> SEQ ID NO 4 <211> LENGTH: 224
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: HTLV-2.RBD
<400> SEQUENCE: 4 Met Gly Asn Val Phe Phe Leu Leu Leu Phe Ser
Leu Thr His Phe Pro 1 5 10 15 Leu Ala Gln Gln Ser Arg Cys Thr Leu
Thr Val Gly Ile Ser Ser Tyr 20 25 30 His Ser Ser Pro Cys Ser Pro
Thr Gln Pro Val Cys Thr Trp Asn Leu 35 40 45 Asp Leu Asn Ser Leu
Thr Thr Asp Gln Arg Leu His Pro Pro Cys Pro 50 55 60 Asn Leu Ile
Thr Tyr Ser Gly Phe His Lys Thr Tyr Ser Leu Tyr Leu 65 70 75 80 Phe
Pro His Trp Ile Lys Lys Pro Asn Arg Gln Gly Leu Gly Tyr Tyr 85 90
95 Ser Pro Ser Tyr Asn Asp Pro Cys Ser Leu Gln Cys Pro Tyr Leu Gly
100 105 110 Cys Gln Ser Trp Thr Cys Pro Tyr Thr Gly Pro Val Ser Ser
Pro Ser 115 120 125 Trp Lys Phe His Ser Asp Val Asn Phe Thr Gln Glu
Val Ser Gln Val 130 135 140 Ser Leu Arg Leu His Phe Ser Lys Cys Gly
Ser Ser Met Thr Leu Leu 145 150 155 160 Val Asp Ala Pro Gly Tyr Asp
Pro Leu Trp Phe Ile Thr Ser Glu Pro 165 170 175 Thr Gln Pro Pro Pro
Thr Ser Pro Pro Leu Val His Asp Ser Asp Leu 180 185 190 Glu His Val
Leu Thr Pro Ser Thr Ser Trp Thr Thr Lys Ile Leu Lys 195 200 205 Phe
Ile Gln Leu Thr Leu Gln Ser Thr Asn Tyr Ser Cys Met Val Cys 210 215
220 <210> SEQ ID NO 5 <211> LENGTH: 178 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: HTLV2.RBD <400>
SEQUENCE: 5 Met Gly Asn Val Phe Phe Leu Leu Leu Phe Ser Leu Thr His
Phe Pro 1 5 10 15 Leu Ala Gln Gln Ser Arg Cys Thr Leu Thr Val Gly
Ile Ser Ser Tyr 20 25 30 His Ser Ser Pro Cys Ser Pro Thr Gln Pro
Val Cys Thr Trp Asn Leu 35 40 45 Asp Leu Asn Ser Leu Thr Thr Asp
Gln Arg Leu His Pro Pro Cys Pro 50 55 60 Asn Leu Ile Thr Tyr Ser
Gly Phe His Lys Thr Tyr Ser Leu Tyr Leu 65 70 75 80 Phe Pro His Trp
Ile Lys Lys Pro Asn Arg Gln Gly Leu Gly Tyr Tyr 85 90 95 Ser Pro
Ser Tyr Asn Asp Pro Cys Ser Leu Gln Cys Pro Tyr Leu Gly 100 105 110
Cys Gln Ser Trp Thr Cys Pro Tyr Thr Gly Pro Val Ser Ser Pro Ser 115
120 125 Trp Lys Phe His Ser Asp Val Asn Phe Thr Gln Glu Val Ser Gln
Val 130 135 140 Ser Leu Arg Leu His Phe Ser Lys Cys Gly Ser Ser Met
Thr Leu Leu 145 150 155 160 Val Asp Ala Pro Gly Tyr Asp Pro Leu Trp
Phe Ile Thr Ser Glu Pro 165 170 175 Thr Gln <210> SEQ ID NO 6
<211> LENGTH: 153 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: HTLV2.RBD <400> SEQUENCE: 6 ataagaaagc
caaacagaca gggcctaggg tactactcgc cttcctacaa tgacccttgc 60
tcgctacaat gcccctactt gggctcccaa tcatggacat gcccatacac ggcccccgtc
120 tccactccat cctggaattt tcattcagat gta 153 <210> SEQ ID NO
7 <211> LENGTH: 51 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV2.RBD <400> SEQUENCE: 7 Ile Arg Lys
Pro Asn Arg Gln Gly Leu Gly Tyr Tyr Ser Pro Ser Tyr 1 5 10 15 Asn
Asp Pro Cys Ser Leu Gln Cys Pro Tyr Leu Gly Ser Gln Ser Trp 20 25
30 Thr Cys Pro Tyr Thr Ala Pro Val Ser Thr Pro Ser Trp Asn Phe His
35 40 45 Ser Asp Val 50 <210> SEQ ID NO 8 <211> LENGTH:
924 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: HTLV1.RBD
<400> SEQUENCE: 8 atgggtaagt ttctcgccac tttgatttta ttcttccagt
tctgccccct catcctcggt 60 gattacagcc ccagctgctg tactctcaca
attggagtct cctcatacca ctctaaaccc 120 tgcaatcctg cccagccagt
ttgttcgtgg accctcgacc tgctggccct ttcagcggat 180 caggccctac
agcccccctg ccctaatcta gtaagttact ccagctacca tgccacctat 240
tccctatatc tattccctca ttggattaaa aagccaaacc gaaatggcgg aggctattat
300 tcagcctctt attcagaccc ttgttcctta aagtgcccat acctggggtg
ccaatcatgg 360 acctgcccct atacaggagc cgtctccagc ccctactgga
agtttcagca agatgtcaat 420 tttactcaag aagtttcacg cctcaatatt
aatctccatt tttcaaaatg cggttttccc 480 ttctcccttc tagtcgacgc
tccaggatat gaccccatct ggttccttaa taccgaaccc 540 agccaactgc
ctcccaccgc ccctcctcta ctcccccact ctaacctaga ccacatcctc 600
gagccctcta taccatggaa atcaaaactc ctgacccttg tccagttaac cctacaaagc
660 actaattata cttgcattgt ctgtatcgat cgtgccagcc tatccacttg
gcacgtccta 720 tactctccca acgtctctgt tccatcctct tcttctaccc
ccctccttta cccatcgtta 780 gcgcttccag ccccccacct gacgttacca
tttaactgga cccactgctt tgacccccag 840 attcaagcta tagtctcctc
cccctgtcat aactccctca tcctgccccc cttttccttg 900 tcacctgttc
ccaccctagg atcc 924 <210> SEQ ID NO 9 <211> LENGTH: 308
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: HTLV1.RBD
<400> SEQUENCE: 9 Met Gly Lys Phe Leu Ala Thr Leu Ile Leu Phe
Phe Gln Phe Cys Pro 1 5 10 15 Leu Ile Leu Gly Asp Tyr Ser Pro Ser
Cys Cys Thr Leu Thr Ile Gly 20 25 30 Val Ser Ser Tyr His Ser Lys
Pro Cys Asn Pro Ala Gln Pro Val Cys 35 40 45 Ser Trp Thr Leu Asp
Leu Leu Ala Leu Ser Ala Asp Gln Ala Leu Gln 50 55 60 Pro Pro Cys
Pro Asn Leu Val Ser Tyr Ser Ser Tyr His Ala Thr Tyr 65 70 75 80 Ser
Leu Tyr Leu Phe Pro His Trp Ile Lys Lys Pro Asn Arg Asn Gly 85 90
95 Gly Gly Tyr Tyr Ser Ala Ser Tyr Ser Asp Pro Cys Ser Leu Lys Cys
100 105 110 Pro Tyr Leu Gly Cys Gln Ser Trp Thr Cys Pro Tyr Thr Gly
Ala Val 115 120 125 Ser Ser Pro Tyr Trp Lys Phe Gln Gln Asp Val Asn
Phe Thr Gln Glu 130 135 140 Val Ser Arg Leu Asn Ile Asn Leu His Phe
Ser Lys Cys Gly Phe Pro 145 150 155 160 Phe Ser Leu Leu Val Asp Ala
Pro Gly Tyr Asp Pro Ile Trp Phe Leu 165 170 175 Asn Thr Glu Pro Ser
Gln Leu Pro Pro Thr Ala Pro Pro Leu Leu Pro 180 185 190 His Ser Asn
Leu Asp His Ile Leu Glu Pro Ser Ile Pro Trp Lys Ser 195 200 205 Lys
Leu Leu Thr Leu Val Gln Leu Thr Leu Gln Ser Thr Asn Tyr Thr 210 215
220
Cys Ile Val Cys Ile Asp Arg Ala Ser Leu Ser Thr Trp His Val Leu 225
230 235 240 Tyr Ser Pro Asn Val Ser Val Pro Ser Ser Ser Ser Thr Pro
Leu Leu 245 250 255 Tyr Pro Ser Leu Ala Leu Pro Ala Pro His Leu Thr
Leu Pro Phe Asn 260 265 270 Trp Thr His Cys Phe Asp Pro Gln Ile Gln
Ala Ile Val Ser Ser Pro 275 280 285 Cys His Asn Ser Leu Ile Leu Pro
Pro Phe Ser Leu Ser Pro Val Pro 290 295 300 Thr Leu Gly Ser 305
<210> SEQ ID NO 10 <211> LENGTH: 228 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: HTLV1.RBD <400> SEQUENCE: 10
Met Gly Lys Phe Leu Ala Thr Leu Ile Leu Phe Phe Gln Phe Cys Pro 1 5
10 15 Leu Ile Phe Gly Asp Tyr Ser Pro Ser Cys Cys Thr Leu Thr Ile
Gly 20 25 30 Val Ser Ser Tyr His Ser Lys Pro Cys Asn Pro Ala Gln
Pro Val Cys 35 40 45 Ser Trp Thr Leu Asp Leu Leu Ala Leu Ser Ala
Asp Gln Ala Leu Gln 50 55 60 Pro Pro Cys Pro Asn Leu Val Ser Tyr
Ser Ser Tyr His Ala Thr Tyr 65 70 75 80 Ser Leu Tyr Leu Phe Pro His
Trp Thr Lys Lys Pro Asn Arg Asn Gly 85 90 95 Gly Gly Tyr Tyr Ser
Ala Ser Tyr Ser Asp Pro Cys Ser Leu Lys Cys 100 105 110 Pro Tyr Leu
Gly Cys Gln Ser Trp Thr Cys Pro Tyr Thr Gly Ala Val 115 120 125 Ser
Ser Pro Tyr Trp Lys Phe Gln His Asp Val Asn Phe Thr Gln Glu 130 135
140 Val Ser Arg Leu Asn Ile Asn Leu His Phe Ser Lys Cys Gly Phe Pro
145 150 155 160 Phe Ser Leu Leu Val Asp Ala Pro Gly Tyr Asp Pro Ile
Trp Phe Leu 165 170 175 Asn Thr Glu Pro Ser Gln Leu Pro Pro Thr Ala
Pro Pro Leu Leu Pro 180 185 190 His Ser Asn Leu Asp His Ile Leu Glu
Pro Ser Ile Pro Trp Lys Ser 195 200 205 Lys Leu Leu Thr Leu Val Gln
Leu Thr Leu Gln Ser Thr Asn Tyr Thr 210 215 220 Cys Ile Val Cys 225
<210> SEQ ID NO 11 <211> LENGTH: 182 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: HTLV1.RBD <400> SEQUENCE: 11
Met Gly Lys Phe Leu Ala Thr Leu Ile Leu Phe Phe Gln Phe Cys Pro 1 5
10 15 Leu Ile Phe Gly Asp Tyr Ser Pro Ser Cys Cys Thr Leu Thr Ile
Gly 20 25 30 Val Ser Ser Tyr His Ser Lys Pro Cys Asn Pro Ala Gln
Pro Val Cys 35 40 45 Ser Trp Thr Leu Asp Leu Leu Ala Leu Ser Ala
Asp Gln Ala Leu Gln 50 55 60 Pro Pro Cys Pro Asn Leu Val Ser Tyr
Ser Ser Tyr His Ala Thr Tyr 65 70 75 80 Ser Leu Tyr Leu Phe Pro His
Trp Thr Lys Lys Pro Asn Arg Asn Gly 85 90 95 Gly Gly Tyr Tyr Ser
Ala Ser Tyr Ser Asp Pro Cys Ser Leu Lys Cys 100 105 110 Pro Tyr Leu
Gly Cys Gln Ser Trp Thr Cys Pro Tyr Thr Gly Ala Val 115 120 125 Ser
Ser Pro Tyr Trp Lys Phe Gln His Asp Val Asn Phe Thr Gln Glu 130 135
140 Val Ser Arg Leu Asn Ile Asn Leu His Phe Ser Lys Cys Gly Phe Pro
145 150 155 160 Phe Ser Leu Leu Val Asp Ala Pro Gly Tyr Asp Pro Ile
Trp Phe Leu 165 170 175 Asn Thr Glu Pro Ser Gln 180 <210> SEQ
ID NO 12 <211> LENGTH: 153 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV1.RBD <400> SEQUENCE: 12 attaaaaagc
caaacccaaa tggcggaggc tattatttag cctcttattc agacccttgt 60
tccttaaaat gcccatacct ggggtgccaa tcatggacct gcccctatac aggagccgtc
120 tccagcccct actggaagtt tcagcaagat gtc 153 <210> SEQ ID NO
13 <211> LENGTH: 51 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV1.RBD <400> SEQUENCE: 13 Ile Lys Lys
Pro Asn Pro Asn Gly Gly Gly Tyr Tyr Leu Ala Ser Tyr 1 5 10 15 Ser
Asp Pro Cys Ser Leu Lys Cys Pro Tyr Leu Gly Cys Gln Ser Trp 20 25
30 Thr Cys Pro Tyr Thr Gly Ala Val Ser Ser Pro Tyr Trp Lys Phe Gln
35 40 45 Gln Asp Val 50 <210> SEQ ID NO 14 <211>
LENGTH: 153 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
HTLV1.RBD <400> SEQUENCE: 14 gttaaaaagc caaaccgaaa tggcggaggc
tattatttag cctcttattc agacccttgt 60 tccttaaaat gcccatacct
ggggtgccaa tcatggacct gcccctatac aggagccgtc 120 tccagcccct
actggaagtt tcagcaagat gtc 153 <210> SEQ ID NO 15 <211>
LENGTH: 51 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
HTLV1.RBD <400> SEQUENCE: 15 Val Lys Lys Pro Asn Arg Asn Gly
Gly Gly Tyr Tyr Leu Ala Ser Tyr 1 5 10 15 Ser Asp Pro Cys Ser Leu
Lys Cys Pro Tyr Leu Gly Cys Gln Ser Trp 20 25 30 Thr Cys Pro Tyr
Thr Gly Ala Val Ser Ser Pro Tyr Trp Lys Phe Gln 35 40 45 Gln Asp
Val 50 <210> SEQ ID NO 16 <211> LENGTH: 51 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: HTLV1.RBD <400>
SEQUENCE: 16 Ile Lys Lys Pro Asn Arg Asn Gly Gly Gly Tyr Tyr Leu
Ala Ser Tyr 1 5 10 15 Ser Asp Pro Cys Ser Leu Lys Cys Pro Tyr Leu
Gly Cys Gln Ser Trp 20 25 30 Thr Cys Pro Tyr Thr Gly Ala Val Ser
Ser Pro Tyr Trp Lys Phe Gln 35 40 45 Gln Asp Val 50 <210> SEQ
ID NO 17 <211> LENGTH: 153 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV1.RBD <400> SEQUENCE: 17 attaaaaagc
caaaccgaaa tggcggaggc tattatttag cctcttattc agacccttgt 60
tccttaaaat gcccatacct ggggtgccaa tcatggacct gcccctatac aggacccgtc
120 tccagcccct actggaagtt tcagcaagat gtc 153 <210> SEQ ID NO
18 <211> LENGTH: 51 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV1.RBD <400> SEQUENCE: 18 Ile Lys Lys
Pro Asn Arg Asn Gly Gly Gly Tyr Tyr Leu Ala Ser Tyr 1 5 10 15 Ser
Asp Pro Cys Ser Leu Lys Cys Pro Tyr Leu Gly Cys Gln Ser Trp 20 25
30 Thr Cys Pro Tyr Thr Gly Pro Val Ser Ser Pro Tyr Trp Lys Phe Gln
35 40 45
Gln Asp Val 50 <210> SEQ ID NO 19 <211> LENGTH: 171
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: HTLV1.RBD
<400> SEQUENCE: 19 attaaaaagc caaaccgaaa tggcggaggc
tatcattcag cctcttattc agacccttgt 60 tccttaaagt gcccatacct
ggggtgccaa tcatggacct gcccctatgc aggagccgtc 120 tccagcccct
actggaagtt tcagcaagat gtcaatttta cccaggaagt a 171 <210> SEQ
ID NO 20 <211> LENGTH: 57 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV1.RBD <400> SEQUENCE: 20 Ile Lys Lys
Pro Asn Arg Asn Gly Gly Gly Tyr His Ser Ala Ser Tyr 1 5 10 15 Ser
Asp Pro Cys Ser Leu Lys Cys Pro Tyr Leu Gly Cys Gln Ser Trp 20 25
30 Thr Cys Pro Tyr Ala Gly Ala Val Ser Ser Pro Tyr Trp Lys Phe Gln
35 40 45 Gln Asp Val Asn Phe Thr Gln Glu Val 50 55 <210> SEQ
ID NO 21 <211> LENGTH: 224 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV4.RBD <400> SEQUENCE: 21 Met Gly Asn
Val Leu Phe Leu Thr Leu Leu Ala Thr Leu Gly Ile Pro 1 5 10 15 Val
Leu Gln Ala Ser Arg Cys Thr Ile Thr Val Gly Ile Ser Ser Tyr 20 25
30 His Ser Ser Pro Cys Ser Pro Ala Gln Pro Leu Cys Thr Trp Ala Leu
35 40 45 Asp Leu Val Ser Ile Thr Lys Asp Gln Leu Leu Tyr Pro Pro
Cys Gln 50 55 60 Asn Leu Ile Thr Tyr Ser Asn Tyr His Lys Thr Tyr
Ser Leu Tyr Leu 65 70 75 80 Phe Pro His Trp Val Gln Lys Pro Leu Arg
Arg Gly Leu Gly Tyr Tyr 85 90 95 Ser Ala Ser Tyr Ser Asp Pro Cys
Ser Leu Gln Cys Pro Tyr Leu Gly 100 105 110 Ser Gln Ser Trp Thr Cys
Pro Tyr Thr Gly Pro Val Ser Ser Pro Thr 115 120 125 Trp Arg Phe Ser
Thr Asp Val Asn Phe Thr Gln Glu Val Ser Arg Val 130 135 140 Ser Leu
Lys Leu His Phe Ser Lys Cys Gly Ser Ser Leu Thr Leu Leu 145 150 155
160 Ile Asp Ala Pro Gly Tyr Asp Pro Leu Trp Tyr Leu Thr Ser Glu Pro
165 170 175 Thr Gln Glu Pro Pro Thr Pro Pro Pro Leu Val Ser Asp Ser
Asp Leu 180 185 190 Glu His Val Leu Thr Pro Ser Ala Ser Trp Ala Ser
Lys Met Leu Thr 195 200 205 Leu Ile His Leu Thr Leu Gln Ser Thr Asn
Tyr Ser Cys Met Val Cys 210 215 220 <210> SEQ ID NO 22
<211> LENGTH: 178 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: HTLV4.RBD <400> SEQUENCE: 22 Met Gly Asn Val Leu
Phe Leu Thr Leu Leu Ala Thr Leu Gly Ile Pro 1 5 10 15 Val Leu Gln
Ala Ser Arg Cys Thr Ile Thr Val Gly Ile Ser Ser Tyr 20 25 30 His
Ser Ser Pro Cys Ser Pro Ala Gln Pro Leu Cys Thr Trp Ala Leu 35 40
45 Asp Leu Val Ser Ile Thr Lys Asp Gln Leu Leu Tyr Pro Pro Cys Gln
50 55 60 Asn Leu Ile Thr Tyr Ser Asn Tyr His Lys Thr Tyr Ser Leu
Tyr Leu 65 70 75 80 Phe Pro His Trp Val Gln Lys Pro Leu Arg Arg Gly
Leu Gly Tyr Tyr 85 90 95 Ser Ala Ser Tyr Ser Asp Pro Cys Ser Leu
Gln Cys Pro Tyr Leu Gly 100 105 110 Ser Gln Ser Trp Thr Cys Pro Tyr
Thr Gly Pro Val Ser Ser Pro Thr 115 120 125 Trp Arg Phe Ser Thr Asp
Val Asn Phe Thr Gln Glu Val Ser Arg Val 130 135 140 Ser Leu Lys Leu
His Phe Ser Lys Cys Gly Ser Ser Leu Thr Leu Leu 145 150 155 160 Ile
Asp Ala Pro Gly Tyr Asp Pro Leu Trp Tyr Leu Thr Ser Glu Pro 165 170
175 Thr Gln <210> SEQ ID NO 23 <211> LENGTH: 1467
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: STLV1.RBD
<400> SEQUENCE: 23 atgggtaagt ttctcgccac tttgatttta
ttcttccagt tctgccccct cattctcggt 60 gattacagcc ccagctgctg
tactctcaca attggagtct cctcatacct ctctaaaccc 120 tgcaatcctg
cccagccagt ttgttcatgg accctcgacc tactggccct ttcagcagac 180
caagccctac agcccccctg ccctaatcta gtaagttact ccagctacca tgccacctat
240 tccctatatc tattccctca ttggattaaa aagccaaacc gaaatggcgg
aggctattat 300 tcggcctctt attcagaccc atgttcttta aagtgcccat
acttagggtg ccaatcatgg 360 acctgcccct atacaggagt cgtctccagc
ccctattgga aatttcagca agatgtcaat 420 tttactcaag aagtttcaca
cctcaatatt aatctccatt tctcaaaatg cggttttccc 480 ttctcccttc
taatcgacgc tccaggatat gaccccatct ggttccttaa taccgaaccc 540
agccaactgc ctcccaccgc ccctcctcta ctcccccact ctaacctgga ccacatcctc
600 gagccctcta taccatggaa atcaaaactt ctgactcttg tccagctaac
cctacaaagc 660 actaattaca cttgcatcgt ctgtatagac cgtgccagcc
tctctacttg gcatgtcctg 720 tactctccca acgtctctgt tccgtcctct
tcttctaccc ccctccttta cccgtcgtta 780 gcgcttccag ctccccacct
gacgctacca tttaactgga cccactgctt tgacccccag 840 attcaagcta
tagtctcctc cccctgtcat aactccctca tcctgccccc cttttccttg 900
tcacctgttc ccaccctagg atcccgctcc cgccgagcgg taccggtggc ggtctggctt
960 gtctccgccc tggccatggg agccggaatt gctggcggga ttaccggctc
catgtccctc 1020 gcctcaggaa agagcctcct acatgaggtg gacaaagata
tttcccaatt aactcaagca 1080 atagtcaaaa accacaaaaa tctactcaaa
attgcacagt atgctgccca gaacaggcga 1140 ggccttgatc tcctgttctg
ggagcaagga ggattatgca aagcattaca agaacagtgc 1200 tgttttctaa
atattaccaa ttcccatgtc tcaatactac aagaaagacc cccccttgag 1260
aatcgagtcc tcactggctg gggccttaac tgggaccttg gcctctcaca gtgggctcga
1320 gaggccttac aaactgggat cacccttgtt gcactactcc ttctcgttat
ccttgcagga 1380 ccatgcatcc tccgtcagct gcgacacctc ccctcgcgcg
tcagataccc ccattattct 1440 cttataaacc ctgagtcatc cctgtaa 1467
<210> SEQ ID NO 24 <211> LENGTH: 488 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: STLV1.RBD <400> SEQUENCE: 24
Met Gly Lys Phe Leu Ala Thr Leu Ile Leu Phe Phe Gln Phe Cys Pro 1 5
10 15 Leu Ile Leu Gly Asp Tyr Ser Pro Ser Cys Cys Thr Leu Thr Ile
Gly 20 25 30 Val Ser Ser Tyr Leu Ser Lys Pro Cys Asn Pro Ala Gln
Pro Val Cys 35 40 45 Ser Trp Thr Leu Asp Leu Leu Ala Leu Ser Ala
Asp Gln Ala Leu Gln 50 55 60 Pro Pro Cys Pro Asn Leu Val Ser Tyr
Ser Ser Tyr His Ala Thr Tyr 65 70 75 80 Ser Leu Tyr Leu Phe Pro His
Trp Ile Lys Lys Pro Asn Arg Asn Gly 85 90 95 Gly Gly Tyr Tyr Ser
Ala Ser Tyr Ser Asp Pro Cys Ser Leu Lys Cys 100 105 110 Pro Tyr Leu
Gly Cys Gln Ser Trp Thr Cys Pro Tyr Thr Gly Val Val 115 120 125 Ser
Ser Pro Tyr Trp Lys Phe Gln Gln Asp Val Asn Phe Thr Gln Glu 130 135
140 Val Ser His Leu Asn Ile Asn Leu His Phe Ser Lys Cys Gly Phe Pro
145 150 155 160 Phe Ser Leu Leu Ile Asp Ala Pro Gly Tyr Asp Pro Ile
Trp Phe Leu 165 170 175 Asn Thr Glu Pro Ser Gln Leu Pro Pro Thr Ala
Pro Pro Leu Leu Pro 180 185 190 His Ser Asn Leu Asp His Ile Leu Glu
Pro Ser Ile Pro Trp Lys Ser 195 200 205 Lys Leu Leu Thr Leu Val Gln
Leu Thr Leu Gln Ser Thr Asn Tyr Thr 210 215 220
Cys Ile Val Cys Ile Asp Arg Ala Ser Leu Ser Thr Trp His Val Leu 225
230 235 240 Tyr Ser Pro Asn Val Ser Val Pro Ser Ser Ser Ser Thr Pro
Leu Leu 245 250 255 Tyr Pro Ser Leu Ala Leu Pro Ala Pro His Leu Thr
Leu Pro Phe Asn 260 265 270 Trp Thr His Cys Phe Asp Pro Gln Ile Gln
Ala Ile Val Ser Ser Pro 275 280 285 Cys His Asn Ser Leu Ile Leu Pro
Pro Phe Ser Leu Ser Pro Val Pro 290 295 300 Thr Leu Gly Ser Arg Ser
Arg Arg Ala Val Pro Val Ala Val Trp Leu 305 310 315 320 Val Ser Ala
Leu Ala Met Gly Ala Gly Ile Ala Gly Gly Ile Thr Gly 325 330 335 Ser
Met Ser Leu Ala Ser Gly Lys Ser Leu Leu His Glu Val Asp Lys 340 345
350 Asp Ile Ser Gln Leu Thr Gln Ala Ile Val Lys Asn His Lys Asn Leu
355 360 365 Leu Lys Ile Ala Gln Tyr Ala Ala Gln Asn Arg Arg Gly Leu
Asp Leu 370 375 380 Leu Phe Trp Glu Gln Gly Gly Leu Cys Lys Ala Leu
Gln Glu Gln Cys 385 390 395 400 Cys Phe Leu Asn Ile Thr Asn Ser His
Val Ser Ile Leu Gln Glu Arg 405 410 415 Pro Pro Leu Glu Asn Arg Val
Leu Thr Gly Trp Gly Leu Asn Trp Asp 420 425 430 Leu Gly Leu Ser Gln
Trp Ala Arg Glu Ala Leu Gln Thr Gly Ile Thr 435 440 445 Leu Val Ala
Leu Leu Leu Leu Val Ile Leu Ala Gly Pro Cys Ile Leu 450 455 460 Arg
Gln Leu Arg His Leu Pro Ser Arg Val Arg Tyr Pro His Tyr Ser 465 470
475 480 Leu Ile Asn Pro Glu Ser Ser Leu 485 <210> SEQ ID NO
25 <211> LENGTH: 486 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: STV2.RBD <400> SEQUENCE: 25 Met Gly Lys
Ile Ile Ala Phe Leu Leu Phe His Leu Thr Cys Ile Thr 1 5 10 15 Ile
Thr Lys Gln Ser Arg Cys Thr Leu Thr Val Gly Val Ser Ser Tyr 20 25
30 His Ser Ser Pro Cys Ser Leu Ala Gln Pro Ile Cys Thr Trp Asp Leu
35 40 45 Asp Leu His Ser Leu Thr Thr Asp Gln Arg Leu Tyr Pro Pro
Cys Pro 50 55 60 Asn Leu Val Ser Tyr Ser Asn Phe His Lys Ser Tyr
Ser Leu Tyr Leu 65 70 75 80 Phe Pro His Trp Val Lys Lys Pro Asn Arg
Gln Gly Leu Gly Tyr Tyr 85 90 95 Ser Ala Ser Tyr Ser Asp Pro Cys
Ser Leu Gln Cys Pro Tyr Leu Gly 100 105 110 Ser Gln Ser Trp Thr Cys
Pro Tyr Thr Gly Pro Ile Ser Ser Pro Ser 115 120 125 Trp Arg Phe His
Arg Asp Val Asn Phe Thr Gln Glu Val Asn His Val 130 135 140 Thr Leu
Arg Leu His Phe Ser Arg Cys Gly Ser Ser Met Thr Leu Leu 145 150 155
160 Ile Asp Ala Pro Gly Tyr Asp Pro Leu Trp Phe Ile Ser Ser Glu Pro
165 170 175 Thr Gln Pro Pro Pro Thr Ser Pro Pro Leu Val Arg Asp Ser
Asp Leu 180 185 190 Glu His Ile Leu Thr Pro Ser Ser Ser Trp Ala Thr
Arg Met Leu Thr 195 200 205 Leu Ile Gln Leu Thr Leu Gln Ser Thr Asn
Tyr Ser Cys Met Val Cys 210 215 220 Ile Asp Arg Thr Ser Leu Ser Ser
Trp His Val Leu Tyr Thr Pro Asn 225 230 235 240 Ile Ser Ala Ser Pro
Gly Gly Asp Ser Leu Pro Ile Leu Tyr Pro Ser 245 250 255 Leu Ala Leu
Pro Ala Pro Gln Pro Gln Pro Phe Ser Trp Ser His Cys 260 265 270 Tyr
Gln Pro His Leu Gln Ala Val Thr Thr Ala Asn Cys Asn Asn Ser 275 280
285 Ile Val Leu Pro Pro Phe Ser Leu Thr Pro Val Pro Ser Pro Gly Thr
290 295 300 Arg Ser Arg Arg Ala Ile Pro Val Ala Val Trp Leu Val Ser
Ala Leu 305 310 315 320 Ala Ala Gly Thr Gly Ile Ala Gly Gly Ile Thr
Gly Ser Leu Ser Leu 325 330 335 Ala Ser Ser Arg Ser Leu Leu Phe Glu
Val Asp Lys Asp Ile Ser His 340 345 350 Leu Thr Gln Ala Ile Val Lys
Asn His Gln Asn Ile Leu Arg Val Ala 355 360 365 Gln Tyr Ala Ala Gln
Asn Arg Arg Gly Leu Asp Leu Leu Phe Trp Glu 370 375 380 Gln Gly Gly
Leu Cys Lys Ala Ile Gln Glu Gln Cys Cys Phe Leu Asn 385 390 395 400
Ile Ser Asn Thr His Val Ser Val Leu Gln Glu Arg Pro Pro Leu Glu 405
410 415 Lys Arg Val Ile Thr Gly Trp Gly Leu Asn Trp Asp Leu Gly Leu
Ser 420 425 430 Gln Trp Ala Arg Glu Ala Leu Gln Thr Gly Ile Thr Ile
Leu Ala Leu 435 440 445 Leu Leu Leu Val Ile Leu Phe Gly Pro Cys Ile
Leu Arg Gln Leu Gln 450 455 460 Ser Leu Pro His Arg Leu Gln Asn Arg
His Asn Gln Tyr Ser Leu Ile 465 470 475 480 Asn Gln Glu Thr Thr Leu
485 <210> SEQ ID NO 26 <211> LENGTH: 930 <212>
TYPE: DNA <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: STLV3.RBD <400>
SEQUENCE: 26 atgggtaagt ttggccttta ttgtcttgtt cacctttaca tacttctccc
tgcctcctct 60 ggcaatccca gtcggtgcac cctgttcata ggggcctctt
cctaccactc cagcccttgc 120 gggtccagcc tcccacggtg tacctggaat
cttgacctat tctccctcac gaaagatcaa 180 agcctaagcc ccccatgtcc
agacttaatt acttactcac aataccacaa gccctactcc 240 ctgtatgtat
tccctcattg gataactaaa cctaaccgcc ggggcttagg ttactattcc 300
gcttcctact cagacccctg tgccatacag tgcccttacc tgggatgcca gtcgtggaca
360 tgcccctata cgggcccggt gtccagtccg cattggagat acacctatga
tcttaacttt 420 acccaggagg tatcatccgt ctccttacac ttgcatttct
ccaaatgcgg atcctcgttc 480 tcctttctac tagacgcacc aggatatgac
ccagtgtggt tcctctcctc ccaggccaca 540 caggctccac ccacacctgc
ccctctcata cgggactcag atctccagta cattctagaa 600 ccgcccattc
cgtggagctc taagattctt aaccttatcc tcctcaccct aaaaagcact 660
aactattctt gcatggtctg tgttgaccgc tccagcctat cctcatggca tgtcctgtat
720 ggacccactc aagtccccag tccacccgac ccccaagccc ggtctatcct
gcgacctgcc 780 ttagctattc ccgccagtaa tatcaccccc ccgtttcctt
ggacccattg ctatcgccct 840 cctccgcaag ccatctcctc ggagaattgt
aacaactctg tagtgctgcc ccccttttct 900 ctgtctccaa ttcctaacgt
ctccagaccc 930 <210> SEQ ID NO 27 <211> LENGTH: 310
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: STLV3.RBD
<400> SEQUENCE: 27 Met Gly Lys Phe Gly Leu Tyr Cys Leu Val
His Leu Tyr Ile Leu Leu 1 5 10 15 Pro Ala Ser Ser Gly Asn Pro Ser
Arg Cys Thr Leu Phe Ile Gly Ala 20 25 30 Ser Ser Tyr His Ser Ser
Pro Cys Gly Ser Ser Leu Pro Arg Cys Thr 35 40 45 Trp Asn Leu Asp
Leu Phe Ser Leu Thr Lys Asp Gln Ser Leu Ser Pro 50 55 60 Pro Cys
Pro Asp Leu Ile Thr Tyr Ser Gln Tyr His Lys Pro Tyr Ser 65 70 75 80
Leu Tyr Val Phe Pro His Trp Ile Thr Lys Pro Asn Arg Arg Gly Leu 85
90 95 Gly Tyr Tyr Ser Ala Ser Tyr Ser Asp Pro Cys Ala Ile Gln Cys
Pro 100 105 110 Tyr Leu Gly Cys Gln Ser Trp Thr Cys Pro Tyr Thr Gly
Pro Val Ser 115 120 125 Ser Pro His Trp Arg Tyr Thr Tyr Asp Leu Asn
Phe Thr Gln Glu Val 130 135 140 Ser Ser Val Ser Leu His Leu His Phe
Ser Lys Cys Gly Ser Ser Phe 145 150 155 160 Ser Phe Leu Leu Asp Ala
Pro Gly Tyr Asp Pro Val Trp Phe Leu Ser 165 170 175 Ser Gln Ala Thr
Gln Ala Pro Pro Thr Pro Ala Pro Leu Ile Arg Asp 180 185 190 Ser Asp
Leu Gln Tyr Ile Leu Glu Pro Pro Ile Pro Trp Ser Ser Lys 195 200 205
Ile Leu Asn Leu Ile Leu Leu Thr Leu Lys Ser Thr Asn Tyr Ser Cys 210
215 220 Met Val Cys Val Asp Arg Ser Ser Leu Ser Ser Trp His Val Leu
Tyr 225 230 235 240
Gly Pro Thr Gln Val Pro Ser Pro Pro Asp Pro Gln Ala Arg Ser Ile 245
250 255 Leu Arg Pro Ala Leu Ala Ile Pro Ala Ser Asn Ile Thr Pro Pro
Phe 260 265 270 Pro Trp Thr His Cys Tyr Arg Pro Pro Pro Gln Ala Ile
Ser Ser Glu 275 280 285 Asn Cys Asn Asn Ser Val Val Leu Pro Pro Phe
Ser Leu Ser Pro Ile 290 295 300 Pro Asn Val Ser Arg Pro 305 310
<210> SEQ ID NO 28 <211> LENGTH: 228 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Rabbit Fc fragment <400>
SEQUENCE: 28 Ala Pro Ser Thr Cys Ser Lys Pro Thr Cys Pro Pro Pro
Glu Leu Leu 1 5 10 15 Gly Gly Pro Ser Val Phe Ile Phe Pro Pro Lys
Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu Val Thr
Cys Val Val Val Asp Val Ser 35 40 45 Gln Asp Asp Pro Glu Val Gln
Phe Thr Trp Tyr Ile Asn Asn Glu Gln 50 55 60 Val Arg Thr Ala Arg
Pro Pro Leu Arg Glu Gln Gln Phe Asp Cys Thr 65 70 75 80 Ile Arg Val
Val Ser Thr Leu Pro Ile Ala His Gln Asp Trp Leu Arg 85 90 95 Gly
Lys Glu Phe Lys Cys Lys Val His Asn Lys Ala Leu Pro Ala Pro 100 105
110 Ile Glu Lys Thr Ile Ser Lys Ala Arg Gly Gln Pro Leu Glu Pro Lys
115 120 125 Val Tyr Thr Met Gly Pro Pro Arg Glu Glu Leu Ser Ser Arg
Ser Val 130 135 140 Ser Leu Thr Cys Met Ile Asn Gly Phe Tyr Pro Ser
Asp Ile Ser Val 145 150 155 160 Glu Trp Glu Lys Asn Gly Lys Ala Glu
Asp Asn Tyr Lys Thr Thr Pro 165 170 175 Ala Val Leu Asp Ser Asp Gly
Ser Tyr Phe Leu Tyr Ser Lys Leu Ser 180 185 190 Val Pro Thr Ser Glu
Trp Gln Arg Gly Asp Val Phe Thr Cys Ser Val 195 200 205 Met His Glu
Ala Leu His Asn His Tyr Thr Gln Lys Ser Ile Ser Arg 210 215 220 Ser
Pro Gly Lys 225 <210> SEQ ID NO 29 <211> LENGTH: 687
<212> TYPE: DNA <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Rabbit Fc
fragment <400> SEQUENCE: 29 gcaccctcga catgcagcaa gcccacgtgc
ccaccccctg aactcctggg gggaccgtct 60 gtcttcatct tccccccaaa
acccaaggac accctcatga tctcacgcac ccccgaggtc 120 acatgcgtgg
tggtggacgt gagccaggat gaccccgagg tgcagttcac atggtacata 180
aacaacgagc aggtgcgcac cgcccggccg ccgctacggg agcagcagtt caacagcacg
240 atccgcgtgg tcagcaccct ccccatcacg caccaggact ggctgagggg
caaggagttc 300 aagtgcaaag tccacaacaa ggcactcccg gcccccatcg
agaaaaccat ctccaaagcc 360 agagggcagc ccctggagcc gaaggtctac
accatgggcc ctccccggga ggagctgagc 420 agcaggtcgg tcagcctgac
ctgcatgatc aacggcttct acccttccga catctcggtg 480 gagtgggaga
agaacgggaa ggcagaggac aactacaaga ccacgccggc cgtgctggac 540
agcgacggct cctacttcct ctacaacaag ctctcagtgc ccacgagtga gtggcagcgg
600 ggcgacgtct tcacctgctc cgtgatgcac gaggccttgc acaaccacta
cacgcagaag 660 tccatctccc gctctccggg taaatga 687 <210> SEQ ID
NO 30 <211> LENGTH: 229 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Mouse Fc fragment <400> SEQUENCE: 30 Val
Asp Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val 1 5 10
15 Pro Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val
20 25 30 Leu Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val
Asp Ile 35 40 45 Ser Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe
Val Asp Asp Val 50 55 60 Glu Val His Thr Ala Gln Thr Gln Pro Arg
Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Phe Arg Ser Val Ser Glu Leu
Pro Ile Met His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Phe Lys
Cys Arg Val Asn Ser Ala Ala Phe Pro Ala 100 105 110 Pro Ile Glu Lys
Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro 115 120 125 Gln Val
Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys 130 135 140
Val Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr 145
150 155 160 Val Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys
Asn Thr 165 170 175 Gln Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val
Tyr Ser Lys Leu 180 185 190 Asn Val Gln Lys Ser Asn Trp Glu Ala Gly
Asn Thr Phe Thr Cys Ser 195 200 205 Val Leu His Glu Gly Leu His Asn
His His Thr Glu Lys Ser Leu Ser 210 215 220 His Ser Pro Gly Lys 225
<210> SEQ ID NO 31 <211> LENGTH: 690 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Mouse Fc fragment <400>
SEQUENCE: 31 gtcgacgtgc ccagggattg tggttgtaag ccttgcatat gtacagtccc
agaagtatca 60 tctgtcttca tcttcccccc aaagcccaag gatgtgctca
ccattactct gactcctaag 120 gtcacgtgtg ttgtggtaga catcagcaag
gatgatcccg aggtccagtt cagctggttt 180 gtagatgatg tggaggtgca
cacagctcag acgcaacccc gggaggagca gttcaacagc 240 actttccgct
cagtcagtga acttcccatc atgcaccagg actggctcaa tggcaaggag 300
ttcaaatgca gggtcaacag tgcagctttc cctgccccca tcgagaaaac catctccaaa
360 accaaaggca gaccgaaggc tccacaggtg tacaccattc cacctcccaa
ggagcagatg 420 gccaaggata aagtcagtct gacctgcatg ataacagact
tcttccctga agacattact 480 gtggagtggc agtggaatgg gcagccagcg
gagaactaca agaacactca gcccatcatg 540 gacacagatg gctcttactt
cgtctacagc aagctcaatg tgcagaagag caactgggag 600 gcaggaaata
ctttcacctg ctctgtgtta catgagggcc tgcacaacca ccatactgag 660
aagagcctct cccactctcc tggtaaatga 690 <210> SEQ ID NO 32
<211> LENGTH: 1230 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: HTLV2.RBD fused to a mouse Fc fragment
<400> SEQUENCE: 32 atgggtaatg ttttcttcct acttttattc
agtctcacac attttccact agcccagcag 60 agccgatgca cactcacagt
tggtatctcc tcctaccact ccagcccctg tagcccaacc 120 caacccgtct
gcacgtggaa cctcgacctt aattccctaa caacggacca acgactacac 180
cccccctgcc ctaacctaat tacttactct ggcttccata agacttattc cttatactta
240 ttcccacatt ggataaaaaa gccaaacaga cagggcctag ggtactactc
gccttcctac 300 aatgaccctt gctcgctaca atgcccctac ttgggctgcc
aatcatggac atgcccatac 360 acgggccccg tctccagtcc atcctggaag
tttcattcag atgtaaattt cacccaggaa 420 gtcagccaag tgtcccttcg
actacacttc tctaagtgcg gctcctccat gaccctccta 480 gtagatgccc
ctggatatga tcctttatgg ttcatcacct cagaacccac tcagggatcc 540
gtcgacgtgc ccagggattg tggttgtaag ccttgcatat gtacagtccc agaagtatca
600 tctgtcttca tcttcccccc aaagcccaag gatgtgctca ccattactct
gactcctaag 660 gtcacgtgtg ttgtggtaga catcagcaag gatgatcccg
aggtccagtt cagctggttt 720 gtagatgatg tggaggtgca cacagctcag
acgcaacccc gggaggagca gttcaacagc 780 actttccgct cagtcagtga
acttcccatc atgcaccagg actggctcaa tggcaaggag 840 ttcaaatgca
gggtcaacag tgcagctttc cctgccccca tcgagaaaac catctccaaa 900
accaaaggca gaccgaaggc tccacaggtg tacaccattc cacctcccaa ggagcagatg
960 gccaaggata aagtcagtct gacctgcatg ataacagact tcttccctga
agacattact 1020 gtggagtggc agtggaatgg gcagccagcg gagaactaca
agaacactca gcccatcatg 1080 gacacagatg gctcttactt cgtctacagc
aagctcaatg tgcagaagag caactgggag 1140 gcaggaaata ctttcacctg
ctctgtgtta catgagggcc tgcacaacca ccatactgag 1200 aagagcctct
cccactctcc tggtaaatga 1230 <210> SEQ ID NO 33 <211>
LENGTH: 11 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE:
<223> OTHER INFORMATION: GLUT1 fragment <400> SEQUENCE:
33 Asn Ala Pro Gln Lys Val Ile Glu Glu Phe Tyr 1 5 10 <210>
SEQ ID NO 34 <211> LENGTH: 22 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: GLUT1 fragment <400> SEQUENCE:
34 Asn Gln Thr Trp Val His Arg Tyr Gly Glu Ser Ile Leu Pro Thr Thr
1 5 10 15 Leu Thr Thr Leu Trp Ser 20 <210> SEQ ID NO 35
<211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: GLUT1 fragment <400> SEQUENCE: 35 Lys Ser Phe
Glu Met Leu Ile Leu Gly Arg 1 5 10 <210> SEQ ID NO 36
<211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: GLUT1 fragment <400> SEQUENCE: 36 Asp Ser Ile
Met Gly Asn Lys Asp Leu 1 5 <210> SEQ ID NO 37 <211>
LENGTH: 14 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: GLUT1
fragment <400> SEQUENCE: 37 Tyr Ser Thr Ser Ile Phe Glu Lys
Ala Gly Val Gln Gln Pro 1 5 10 <210> SEQ ID NO 38 <211>
LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: GLUT1
fragment <400> SEQUENCE: 38 Glu Gln Leu Pro Trp Met Ser Tyr
Leu Ser 1 5 10 <210> SEQ ID NO 39 <211> LENGTH: 7
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: GLUT1 fragment
<400> SEQUENCE: 39 Gln Tyr Val Glu Gln Leu Cys 1 5
<210> SEQ ID NO 40 <211> LENGTH: 13 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: GLUT1 fragment <400> SEQUENCE:
40 Ile Val Gly Met Cys Phe Gln Tyr Val Glu Gln Leu Cys 1 5 10
<210> SEQ ID NO 41 <211> LENGTH: 304 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: HTLV2.RBD <400> SEQUENCE: 41
Met Gly Asn Val Phe Phe Leu Leu Leu Phe Ser Leu Thr His Phe Pro 1 5
10 15 Pro Val Gln Gln Ser Arg Cys Thr Leu Thr Val Gly Ile Ser Ser
Tyr 20 25 30 His Ser Ser Pro Cys Ser Pro Thr Gln Pro Val Cys Thr
Trp Asn Leu 35 40 45 Asp Leu Asn Ser Leu Thr Thr Asp Gln Arg Leu
His Pro Pro Cys Pro 50 55 60 Asn Leu Ile Thr Tyr Ser Gly Phe His
Lys Thr Tyr Ser Leu Tyr Leu 65 70 75 80 Phe Pro His Trp Ile Lys Lys
Pro Asn Arg Gln Gly Leu Gly Tyr Tyr 85 90 95 Ser Pro Ser Tyr Asn
Asp Pro Cys Ser Leu Gln Cys Pro Tyr Leu Gly 100 105 110 Cys Gln Ser
Trp Thr Cys Pro Tyr Thr Gly Pro Val Ser Ser Pro Ser 115 120 125 Trp
Lys Phe His Ser Asp Val Asn Phe Thr Gln Glu Val Ser Gln Val 130 135
140 Ser Leu Arg Leu His Phe Ser Lys Cys Gly Ser Ser Met Thr Leu Leu
145 150 155 160 Val Asp Ala Pro Gly Tyr Asp Pro Leu Trp Phe Ile Thr
Ser Glu Pro 165 170 175 Thr Gln Pro Pro Pro Thr Pro Pro Pro Leu Val
His Asp Ser Asp Leu 180 185 190 Glu His Val Leu Thr Pro Ser Thr Ser
Trp Thr Thr Lys Met Leu Lys 195 200 205 Phe Ile Gln Leu Thr Leu Gln
Ser Thr Asn Tyr Ser Cys Met Val Cys 210 215 220 Val Asp Arg Ser Ser
Leu Ser Ser Trp His Val Leu Tyr Thr Pro Asn 225 230 235 240 Ile Ser
Ile Pro Gln Gln Thr Ser Ser Arg Thr Ile Leu Phe Pro Ser 245 250 255
Leu Ala Leu Pro Ala Pro Pro Phe Gln Pro Phe Pro Trp Thr His Cys 260
265 270 Tyr Gln Pro Arg Leu Gln Ala Ile Thr Thr Asp Asp Cys Asn Asn
Ser 275 280 285 Ile Ile Leu Pro Pro Phe Ser Leu Ala Pro Val Pro Pro
Pro Ala Thr 290 295 300 <210> SEQ ID NO 42 <211>
LENGTH: 20 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION: human
IL-2 peptide signal <400> SEQUENCE: 42 Met Tyr Arg Met Gln
Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu 1 5 10 15 Val Thr Asn
Ser 20 <210> SEQ ID NO 43 <211> LENGTH: 18 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: human albumine peptide
signal <400> SEQUENCE: 43 Met Lys Trp Val Thr Phe Ile Ser Leu
Leu Phe Leu Phe Ser Ser Ala 1 5 10 15 Tyr Ser <210> SEQ ID NO
44 <211> LENGTH: 18 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: human chymotryosinogen peptide signal
<400> SEQUENCE: 44 Met Ala Phe Leu Trp Leu Leu Ser Cys Trp
Ala Leu Leu Gly Thr Thr 1 5 10 15 Phe Gly <210> SEQ ID NO 45
<211> LENGTH: 15 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: human trypsinogen-2 peptide signal <400>
SEQUENCE: 45 Met Asn Leu Leu Leu Ile Leu Thr Phe Val Ala Ala Ala
Val Ala 1 5 10 15 <210> SEQ ID NO 46 <211> LENGTH: 17
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: gaussia
luciferase peptide signal <400> SEQUENCE: 46 Met Gly Val Lys
Val Leu Phe Ala Leu Ile Cys Ile Ala Val Ala Glu 1 5 10 15 Ala
<210> SEQ ID NO 47 <211> LENGTH: 21 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Mouse IgM peptide signal <400>
SEQUENCE: 47
Met Lys Phe Ser Trp Val Met Phe Phe Leu Met Ala Val Val Thr Gly 1 5
10 15 Val Asn Ser Glu Phe 20 <210> SEQ ID NO 48 <211>
LENGTH: 2208 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Nucleic acid HTLV4 <400> SEQUENCE: 48 atgggatgtc ttgggaatca
gctgcttatc gccatcttgc ttttaagtgt ctatgggatc 60 tattgtactc
aatatgtcac agtcttttat ggtgtaccag cttggaggaa tgcgacaatt 120
cccctcttct gtgcaaccaa gaatagggat acttggggaa caactcagtg cctaccagat
180 aatggtgatt attcagaatt ggcccttaat gttacagaaa gctttgatgc
ttgggagaat 240 acagtcacag aacaggcaat agaggacgta tggcaactct
ttgagacctc aataaagcct 300 tgtgtaaaat tatccccatt atgcattact
atgagatgca ataaaagtga gacagataga 360 tggggattga caaaatcatc
aacaacaata acaacagcag caccaacatc agcaccagta 420 tcagaaaaaa
tagacatggt caatgagact agttcttgta tagctcagaa taattgcaca 480
ggcttggaac aagagcaaat gataagctgt aaattcacca tgacagggtt aaaaagagac
540 aagacaaagg agtacaatga aacttggtac tctacagatt tggtttgtga
acaagggaat 600 agcactgata atgaaagcag atgctacata aatcactgta
acacttctgt tatccaagag 660 tcttgtgaca aacattattg ggatactatt
agatttaggt attgtgcacc tccaggttat 720 gctttgctta gatgtaatga
cacaaattat tcaggcttta tgcctaaatg ttctaaggtg 780 gtggtctctt
catgcacaag gatgatggag acacagactt ctacttggtt tggctttaat 840
ggaactagag cagaaaatag aacttatatt tactggcatg gtagggataa taggactata
900 attagtttaa ataagtatta taatctaaca atgaaatgta gaagaccagg
aaataagaca 960 gttttaccag tcaccattat gtctggattg gttttccact
cacaaccaat caatgatagg 1020 ccaaagcagg catggtgttg gtttggagga
aaatggaagg atgcaataaa agaggtgaaa 1080 cagaccattg tcaaacatcc
caggtatact ggaactaaca atactgataa aatcaattta 1140 acggctcctg
gaggaggaga tccagaagtt accttcatgt ggacaaattg cagaggagag 1200
ttcctctact gtaaaatgaa ttggtttcta aattgggtag aggataggga tgtaactacc
1260 cagaggccaa aggaacggca tagaaggaat tacgtgccgt gtcatattag
acaagtaatc 1320 aacacttggc ataaagtagg caaaaatgtt tatttgcctc
caagagaggg agacctcacg 1380 tgtaactcca cagtgaccag tctcatagca
aacatagatt ggactgatgg aaaccaaact 1440 aatatcacca tgagtgcaga
ggtggcagaa ctgtatcgat tggagttggg agattataaa 1500 ttagtagaga
tcactccgat cggcttggcc cccacagatg tgaagaggta cactactggt 1560
ggcacctcaa gaaataaaag aggggtcttt gtgctagggt tcttgggttt tctcgcaacg
1620 gcaggttctg caatgggcgc ggcgtcgttg acgctgaccg ctcagtcccg
gactttattg 1680 gctgggatag tgcagcaaca gcaacagctg ttggacgtgg
tcaagagaca acaagaattg 1740 ttgcgactga ccgtctgggg aacaaagaac
ctccagacta gggtcactgc catcgagaag 1800 tacttaaagg accaggcgca
gctgaatact tggggatgtg cgtttagaca agtctgccac 1860 actactgtac
catggccaaa tgcaagtcta acaccagact ggaacaatga tacttggcaa 1920
gagtgggagc gaaaggttga cttcttggag gaaaatataa cagccctcct agaagaggca
1980 caaattcaac aagagaagaa catgtatgaa ttacaaaagt taaatagctg
ggatgtgttt 2040 ggcaattggt ttgaccttgc ttcttggata aagtatatac
aatatggaat ttatgtagtt 2100 gtaggagtaa tactgttaag aatagtgatc
tatatagtac aaatgctagc taagttaagg 2160 caggggtata ggccagtgtt
ctcttcccca ccctcttatt tccagtag 2208 <210> SEQ ID NO 49
<211> LENGTH: 735 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Amino acid HTLV4 <400> SEQUENCE: 49 Met Gly Cys
Leu Gly Asn Gln Leu Leu Ile Ala Ile Leu Leu Leu Ser 1 5 10 15 Val
Tyr Gly Ile Tyr Cys Thr Gln Tyr Val Thr Val Phe Tyr Gly Val 20 25
30 Pro Ala Trp Arg Asn Ala Thr Ile Pro Leu Phe Cys Ala Thr Lys Asn
35 40 45 Arg Asp Thr Trp Gly Thr Thr Gln Cys Leu Pro Asp Asn Gly
Asp Tyr 50 55 60 Ser Glu Leu Ala Leu Asn Val Thr Glu Ser Phe Asp
Ala Trp Glu Asn 65 70 75 80 Thr Val Thr Glu Gln Ala Ile Glu Asp Val
Trp Gln Leu Phe Glu Thr 85 90 95 Ser Ile Lys Pro Cys Val Lys Leu
Ser Pro Leu Cys Ile Thr Met Arg 100 105 110 Cys Asn Lys Ser Glu Thr
Asp Arg Trp Gly Leu Thr Lys Ser Ser Thr 115 120 125 Thr Ile Thr Thr
Ala Ala Pro Thr Ser Ala Pro Val Ser Glu Lys Ile 130 135 140 Asp Met
Val Asn Glu Thr Ser Ser Cys Ile Ala Gln Asn Asn Cys Thr 145 150 155
160 Gly Leu Glu Gln Glu Gln Met Ile Ser Cys Lys Phe Thr Met Thr Gly
165 170 175 Leu Lys Arg Asp Lys Thr Lys Glu Tyr Asn Glu Thr Trp Tyr
Ser Thr 180 185 190 Asp Leu Val Cys Glu Gln Gly Asn Ser Thr Asp Asn
Glu Ser Arg Cys 195 200 205 Tyr Ile Asn His Cys Asn Thr Ser Val Ile
Gln Glu Ser Cys Asp Lys 210 215 220 His Tyr Trp Asp Thr Ile Arg Phe
Arg Tyr Cys Ala Pro Pro Gly Tyr 225 230 235 240 Ala Leu Leu Arg Cys
Asn Asp Thr Asn Tyr Ser Gly Phe Met Pro Lys 245 250 255 Cys Ser Lys
Val Val Val Ser Ser Cys Thr Arg Met Met Glu Thr Gln 260 265 270 Thr
Ser Thr Trp Phe Gly Phe Asn Gly Thr Arg Ala Glu Asn Arg Thr 275 280
285 Tyr Ile Tyr Trp His Gly Arg Asp Asn Arg Thr Ile Ile Ser Leu Asn
290 295 300 Lys Tyr Tyr Asn Leu Thr Met Lys Cys Arg Arg Pro Gly Asn
Lys Thr 305 310 315 320 Val Leu Pro Val Thr Ile Met Ser Gly Leu Val
Phe His Ser Gln Pro 325 330 335 Ile Asn Asp Arg Pro Lys Gln Ala Trp
Cys Trp Phe Gly Gly Lys Trp 340 345 350 Lys Asp Ala Ile Lys Glu Val
Lys Gln Thr Ile Val Lys His Pro Arg 355 360 365 Tyr Thr Gly Thr Asn
Asn Thr Asp Lys Ile Asn Leu Thr Ala Pro Gly 370 375 380 Gly Gly Asp
Pro Glu Val Thr Phe Met Trp Thr Asn Cys Arg Gly Glu 385 390 395 400
Phe Leu Tyr Cys Lys Met Asn Trp Phe Leu Asn Trp Val Glu Asp Arg 405
410 415 Asp Val Thr Thr Gln Arg Pro Lys Glu Arg His Arg Arg Asn Tyr
Val 420 425 430 Pro Cys His Ile Arg Gln Val Ile Asn Thr Trp His Lys
Val Gly Lys 435 440 445 Asn Val Tyr Leu Pro Pro Arg Glu Gly Asp Leu
Thr Cys Asn Ser Thr 450 455 460 Val Thr Ser Leu Ile Ala Asn Ile Asp
Trp Thr Asp Gly Asn Gln Thr 465 470 475 480 Asn Ile Thr Met Ser Ala
Glu Val Ala Glu Leu Tyr Arg Leu Glu Leu 485 490 495 Gly Asp Tyr Lys
Leu Val Glu Ile Thr Pro Ile Gly Leu Ala Pro Thr 500 505 510 Asp Val
Lys Arg Tyr Thr Thr Gly Gly Thr Ser Arg Asn Lys Arg Gly 515 520 525
Val Phe Val Leu Gly Phe Leu Gly Phe Leu Ala Thr Ala Gly Ser Ala 530
535 540 Met Gly Ala Ala Ser Leu Thr Leu Thr Ala Gln Ser Arg Thr Leu
Leu 545 550 555 560 Ala Gly Ile Val Gln Gln Gln Gln Gln Leu Leu Asp
Val Val Lys Arg 565 570 575 Gln Gln Glu Leu Leu Arg Leu Thr Val Trp
Gly Thr Lys Asn Leu Gln 580 585 590 Thr Arg Val Thr Ala Ile Glu Lys
Tyr Leu Lys Asp Gln Ala Gln Leu 595 600 605 Asn Thr Trp Gly Cys Ala
Phe Arg Gln Val Cys His Thr Thr Val Pro 610 615 620 Trp Pro Asn Ala
Ser Leu Thr Pro Asp Trp Asn Asn Asp Thr Trp Gln 625 630 635 640 Glu
Trp Glu Arg Lys Val Asp Phe Leu Glu Glu Asn Ile Thr Ala Leu 645 650
655 Leu Glu Glu Ala Gln Ile Gln Gln Glu Lys Asn Met Tyr Glu Leu Gln
660 665 670 Lys Leu Asn Ser Trp Asp Val Phe Gly Asn Trp Phe Asp Leu
Ala Ser 675 680 685 Trp Ile Lys Tyr Ile Gln Tyr Gly Ile Tyr Val Val
Val Gly Val Ile 690 695 700 Leu Leu Arg Ile Val Ile Tyr Ile Val Gln
Met Leu Ala Lys Leu Arg 705 710 715 720 Gln Gly Tyr Arg Pro Val Phe
Ser Ser Pro Pro Ser Tyr Phe Gln 725 730 735 <210> SEQ ID NO
50 <211> LENGTH: 1485 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Nucleic acid HTLV3 <400> SEQUENCE: 50
atgggtaagt ccggtcttta tttcagtctc atttgttttt acacactctt cccttcctct
60 tttggcaatc ccagccgatg caccctgttc ataggagctt cctcctacca
ctctgacccc 120
tgtgggtcca accacccacg atgtacctgg agacttgacc tcttttccct cacaaaggat
180 caaagcctaa gccccccatg tccaggctta gttacttact cacagtacca
taaaccctac 240 tccctatatg tatttcctca ttggatagcc aaacctgacc
gtcgaggcct aggttactat 300 tctgcttcct actcggaccc ctgcgctata
caatgccctt acctaggatg ccagtcatgg 360 acgtgcccct atacaggtcc
ggtgtccaac ccacattgga aatacacctc tgatcttaac 420 ttcacccaag
aagtatcatc catttcccta cacttgcact tttccaaatg tgggtcctca 480
ttctcctttc tattagatgc gccaggatat gacccagtgt ggctcctctc atcccaggcc
540 acccaaattc cacccacgcc cgcccctctc atacaggact cagatctcca
acatatcctg 600 gaaccttcta tcccatggag ttctaaaatc cttaacctta
tcctccttgc tttaaagagc 660 actaattatt cttgcatggt ctgtgtcgat
cgctccagcc tctcttcatg gcatgttctg 720 tacgacccac tcaaagcccc
cagttcaccc gacccccaag cccagtctat cctacggccc 780 tccttagcca
ttcccgccag taacatcacc cctccgtttc cttggaccca ctgctatcgc 840
cctcctctac aggccatctc ctcagaaaac tgcaataact ctgtaatact gccccccttc
900 tccctgtccc caattcctga tgtctctaga ccccggaagc gccgagcagt
ccccatcgct 960 atatggctgg tatccgccct agcggccggc acgggtatag
caggcggagt taccggctcc 1020 ctgtccctgg cgtccagcaa gagtctgttg
cgcgaggttg accaggacat agatcaccta 1080 acccgggcaa ttgtaaagaa
ccatgacaac atccttcggg ttgctcagta cgcagcccaa 1140 aatcgccgcg
gcctagacct gcttttttgg gagcagggag gtctttgtaa ggccatccag 1200
gagcaatgtt gtttccttaa tatcagcaac acccatgtgt cagtccttca ggaaagacct
1260 cctctagaaa aaagggtaat taccggctgg gggctcaatt gggaccttgg
gctctcccaa 1320 tgggcccgag aggccctcca gacaggtata acactcttgg
ccctctttct cctcctcatt 1380 gtcgtagggc cctgtgtcat acgtcagctg
cagaccctcc cctcccgcct gcagcaccgc 1440 agccaaccct actcccttct
caattatgaa accaacttat aataa 1485 <210> SEQ ID NO 51
<211> LENGTH: 493 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Amino acid HTLV3 <400> SEQUENCE: 51 Met Gly Lys
Ser Gly Leu Tyr Phe Ser Leu Ile Cys Phe Tyr Thr Leu 1 5 10 15 Phe
Pro Ser Ser Phe Gly Asn Pro Ser Arg Cys Thr Leu Phe Ile Gly 20 25
30 Ala Ser Ser Tyr His Ser Asp Pro Cys Gly Ser Asn His Pro Arg Cys
35 40 45 Thr Trp Arg Leu Asp Leu Phe Ser Leu Thr Lys Asp Gln Ser
Leu Ser 50 55 60 Pro Pro Cys Pro Gly Leu Val Thr Tyr Ser Gln Tyr
His Lys Pro Tyr 65 70 75 80 Ser Leu Tyr Val Phe Pro His Trp Ile Ala
Lys Pro Asp Arg Arg Gly 85 90 95 Leu Gly Tyr Tyr Ser Ala Ser Tyr
Ser Asp Pro Cys Ala Ile Gln Cys 100 105 110 Pro Tyr Leu Gly Cys Gln
Ser Trp Thr Cys Pro Tyr Thr Gly Pro Val 115 120 125 Ser Asn Pro His
Trp Lys Tyr Thr Ser Asp Leu Asn Phe Thr Gln Glu 130 135 140 Val Ser
Ser Ile Ser Leu His Leu His Phe Ser Lys Cys Gly Ser Ser 145 150 155
160 Phe Ser Phe Leu Leu Asp Ala Pro Gly Tyr Asp Pro Val Trp Leu Leu
165 170 175 Ser Ser Gln Ala Thr Gln Ile Pro Pro Thr Pro Ala Pro Leu
Ile Gln 180 185 190 Asp Ser Asp Leu Gln His Ile Leu Glu Pro Ser Ile
Pro Trp Ser Ser 195 200 205 Lys Ile Leu Asn Leu Ile Leu Leu Ala Leu
Lys Ser Thr Asn Tyr Ser 210 215 220 Cys Met Val Cys Val Asp Arg Ser
Ser Leu Ser Ser Trp His Val Leu 225 230 235 240 Tyr Asp Pro Leu Lys
Ala Pro Ser Ser Pro Asp Pro Gln Ala Gln Ser 245 250 255 Ile Leu Arg
Pro Ser Leu Ala Ile Pro Ala Ser Asn Ile Thr Pro Pro 260 265 270 Phe
Pro Trp Thr His Cys Tyr Arg Pro Pro Leu Gln Ala Ile Ser Ser 275 280
285 Glu Asn Cys Asn Asn Ser Val Ile Leu Pro Pro Phe Ser Leu Ser Pro
290 295 300 Ile Pro Asp Val Ser Arg Pro Arg Lys Arg Arg Ala Val Pro
Ile Ala 305 310 315 320 Ile Trp Leu Val Ser Ala Leu Ala Ala Gly Thr
Gly Ile Ala Gly Gly 325 330 335 Val Thr Gly Ser Leu Ser Leu Ala Ser
Ser Lys Ser Leu Leu Arg Glu 340 345 350 Val Asp Gln Asp Ile Asp His
Leu Thr Arg Ala Ile Val Lys Asn His 355 360 365 Asp Asn Ile Leu Arg
Val Ala Gln Tyr Ala Ala Gln Asn Arg Arg Gly 370 375 380 Leu Asp Leu
Leu Phe Trp Glu Gln Gly Gly Leu Cys Lys Ala Ile Gln 385 390 395 400
Glu Gln Cys Cys Phe Leu Asn Ile Ser Asn Thr His Val Ser Val Leu 405
410 415 Gln Glu Arg Pro Pro Leu Glu Lys Arg Val Ile Thr Gly Trp Gly
Leu 420 425 430 Asn Trp Asp Leu Gly Leu Ser Gln Trp Ala Arg Glu Ala
Leu Gln Thr 435 440 445 Gly Ile Thr Leu Leu Ala Leu Phe Leu Leu Leu
Ile Val Val Gly Pro 450 455 460 Cys Val Ile Arg Gln Leu Gln Thr Leu
Pro Ser Arg Leu Gln His Arg 465 470 475 480 Ser Gln Pro Tyr Ser Leu
Leu Asn Tyr Glu Thr Asn Leu 485 490 <210> SEQ ID NO 52
<211> LENGTH: 1476 <212> TYPE: DNA <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Nucleic acid STLV3 <400> SEQUENCE: 52
atgggtaagt ccggctttta tttctgtttt atttacactc tcttccctgc ctcctttggc
60 aaccccagtc gatgcaccct gttcataggg gcctcttcct accactccga
cccttgtggg 120 tccaatcacc cacaatgtac ctggaggctc gacctattct
ccctcacaag ggatcaaagc 180 ctgagccccc catgtccaga cttagtcact
tactcacagt atcataaacc ctactccctg 240 tatgtatttc cccattggat
ggccaaacct aaccgtcaag gcctaggcta ctattctgct 300 tcctactcag
acccttgtgc tatacagtgc ccttacctag gatgccagtc atggacctgt 360
ccctacacag gcccggtgtc cagcccgcat tggaaatact cctccgatct taattttacc
420 caagaggtat catctatctc cctacactta catttttcca aatgcgggtc
ttcattctct 480 tttctactag atgcaccggg gtacgaccct gtgtggttcc
tctcctccca ggccacacag 540 gttccaccca cgcccgcccc tctcatacag
gactctaatc tccaacatat cctggaaccc 600 tccgtcccgt ggagctccaa
aatcctcaat ctcatcctcc tcaccttaaa aagcactaac 660 tattcttgta
tggtctgtgt cgaccgctcc agcctatctt cgtggcatgt tctatatgac 720
ccactcaaag cccccggtcc acccgacccc caagcccagt ctatcttgcg accctcctta
780 gccattcccg ccagtaatat cacccctccg tttccctgga cccattgcta
tcgccctctt 840 ctacaggcca tctcctcaga acactgcaac aactccgtag
tgctgccccc cttttccctg 900 tccccacttc ctaacgcctt cagaccccga
aagcgccggg cagtccccat cgccatatgg 960 ctagtatccg cccttgcggc
cggcaccggt atagctggtg gagttacagg ctccctgtct 1020 ctggcctccg
gcaaaagcct gttacacgaa gtagaccaag acatagatca cctgacgcgg 1080
gcaattgtaa agaaccatga caatatcctt cgggtcgctc agtatgcagc ccaaaatcgt
1140 cgcggcctag atctgctttt ctgggaacaa ggaggccttt gtaaggccat
ccaagagcaa 1200 tgttgtttcc tcaatatcag taacacccat gtgtccgtcc
tccaggaaag acccccccta 1260 gaaaaaagag taatcacggg ctgggggctc
aattgggacc tcgggctctc ccaatgggcc 1320 cgagaggccc ttcagacagg
tataaccctc ttggccctct ttctcctcct tattgtggtc 1380 gggccctgcg
tcatacgcca gctgcaggcc ctcccttccc gcctgcagcc tcgcagccag 1440
ccctactccc ttctaaatta tgaaaccaac ttataa 1476 <210> SEQ ID NO
53 <211> LENGTH: 491 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Amino acid STLV3 <400> SEQUENCE: 53 Met
Gly Lys Ser Gly Phe Tyr Phe Cys Phe Ile Tyr Thr Leu Phe Pro 1 5 10
15 Ala Ser Phe Gly Asn Pro Ser Arg Cys Thr Leu Phe Ile Gly Ala Ser
20 25 30 Ser Tyr His Ser Asp Pro Cys Gly Ser Asn His Pro Gln Cys
Thr Trp 35 40 45 Arg Leu Asp Leu Phe Ser Leu Thr Arg Asp Gln Ser
Leu Ser Pro Pro 50 55 60 Cys Pro Asp Leu Val Thr Tyr Ser Gln Tyr
His Lys Pro Tyr Ser Leu 65 70 75 80 Tyr Val Phe Pro His Trp Met Ala
Lys Pro Asn Arg Gln Gly Leu Gly 85 90 95 Tyr Tyr Ser Ala Ser Tyr
Ser Asp Pro Cys Ala Ile Gln Cys Pro Tyr 100 105 110 Leu Gly Cys Gln
Ser Trp Thr Cys Pro Tyr Thr Gly Pro Val Ser Ser 115 120 125 Pro His
Trp Lys Tyr Ser Ser Asp Leu Asn Phe Thr Gln Glu Val Ser 130 135 140
Ser Ile Ser Leu His Leu His Phe Ser Lys Cys Gly Ser Ser Phe Ser 145
150 155 160 Phe Leu Leu Asp Ala Pro Gly Tyr Asp Pro Val Trp Phe Leu
Ser Ser
165 170 175 Gln Ala Thr Gln Val Pro Pro Thr Pro Ala Pro Leu Ile Gln
Asp Ser 180 185 190 Asn Leu Gln His Ile Leu Glu Pro Ser Val Pro Trp
Ser Ser Lys Ile 195 200 205 Leu Asn Leu Ile Leu Leu Thr Leu Lys Ser
Thr Asn Tyr Ser Cys Met 210 215 220 Val Cys Val Asp Arg Ser Ser Leu
Ser Ser Trp His Val Leu Tyr Asp 225 230 235 240 Pro Leu Lys Ala Pro
Gly Pro Pro Asp Pro Gln Ala Gln Ser Ile Leu 245 250 255 Arg Pro Ser
Leu Ala Ile Pro Ala Ser Asn Ile Thr Pro Pro Phe Pro 260 265 270 Trp
Thr His Cys Tyr Arg Pro Leu Leu Gln Ala Ile Ser Ser Glu His 275 280
285 Cys Asn Asn Ser Val Val Leu Pro Pro Phe Ser Leu Ser Pro Leu Pro
290 295 300 Asn Ala Phe Arg Pro Arg Lys Arg Arg Ala Val Pro Ile Ala
Ile Trp 305 310 315 320 Leu Val Ser Ala Leu Ala Ala Gly Thr Gly Ile
Ala Gly Gly Val Thr 325 330 335 Gly Ser Leu Ser Leu Ala Ser Gly Lys
Ser Leu Leu His Glu Val Asp 340 345 350 Gln Asp Ile Asp His Leu Thr
Arg Ala Ile Val Lys Asn His Asp Asn 355 360 365 Ile Leu Arg Val Ala
Gln Tyr Ala Ala Gln Asn Arg Arg Gly Leu Asp 370 375 380 Leu Leu Phe
Trp Glu Gln Gly Gly Leu Cys Lys Ala Ile Gln Glu Gln 385 390 395 400
Cys Cys Phe Leu Asn Ile Ser Asn Thr His Val Ser Val Leu Gln Glu 405
410 415 Arg Pro Pro Leu Glu Lys Arg Val Ile Thr Gly Trp Gly Leu Asn
Trp 420 425 430 Asp Leu Gly Leu Ser Gln Trp Ala Arg Glu Ala Leu Gln
Thr Gly Ile 435 440 445 Thr Leu Leu Ala Leu Phe Leu Leu Leu Ile Val
Val Gly Pro Cys Val 450 455 460 Ile Arg Gln Leu Gln Ala Leu Pro Ser
Arg Leu Gln Pro Arg Ser Gln 465 470 475 480 Pro Tyr Ser Leu Leu Asn
Tyr Glu Thr Asn Leu 485 490 <210> SEQ ID NO 54 <211>
LENGTH: 0 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
HTLV1.RBD <400> SEQUENCE: 54 000 <210> SEQ ID NO 55
<211> LENGTH: 0 <212> TYPE: DNA <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: STLV2.RBD <400> SEQUENCE: 55 000
* * * * *